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Abstract
The fundamental goal of radiotherapy is to maximize the radiation dose to enhance the tumor
control while minimizing dose to the normal tissues. Proton radiotherapy for clinical use has
increased in the last decade. Currently, the use of pencil beam scanning (PBS) proton therapy
technology for the treatment of various cancers is gaining popularity. The potential challenge of
clinical utilization of PBS proton therapy occurs in the case of mobile tumors such as lung. The
mitigation of interplay effect in PBS proton therapy is critical to maintain a higher local control.
Volumetric repainting is considered as one of the tumor motion management techniques in PBS
proton treatment. Volumetric repainting is accomplished by scanning the entire target volume
repeatedly.
This thesis examines the application of volumetric repainting in PBS proton therapy, with a
particular emphasis on the alternating order repainting technique. The experiments were carried
out on an IBA ProteusPLUS PBS proton system operating in a "magnetic field regulation" mode.
The “magnetic field regulation” mode on an IBA ProteusPLUS PBS proton system is capable of
delivering a proton beam from the distal end to proximal end and vice-versa, with a faster energy
layer switching. There is a lack of published scientific guidelines on the implementation of such
commercially available advanced technology in a clinical setting. This thesis work is primarily
focused on investigating the feasibility of clinical implementation of volumetric repainting
technique in an alternating order to treat lung tumors in PBS proton therapy. Specifically, this
thesis work provides the experimental results for a PBS proton beam model as well as addresses
the interplay effect, proton dose calculation algorithms, spot size and position errors, treatment
plan robustness, radiobiological analysis, and dose-averaged linear energy transfer (LETd)
distributions in PBS proton lung cancer patients.
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Chapter 1
Introduction
1.1

Overview

Radiation therapy provides a targeted or regionalized, minimally invasive alternative to surgery in
many cases. It is considered as one of the standard cares of cancer patients. The existence of a
tumor near vital organs, failure of a patient to receive anesthesia, or because of the undesired results
from surgeries or other side effects may aid radiation when therapeutic resection of the tumor
tissue is not feasible.
The primary goal of radiotherapy is to increase the radiation dose to enhance the tumor control
and reduce the radiation exposure to the normal tissues. Escalating radiation exposure reduces the
likelihood of most cancers but tends to increase significant harm to normal tissues/organs at risks
(OARs) (1). Radiation is more lethal to cancer cells than it is to normal tissue cells, and therefore
the prescribed radiation dose can cause the lethal damage to cancer cells and sublethal damage to
the normal tissues (2). Radiation therapy, however, may have destructive effects in pediatric
patients (3). Children and young adults are particularly vulnerable to radiation-related secondary
cancers (3). The diagnosis of tumors in the central nervous system (CNS) is very difficult because
the tumor is attached to many vital structures. In particular, the developing brain is highly sensitive
to radiation. CNS radiation can lead to irreversible functional losses, along with neurocognitive
impairments, intelligence changes, hearing loss, and eye loss (3). Other potential radiation side
effects include cardiac and pulmonary toxicities, rectal bleeding, desquamation, lung fibrosis,
necrosis of tissue, etc. (3).
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Proton radiotherapy for clinical use has increased in the last decade. The main advantage of proton
therapy in comparison to mega-voltage X-ray (photon) therapy is the finite range that produces no
exit dose if small neutron dose downstream of the spread-out Bragg peak (SOBP) is neglected (4).
[Figure 1.1] As the photons transverse the matter, they do not lose the energy continuously. The
intensity of photon beams in the matter is attenuated exponentially with depth. Since photons do
not stop at a given depth, the normal tissues beyond the tumor receive extra radiation.

Figure 1.1: Depth dose illustration of 10 MV photon (X-ray) and proton beams. The spread-out
Bragg peak (SOBP) is formed by combining multiple Bragg peaks of different energies. Bragg
peak: dashed blue curve; SOBP: solid blue curves; photon: solid red curve. Source: (5)
In contrast, protons being charged particles are slowed down due to their interactions with the
medium (6). Specifically, a “decrease in energy of the incident proton leads to an increase in energy
locally deposited (dE/dx) due to the increasing time the proton remains within the electron’s
vicinity (6).” The stopping power (dE/dx) is defined in equation 1.1 (see section 1.2). The incident
proton stops at a certain depth depending on its incident energy and density of the medium. This
depth is often known as “range” (see section 1.2.2) in proton therapy. The depth distribution of the
monoenergetic proton beam is characterized by a "Bragg Peak." Figure 1.2 displays the Bragg
peaks for various energies. Figure 1.1 shows the spread-out Bragg peak (SOBP), which can be
generated by combining pristine Bragg peaks of various energies.
Proton beam’s lateral penumbra results in lateral dose control, improving the dose conformality
around the tumor volume and protecting the tumor-contiguous normal tissues and vital structures
(4, 7). Since the interaction of photons and protons with matter differ, they provide very different
3D dose distributions in a patient. The dose distributions from a patient treatment plan can be
utilized to predict the tumor control probability (TCP) and normal tissue complication probability
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(NTCP) in a cancer patient (8). Proton treatment has been shown to have therapeutic benefits over
photon therapy in pediatric brain tumor patients (9, 10). As the interest in using proton therapy for
cancer treatment continues to grow, several randomized clinical trials are underway in evaluating
the benefits and harms of proton therapy for different types of cancer (11).
1.2

Proton Interactions

Three basic processes govern the interaction of a proton with an atom or nucleus (6). Protons
continually lose kinetic energy due to frequent inelastic Coulombic interactions with the atom's
electrons. This effect ionizes and excites the atoms along their course. The electronic stopping
power can describe the inelastic coulomb interactions that increase as the kinetic energy of the
protons diminishes in water to a maximum of around 0.1 MeV. For elastic Coulombic interaction,
when a proton approaches the atomic nucleus, it encounters a repulsive force due to the large
nucleus mass that changes the proton’s trajectory from its original path. Whereas orbital electron
collisions are the main energy loss mechanism and are responsible for the shape of the proton
depth dose distribution. The atomic nuclei elastic scattering is mostly responsible for the off-axis
or lateral dose distribution. Rutherford scattering basically describes the degree of elastic
scattering, i.e., a proton is deflected as it travels through the positive charged nucleus’s electric
field. The energy loss of a proton per unit path length in an absorber (−dE/dx) is given by the
Bethe-Bloch Equation (12-14).
=−
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−

where,
NA = Avogadro’s number
re = classical electron radius
me = mass of an electron
z = charge of the proton
Z = absorbing material’s atomic number
A = absorbing material’s atomic weight
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(Eq. 1.1)

β = v/c where v is the velocity of the proton and c is the speed of light
γ = (1 − β2)−1/2
I = absorbing material’s mean excitation potential
δ = density corrections term
C = shell correction term
The inverse relationship between proton velocity and energy loss is explained by the depth dose
profile and the Bragg peak as the proton starts to slow finally stops in the medium. Low-speed
protons have more time to interact with the medium's orbital electrons, while faster protons pass
through the media quickly (6).
1.2.1

Multiple Coulomb Scattering

When protons interact with atomic electrons in low-Z materials or atomic nuclei, multiple
Coulomb scattering (MCS) occurs (6, 15). MCS is the random deflection of protons caused by
electromagnetic interactions and dominated by scattering from nuclei (6, 15). The angular
distribution features a slow-falling tail and a Gaussian center. Because 99% of the protons are
concentrated in the center of the proton beam, the Gaussian approximation is adequate for the
great majority of proton radiation treatment situations (16). The Gaussian width parameter is
dependent on the kind of particle, incident protons’ energy, the target's thickness, and atomic
characteristics (6, 15).
MCS in the treatment head of the proton machine is beneficial in clinical proton therapy, as it
enables laterally extending the beam to appropriate dimensions. This makes a proton beam large
and flat so that a uniform dose can completely cover the tumor (16). Additionally, MCS occurs in
the patient too. The MCS in the treatment machine head and patient blurs the sharpness of the
lateral penumbra. It shows an increment of the penumbra at the edge of the collimated beams or
the spot size of the scanned beam (17). Maintaining the sharpness of the penumbra is necessary to
achieve the maximum value of proton therapy in protecting critical structures and other normal
tissues.
1.2.2

Proton Range
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“Range is the depth at which half the protons are at rest in the medium (6).” The energy loss of
each proton is slightly varied. This effect is known as range straggling (6). As a consequence, the
range is defined implicitly as an average value for a beam rather than for an individual particle (6).
About 50 percent of the protons in a beam protons passing through the absorber are absorbed, but
in certain situations, it can be interpreted as the half of the protons surviving until close to the
range’s end (6). The range is often measured by a detector in a water tank that yields a Bragg peak
curve (6). In the clinic, the range is equivalent to the distal 90% point of the Bragg peak curve’s
depth. Bragg peak curve is a depth-dose distribution that is achieved by irradiating with a
monoenergetic proton beam (6). The decreasing peak entrance dose ratio with proton range is
increasing due to the Coulomb scattering of protons (see Figure 1.2).

Figure 1.2: Bragg peaks for various energies. The measured Bragg peaks are represented by red
curves.

Figure 1.3: An example of proton depth-dose profile of a pristine Bragg peak of 225 MeV energy.
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1.3
1.3.1

Proton Beam Delivery System
Passive Scattering

For passive scattering beam delivery, the flatness of the lateral dose profile is fine-tuned by the
fixed lead scatterers (18). Dose profile varies with the scatter in the fixed scatterers and range
modulator. Effective scattering decreases with greater range. Increasing the amount of lead retains
a flat dose profile. The track of range modulator is configured as an increased thickness in several
steps. The current modulation in conjunction with the decreasing angular width of the multi-step
range modulator maintains SOBP flatness in the direction of depth. Passive scattering method
details are available from published literature (18-20).

Figure 1.4: Schematic diagram of double scattering nozzle of IBA beam delivery system. (Note:
the diagram is not to scale); Source (21)

Figure 1.5: A three-track range modulator wheel that may be used for various modulation widths.
The uniform scanning beam delivery is also considered as one of the passive scattering techniques.
The design of the nozzle utilized to deliver the uniform scanning proton beam is shown in Figure
1.6. Rana et al. (7) describes the beam transport in uniform scanning proton therapy system of the
Oklahoma Proton Center – “as the proton beam enters the nozzle, the first scatterer widens the
high-energy proton beam, which gets downgraded to lower energy after passing through the range
modulator wheel. The degraded beam is then scanned laterally in a zigzag pattern by horizontal
6

scanning. The beam is scanned with a constant frequency in order to deliver a uniform dose for a
near rectangular scanning area. The scanning beam passes through the main and backup ionization
chambers that monitor the proton dose. As the beam exits the nozzle, it passes through the
extendable snout which holds an aperture and compensator before reaching the patient.”

Figure 1.6: Schematic diagram of uniform scanning beam delivery system. (Note: the diagram is
not to scale) Source: (7)

Figure 1.7: Passive scattering dose distribution (on the left) and pencil beam scanning plan dose
distribution (on the right). The PBS plan exhibits better dose conformality than the passive
scattering plan. For the posterior beam, irradiation to normal tissue in the proximal region is
greater using the passive scattering technique. Source:(23)
1.3.2

Pencil Beam Scanning

In PBS proton treatment, a broad beam is changed to a narrow mono-energetic “pencil” beam that
can be magnetically scanned through the 3D tumor volume consisting of several layers (22). To
achieve PBS beam delivery for clinical treatment, various measurements need to be performed to
generate a proton beam model in the treatment planning software (23). Clasie et al. (24) has
published on “Golden” beam data for PBS protons by quantifying “the pristine Bragg peak depth
dose distribution in terms of primary, multiple Coulomb scatter, and secondary, nuclear scatter,
components.” Clasie et al. (24) verified the Golden beam data could produce clinically acceptable
absolute dosimetry results on their PBS beam delivery systems. In the proton therapy clinic's
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current standard of care, the scanning starts at the deepest layer, corresponding to the highest
proton energy available in a given treatment beam. After delivering the x-y scan, the energy of the
proton beam is reduced to scan the following layer. This procedure is continued until all energy
layers of the given proton field are delivered. In PBS proton therapy, energy layers can have
various amounts of dose, and each layer is intensity-modulated to achieve a uniform dose
distribution throughout the tumor volume (16, 22).

Figure 1.8: A schematic of 3-D intensity-modulated proton therapy (IMPT) treatment planning
method. This figure shows several spots of different weights in black circles of various sizes;
Source (27)
The PBS treatment in patients can be delivered in two ways: discrete spot scanning and continuous
scanning techniques. Discrete spot scanning follows the step and shoot approach such that pencil
proton beam is aimed at a specific location (a certain volume element, a spot, or voxel) for given
magnet settings (16, 22). Then the proton beam is switched on to deliver the predetermined dose
at that specific location. This is followed by turning off the beam, change in the settings of the
magnets to aim the next location, delivery of the predetermined dose to this new location, and so
forth. During the continuous scanning technique, the magnets allow the beam to make a continuous
shift over the target volume (16, 22).The pattern of the shifts during continuous scanning can be a
series of lines (parallel, zig-zag raster, or curved) and the dose deposition along a line varies. The
continuous scanning is achieved by either adjusting the scan speed at a constant beam intensity or
by varying the beam intensity while keeping the scanning speed constant (25).
1.3.2.1

IBA PBS Dedicated Nozzle

Figure 1.9 shows the schematic illustration of beam delivery system equipment for ProteusPLUS
in a PBS treatment mode (26). As the beam reaches the nozzle, the alignment of the beam at the
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nozzle entrance is checked by the first ionization chamber (IC1). Two quadrupole magnets are
then used to focus the proton beam at the isocenter. A vertical scanning magnet scans the proton
beam in the Y direction, followed by a horizontal scanning magnet scanning it in the X-direction.
Using magnetic fields, the beam direction is steered to a specific area on a target. The dose and
beam characteristics (beam size, beam position, and flatness of the beam) are monitored by the
second and third ionization chambers (IC 2/3). Snout holder enables accessory drawer movement,
including absorber (also known as range shifter). Additional information on ProteusPLUS PBS
machine may be found elsewhere (26).

Figure 1.9: Schematic illustration of the beam delivery system equipment in the IBA ProteusPLUS
gantry-based PBS treatment system. The retractable X-ray tube (portal) is in the pre-assembly
nozzle under vacuum. (Note: the diagram is not to scale); Source: (26)
1.3.2.2

IBA PBS Beam Delivery

In PBS treatment, a proton beam is spread over the treatment area by moving the beam throughout
the treatment region. This can be achieved by beam scanning using fast magnets, which can deflect
the pencil beam in two orthogonal planes (22). By varying the energies of protons, pencil beams
can be used to transverse with different depths and scan the tumor volume. The proton range can
be changed as the proton beam passes through the degrader system of variable thicknesses. Other
beam properties that can be changed for pencil proton beams include position, size, and intensity.
During PBS beam delivery, it could involve the variation of different beam parameters (energy,
size, position, and intensity) such that the adjustment of these parameters can lead to deposition of
accurate dose at the correct treatment volume and time while minimizing dose outside the tumor
volume (22).
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The size of a pencil proton beam in the air is “primarily dictated by MCS and beam emittance,
which is a function of dipole field uniformity, quadrupole tuning, and energy spread of the pencil
beam (15, 27).” If a proton beam has lower energy, the forward beam emittance decreases,
increasing the wide-angle scattering (15, 27). The forward beam emittance increases with an
increase in the proton beam’s energy (15, 27). For the IBA ProteusPLUS PBS system, two
quadrupole magnets are utilized to adjust spot size in the nozzle. To define the trajectory of the
beam reaching the tumor volume, the position and angle of the pencil beam must be controlled.
The excitation of the magnetic field in the scanning dipoles determines the final path angle of the
pencil proton beam as well as its position in the tumor volume (22). The speed of the scan will be
determined by the overall system, which includes the power supply and dipole (22). A change in
energy is made after all of the spots of a particular layer have been delivered in order to deliver
the following layer at a different depth inside the target volume. The intensity of pencil proton
beams is modulated throughout the beam delivery.

Figure 1.10: For the ProteusPLUS PBS system with a magnetic field regulation feature, Hall
probes are mounted inside the 30⁰ bending magnet (B2E) of the energy selection system (ESS) and
bending magnets (B1Gx at 45⁰ and B2Gx at 135⁰) of the gantry. This figure is adapted from Rana
et al.(28).
More recently, IBA has implemented a “magnetic field regulation” feature on their latest
ProteusPLUS PBS machines (28, 29). For a magnetic field regulation mode, Hall probes are
mounted inside specific groups of magnets in the beamline. (Figure 1.10) This allows the reduction
in beam stabilization delays and layer switching time when delivering proton beam in both “down”
and “up” directions (28, 29). Figure 1.11 illustrates the beam delivery in “down” and “up”
directions. The “down” direction means the proton beam is delivered from the most distal layer
10

(highest energy) to the proximal layer (lowest energy). Similarly, the “up” direction means the
proton beam is delivered from the most proximal layer (lowest energy) to the distal layer (highest
energy).

Figure 1.11: Examples of beam delivery directions in nominal plan (1 painting) and volumetric
repainting plan (2 repaintings in an alternating order); For volumetric repainting plan, beam
delivery starts from the distal energy layer to the proximal energy layer and then follows an
alternating order.

1.4

Research Problem

The availability of a magnetic field regulation feature on the latest IBA ProteusPLUS PBS proton
centers has shown the feasibility of reducing the energy layer switching time in the “up” direction
from 6 seconds to about 1 second (28, 29). The reduction of energy layer switching time in the
“up” direction on the IBA’s ProteusPLUS proton machines can be advantageous in at least two
clinical applications: (i) volumetric repainting and (ii) proton arc therapy. There are different
approaches of re-scanning of a beam when a volumetric repainting plan is delivered on the proton
machine. The volumetric repainting in an alternating order with a reduced layer switching time
provides a new option to rescan the beam and mitigate the interplay effect in PBS protons. In a
proton arc therapy treatment plan, Engwall et al. (30) demonstrated the need of energy jumps from
high-energy to lower-energy, and vice-versa. To date, the magnetic field regulation feature from
the IBA is available for conventional IMPT only. To the best of my knowledge, the potential
application of magnetic field regulation to reduce layer switching time in the “up” direction for
proton arc therapy treatment is yet to be explored by the IBA. There is a lack of published scientific
guidelines on the implementation of such commercially available advanced technology in a
clinical setting. This thesis investigates the feasibility of applying magnetic field regulation on the
ProteusPLUS proton machine for one of the clinical applications as mentioned above. Specifically,
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this thesis work is primarily focused on investigating the feasibility of clinical implementation of
volumetric repainting technique in an alternating order to treat lung tumors in PBS proton therapy.
The thesis will answer several key questions with a focus on experimental measurements of spot
size, position, and beam range, interplay effect, proton dose calculation algorithms, spot size, and
position errors simulation, treatment plan robustness, radiobiological analysis, and dose-averaged
linear energy transfer (LETd) distributions and RBE-weighted dose.

1.5

Aims and Objectives

The aims of this thesis are to:
Aim 1: Assess the impact of magnetic field regulation in conjunction with volumetric
repainting technique on the spot positions, spot size, and beam range in PBS proton
therapy.
Research Questions:


How does magnetic field regulation impact the proton beam energy/ranges?



Is it necessary to have a new beam model based on range measurements acquired in
magnetic field regulation mode if pre-existing beam model was based on the current
regulation mode?



How does beam delivery direction (“down” vs. “up”) impact the spot size and position
errors in magnetic field regulation mode?



Should there be a change in the quality assurance (QA) protocol to accommodate the
magnetic field regulation and volumetric repainting technique?

These research questions are addressed in Chapters 3 and 4. Comprehensive experimental
measurements have been performed on an IBA ProteusPLUS machine with a PBS dedicated
nozzle. Beam ranges were acquired using a multi-layer ionization chamber. Spot sizes were
measured using a 2D Lynx scintillation detector. Spot positions were measured using 2D Lynx
and 3D XRV-124 scintillation detectors.
Aim 2: Parametrization of in-air spot size as a function of energy and air gap for the
ProteusPLUS PBS proton therapy system
Research Questions:
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What are the experimental spot size results for various combinations of air gaps and
energies for the IBA PBS proton therapy system?



What is the difference in spot size between range shifter thicknesses of 75 mm vs. 40 mm?



How to obtain the analytical beam model demonstrating the relationship of the spot size
with the proton energy at the nozzle exit and air gap for commonly used range shifters of
thicknesses of 75 mm and 40 mm?



What is the accuracy of the analytical beam model compared to the experimental
measurements?

These research questions have been answered in Chapter 5. The 2D Lynx scintillator detector was
utilized to measure in-air spot sizes on the IBA ProteusPLUS machine with a PBS dedicated
nozzle. MatLab software (Version R2019b; MathWorks, Natick, MA, USA) was used to perform
data analysis. The analytical equations presented in Chapter 5 can be useful to clinical proton
physicists for estimating the spot size of a pencil proton beam when a range shifter and various air
gaps are present in the proton beam path.
Aim 3: Investigation on volumetric repainting to mitigate interplay effect on 4D robustly
optimized lung cancer plans in PBS proton therapy
Research Questions:


How much interplay effect is present for 4D robustly optimized volumetric repainting
lung plans with beam delivery directions in an alternating order?



How to quantify the worst-case scenario (WCS) evaluation for each of the ten different
breathing phases from 4D computed tomography (4DCT)?



How to implement a method to determine the number of volumetric repaintings needed
for an acceptable PBS lung cancer treatment plan?



What should be the optimal number of volumetric repaintings with an alternating order
for PBS lung cancer plans?

These clinical research questions have been addressed in Chapter 6. RayStation TPS (version 9B)
was utilized to generate 4D robustly optimized PBS lung cancer plans. The 4DCT dataset of 10
lung cancer patients was anonymized prior to this retrospective in-silico treatment planning study.
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Aim 4: Assess the impact of proton dose calculation algorithms on the interplay effect in
stereotactic body radiation therapy (SBRT) PBS lung plans
Research Questions:


What are the impact of RayStation analytical pencil beam algorithm (APB) and Monte
Carlo (MC) algorithms on the interplay effect?



What is the combined effect of the volumetric repainting and dose calculation engines
(RayStation ABP and MC) on the interplay effect?

These questions have been answered in Chapter 7. RayStation TPS (version 9B) was utilized to
generate SBRT PBS lung plans. The 4DCT dataset of 6 lung cancer patients was anonymized prior
to this retrospective in-silico treatment planning study.
Aim 5: Asses the dosimetric and radiobiological impact of spot size on the interplay effect,
plan robustness, and normal tissue complication probability (NTCP) for volumetric
repainting lung cancer plans in intensity-modulated proton therapy
Research Questions:


What is the impact of spot size on the interplay effect in lung cancer if a proton beam is
delivered using a volumetric repainting technique in an alternating order?



What is the dosimetric impact of spot size on plan robustness for lung cancer? For plan
robustness, the setup error is combined with the range error.



How does the combination of range and setup errors affect the equivalent uniform dose
(EUD) and NTCP for the OARs in lung cancer?

These questions have been answered in Chapter 8. The 4DCT data set of thirteen lung cancer
patients was anonymized prior to conducting this study. RayStation TPS (version 9B) was utilized
to conduct this study.
Aim 6: Investigation on the effect of errors in spot positions and sizes in conjunction with
setup and range uncertainties for volumetric repainting lung cancer PBS plans
Research Questions:


What is the dosimetric impact of spot size errors of ±10%, ±15%, and ±20%?
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What is the dosimetric impact of spot size and position errors occurring simultaneously?
The simultaneous evaluation is performed by combining spot size and position errors
(spot size: ±10% and spot position: ±1 and ±2 mm)?



What are the overall effects of spot size (±10%) and position (±1 mm) errors in
conjunction with either setup (±5 mm) or range (±3.5%) errors?

These questions have been addressed in Chapter 9. In this retrospective study, PBS lung plans
were re-planned on the CT data set of five lung patients were anonymized. RayStation TPS
(version 9B) and MatLab code (version R2019b) were utilized to conduct this study.
Aim 7: Perform quantitative analysis of dose-averaged linear energy transfer (LETd)
robustness in PBS proton lung plans with volumetric repainting technique
Research Questions:


What is the combined effect of range and setup uncertainties on the LETd distribution in
the target volumes and OARs?



What is the variation in the LETd in the target volumes and OARs due to breathing
phases?



What is the combined effect of range and setup uncertainties on the RBE-weighted dose
to the OARs?



Does the breathing phase have any effect on the RBE-weighted dose values in the OARs?

These questions have been answered in Chapter 10. The data set of six lung cancer patients was
anonymized prior to conducting this study. RayStation's research version was utilized for LETd
calculations.
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Chapter 2
Literature Review
The current trend in proton therapy shows that the proton vendors are focused on advancing PBS
technology instead of passive scattering. The proton therapy community is gaining more
confidence in utilizing PBS for the treatment of different types of cancers. PBS allows the
individual placements of thousands of spots (each spot representing a Bragg peak) in the tumor
volume. Additionally, the intensity of spots in a PBS treatment plan is modulated. The potential
challenge of clinical use of PBS protons occurs in the case of mobile tumors (31, 32). Treatment
of moving lung tumor presents two dynamic systems – motion of the lung tumor and dynamic
pencil proton beams. The interference effects between tumor motion and dynamic pencil proton
beam can lead to under-dose of the tumor because of dose inhomogeneities within the tumor
volume (31). This effect is known as the “interplay effect” (31). The mitigation of interplay effect
in PBS proton therapy is critical to maintaining a higher local control, which is correlated to the
minimum dose delivered to the tumor volume (33).
Lung tumor motion management in proton therapy may include margin approach, breath-hold,
beam gating, beam tracking, abdominal compression, large spots, and repainting (31). The margin
approach is based on the 4DCT scans, which include a tumor motion in ten different breathing
phases (34). The internal target volume (ITV) is generated by expanding the clinical target volume
(CTV) such that the largest motion of the tumor is included. The breath-hold technique has been
utilized in protons (31, 34), but it requires patient cooperation as well as reproducibility of the
tumor position between each breath-hold. For patients with poor lung function, holding their breath
during beam delivery can be challenging. In beam gating treatment, the patient can breathe freely,
17

and beam on and off is triggered based on the pre-defined window of a breathing cycle (31, 34).
The gating requires either internal or external surrogates for the motion monitoring (31, 34). In
beam tracking, spatial positions of the beam are varied dynamically such that they follow the tumor
motion (31). Beam tracking is yet to be fully explored in the proton therapy community.
Abdominal compression belts can be utilized to reduce the tumor motion in proton treatment (35).
However, the use of abdominal compression devices can result in an inconsistent reduction in
motion and may have a detrimental effect on tumor motion (36, 37). Repainting (also known as
rescanning) has been proposed to mitigate the interplay effect in particle therapy. Repainting is
performed by having the energy layers of the proton beam delivered more than once to achieve
statistical averaging of motion effects (38-40). Repainting can reduce the dose heterogeneities,
which are the result of the interplay effect (38-40). Repainting is usually done using either
volumetric or layer repainting techniques.
Volumetric repainting is delivered by repetitive scanning through the whole target volume,
whereas in layered repainting, the energy layer is rescanned more than once before switching to
the next energy layer (38-40). Figure 1.11 shows the schematic of a volumetric repainting
technique. One of the advantages of delivering PBS proton beam using repainting techniques over
breath-hold and beam gating is the absence of external equipment that could require cooperation
from the patient (41). Early investigators (40, 41) have pointed out the need for a faster energy
layer switching to mitigate the interplay effect in PBS protons if a volumetric repainting technique
is applied. It was not until recently that proton manufacturers were producing PBS machines with
a faster energy layer switching mechanism, and this has generated a renewed interest in applying
volumetric repainting for PBS proton treatments. However, it must be noted that volumetric
repainting is machine-specific and will differ from one manufacturer to another (41).
The implementation of volumetric repainting technique requires a clinical validation by the user.
The current standard practice in clinical proton therapy includes a treatment plan that has a spot
map with a beam delivery sequence in “down” direction (from distal to proximal) only. The
availability of a magnetic field regulation feature (described in Chapter 3) on the latest
ProteusPLUS PBS proton machine provides an opportunity to use the volumetric repainting
technique in an alternating order (i.e., beam delivery sequences in “down” and “up” directions) to
treat moving tumors in proton therapy. On the IBA’s latest ProteusPLUS PBS proton machine,
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magnetic field regulation allows the reduction of the layer switching time in both “down” and “up”
directions. This is achieved by reducing the beam stabilization delays. Hall probes are mounted
inside specific groups of magnets in the beamline (Figure 1.10). The Hall probes allow measuring
the magnetic field in real-time. This configuration allows the application of a magnetic field
setpoint to the specific groups of magnets and eliminates the cycling of the magnets (except for
the first energy layer on the map).
Previous investigators (23, 42-49) have focused on measuring the beam range, spot size, and spot
position in the current regulation mode but not in the magnetic field regulation mode. Psoroulas et
al.(46) investigated that the incorrect magnetic field from the magnets on the gantry can result in
spot position errors. The addition of Hall probes to the bending magnets in the beamline can have
a potential impact on the placement of spots as well as beam range and spot sizes. The impact of
the magnetic field regulation in conjunction with the volumetric technique on the spot position,
size, and beam range remains to be addressed in the literature, especially for the IBA ProteusPLUS
PBS machine with a dedicated nozzle.

Figure 2.1: (a) In-air spot profiles measured at the isocenter for various energies (70 – 226.5
MeV); (b) In-air spot profiles of 100, 150, and 225 MeV at isocenter. These profiles were measured
on a ProteusPLUS system with a PBS dedicated nozzle.
Spots profiles are essential to generate a proton beam model. Figure 2.1 shows the in-air spot
profiles for various energies. In the last decade, proton vendors have worked on reducing the spot
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size on their beam delivery system. The reduction of spot size can potentially reduce the dose to
the OARs (50). However, in a clinical environment, spot sizes can be enhanced when range
shifters/pre-absorbers are used for the treatment (51-54). Gottschalk (55) has detailed the scattering
power of protons in radiation therapy. The enhancement of spot size will lead to an increase in the
lateral penumbra (51-54). Although there are already several publications (27, 45, 56-60) involving
range shifter measurements in PBS proton therapy, the analytical beam model to predict spot sizes
for various combinations of energy and air gap is lacking. Additionally, the analytical beam model
obtained for measurements using the magnetic field regulation feature on a ProteusPLUS PBS
machine is not available. The analytical equations can be useful to clinical proton physicists for
estimating the spot size of a pencil proton beam when a range shifter and various sizes of air gaps
are present in the proton beam path. It is paramount to perform a comprehensive QA of such an
advanced proton therapy technology and understand its benefits and drawbacks before the clinical
implementation. The assessment of volumetric repainting technique using patients’ CT data is also
necessary.
As described earlier in this chapter, the interplay effect between moving lung tumor and dynamic
pencil beam is a concern in proton therapy. Several researchers (38, 39, 61, 62) have studied
volumetric repainting techniques for lung cancer treatment and provided contradictory
conclusions. For example, Grassberger et al. (61) showed that layered repainting is superior or
equal to volumetric repainting. Interestingly, Seco et al. (39) showed that volumetric repainting
produced better results than layered repainting. Those studies (38, 39, 61, 62) were conducted with
beam delivery sequence in the “down” direction only, but not addressing volumetric repainting in
an alternating order. Two clinically relevant key items remain to be addressed: (i) the interplay
effect evaluation on 4D robustly optimized volumetric repainting plans in an alternating order, and
(ii) a method to determine the number of volumetric repaintings needed for an acceptable PBS
lung cancer treatment plan.
Currently, the interplay effect evaluation in RayStation TPS is available through the scripting
environment only. RayStation is considered as one of the most advanced treatment planning
software in proton therapy. In addition to providing an excellent scripting environment in its
platform, it allows optimizing proton plans with the Monte Carlo algorithm as well as final dose
calculations with the Monte Carlo algorithm. RayStation Monte Carlo and analytical pencil beam
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(APB) algorithms are described in Chapter 7. Since both Monte Carlo and APB algorithms are
available for clinical use, this leads to the question – which algorithm needs to be used if we
generate volumetric repainting lung plans in alternating order to mitigate the interplay effect?
Investigations by several researchers (57, 62-67) have shown that RayStation MC is more accurate
than APB when range shifter and inhomogeneities are encountered in the proton beam path.
However, Teoh et al. (68) found that the RayStation APB algorithm may be acceptable when PBS
lung cancer plans involve the mediastinum and range shifters are absent in the proton beam path.
However, the combined effect of RayStation dose calculation algorithms (Monte Carlo and APB)
and interplay effect in SBRT lung treatment plans remains to be investigated.
The proton therapy community continues to pursue research in motion management very actively.
It has been suggested that the PBS machine with a large spot size is better in mitigating the
interplay effect in lung cancer when compared to a small spot size PBS machine (69). In contrast,
a different research group (70) reported that small spot and large spot machines produced
comparable interplay effect in lung cancer patients. New proton therapy centers are equipped with
small spot sizes. Proton therapy vendors may also provide an additional option for a large spot size
on the same machine. There is no published literature making a case to commission both small
spot and large spot beam models for the same proton machine. There is also lack of data showing
how the size of the spot in conjunction with a volumetric repainting (with an alternating order)
technique can impact the interplay effect and improve plan robustness in terms of range uncertainty
and setup errors.
In PBS proton therapy, the beam is delivered on the machine based on the spot map. The accuracy
of spot size and position is essential to reduce the discrepancies between the computed and
delivered doses. Additionally, it has been reported that the variations in spot sizes and positions
on the machine could lead to perturbation of dose distributions impacting the quality of the
treatment plan delivered to the patient (71-77). Several investigators (44, 71-78) have reported the
impact of variations in spot size and position in the phantoms and disease sites but not for the lung.
Additionally, none of the previous studies (44, 71-78) have studied the impact of the errors in spot
sizes and positions simultaneously. Therefore, it is essential to study the effects of errors in spot
sizes and positions on robustly optimized PBS lung cancer plans.

21

The current clinical practice in proton therapy uses a constant relative biological effectiveness
(RBE) of 1.1 (79). The RBE is defined as (equation 2.1) “the ratio of doses to reach the same level
of clinical endpoints by a radiation modality (e.g., proton therapy), as compared to reference
modality (e.g., Co-60 photon or 250 kVp X-ray) (79).”
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(Eq. 2.1)

Studies have shown that the RBE of the proton is not constant (79). Instead, it varies depending
on various parameters such as dose, radiosensitivity of the tissues (α/β), oxygenation, cell type,
clinical or biological endpoint, treatment technique, and linear energy transfer (LET) (79). If the
RBE is greater than 1.1 around high LET locations, such as in the distal end of Bragg peak, but
the clinical plan uses the constant RBE of 1.1, this may lead to an increase of toxicities in the
nearby critical structures (80). Figure 2.2 illustrates an increase in RBE-weighted dose with depth.

Figure 2.2: An increasing RBE with depth cause an extended biologically effective range (1-2
mm); Source: Harald Paganetti; Biological Uncertainties in Proton (Ion) Therapy;
https://www.aapm.org/meetings/09prs/documents/Paganetti.pdf
One way of predicting the increase in the proton RBE is to quantify the dose-averaged LET (LETd)
for therapeutic proton energies. Figure 2.3 shows the line profiles displaying dose (physical dose
× RBE of 1.1) and LETd in an example patient. In LETd calculations (equation 2.2), “the electronic
stopping power of each individual particle is weighted over its contribution to the local deposited
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dose (81).” In proton therapy, LETd varies from 1 to 15 keV/µm from the entrance to the distal
part of the SOBP depending on passive or PBS mode delivery and a particular plan. (81, 82).
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where, Li = total electronic stopping power and εi = energy loss of particle i in a small volume.

Figure 2.3: Profiles displaying the dose (black color) and LETd (blue color) in an example patient.
The line profiles were drawn along the central axis of the beam through the isocenter, which was
placed at the center of the CTV. In this figure, the dose is the product of the physical dose and the
RBE of 1.1. Adapted from Chapter 10 (journal article under review)
Several RBE models have been proposed in proton therapy (83). Kalholm et al. (84) provided a
systematic review of the usage of LETd in particle therapy. Some of the RBE models are based on
the linear-quadratic model and fitted to pre-clinical data (84-88). Although available RBE models
could yield different results, these models demonstrated an increase in RBE with LET increasing
(89). Investigators (86, 89-91) have identified a linear association between RBE and LETd at
clinically relevant LETd values. Another important finding from these RBE models is an increase
in the biological dose at the distal end of the SOBP due to an increase in LETd (85), thus potentially
increasing the tissue toxicities beyond the target area in-high dose regions (92). The variable proton
RBE can potentially affect the clinical outcome of proton therapy patients (93). The evaluation of
consequence of the RBE-weighted biological dose is yet to implemented in the routine clinical
practice.
From a clinical perspective, the correlation between LETd and biologically effective dose has been
demonstrated by showing increased radiation-induced brain toxicity with high LETd in the high23

dose regions in glioma patients (94, 95). In most situations, the highest LETd is associated with
low physical doses at the very distal part of the SOBP (94, 95). Nevertheless, increasing LETd
leads to propagation of higher RBE-weighted dose in-depth in comparison with physical dose
multiplied by 1.1, which should be considered when an OAR is in close proximity to the target
volume (94, 95).
McMahon et al. (91) showed that the LET-weighted dose metric (Physical Dose × (1 + cLETd))
could be used to reduce the “biological variability resulting from changing RBE in proton therapy.”
The constant ‘c’ is a cell line-related parameter which is approximately 0.04 for most cell lines.
The authors (91) also noted that the use of such metrics could help in identifying the areas with
elevated biological effects due to high LET. The LET-weighted dose, as mentioned above, is
defined as D + (D × cLETd), where D is the physical dose, and c is the empirical fitting parameter
with units of µm/keV (91, 96). In this thesis, we utilized the research version of RayStation proton
treatment planning system which incorporates the fitting parameters from Unkelbach et al. (96).
The RBE-weighted biological dose evaluation can be extended to identify the unintended high
biological doses in critical structures as a result treatment uncertainties such as range and setup
errors.
PBS proton therapy is sensitive to treatment uncertainties (e.g., range and setup errors). Several
studies have quantified the dosimetric impact of range and setup errors for various disease sites in
PBS proton therapy (97-100). The range and setup uncertainties can have a negative impact on the
quality of the delivered PBS treatment plan. Hahn et al. (101) investigated the impact of range
uncertainty on the LETd distributions on the brain, head and neck, and prostate plans. Other
investigators (102-109) have quantified the LETd values in the target volumes of nominal plans
for the head and neck, liver, prostate, and brain cancers. Shang et al. (110) investigated the impact
of multiple beams on the LETd distributions in lung plans. However, the impact of treatment
uncertainties on the LETd distributions in lung plans was not considered (110). Due to large density
variations between air and lung tissue, range and setup uncertainties may further degrade the
quality of the delivered lung plan. Also, the impact of different breathing phases on the LETd
distributions was not quantified (110). Proton treatment delivery can start in any breathing phase
when treating a moving lung tumor. The quantitative assessment of the impact of the breathing
phase and range and setup uncertainties will provide guidance for LET evaluation in the clinic.
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Chapter 3
Impact of magnetic field regulation in conjunction
with the volumetric repainting technique on the spot
positions and beam range in pencil beam scanning
proton therapy
This chapter has been published in the Journal of Applied Clinical Medical Physics:
Rana S, Bennouna J, Gutierrez AN, Rosenfeld AB. Impact of magnetic field regulation in
conjunction with the volumetric repainting technique on the spot positions and beam range in
pencil beam scanning proton therapy. Journal of Applied Clinical Medical Physics.
2020;21(11):124-131.

3.1

Introduction

Pencil beam scanning (PBS) delivery technique has become a preferred method relative to passive
scattering methods in proton therapy (111, 112). PBS technique delivers a single pristine beam at
a time. Several studies have pointed out the interplay effect between mobile tumor and the delivery
of pencil proton beam therapy (31, 38, 39, 113, 114) and carbon ion therapy (115-117). A
volumetric repainting technique has been proposed as one of the motion management techniques
to mitigate the interplay in PBS proton therapy (38, 40, 46, 117). Volumetric repainting implies
repetitive scanning through the whole target volume (40, 118). During volumetric repainting,
repeated scans are delivered in depth, not in the plane transverse to the beam (40, 118). The beam
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delivery sequence for volumetric repainting can take several approaches. For example, the whole
target volume is irradiated by delivering the proton beam either from the deepest layer to the most
proximal layer (“down” direction) or from the most proximal layer to the deepest layer (“up”
direction), or a combination of both. The repeated scans of the entire volume allow the delivery of
planned dose to the tumor volume repeatedly, thus providing the statistical averaging of dose
heterogeneity (119).
The volumetric repainting technique can be an attractive option to mitigate the interplay effect,
mainly because it is independent of any external hardware that may require cooperation from the
patient (113). Zhang et al. (113) highlighted the fact that the performance of repainting technique
is highly machine-specific, since spot positions, dose rate, energy switching time, etc. can have an
impact on the delivered dose distributions and interplay effect. As pointed out by Zenklusen et
al.(40), the repainting technique requires a fast energy switching time. Volumetric repainting can
be delivered by repetitive scans in depth with beam delivery sequence in “down” direction only.
In this case, for multiple repainting, it will require the beamline to switch from the lowest energy
to the highest energy of the treatment plan. Big energy jumps in the treatment plan can lead to spot
position errors as demonstrated by Pedroni et al.(120). Specifically, Pedroni et al.(120) observed
beam positioning displacements of 1 to 3 mm with big energy steps (of the order of the full energy
range). An alternative way of delivering the volumetric plan would be to set the beam delivery
sequence in “down” direction followed by “up” direction. This would eliminate the need of
switching the beamline from the lowest energy to the highest energy of the treatment plan. Instead,
after completing the beam delivery in “down” direction, smaller energy steps can be used for the
“up” direction. This requires a strategy to regulate the current to various magnets in the beamline
while overcoming the hysteresis of the magnets.
At Miami Cancer Institute, PBS proton therapy is delivered using a ProteusPLUS proton therapy
system with a PBS dedicated nozzle (Ion Beam Applications, Louvain-la-Neuve, Belgium). The
clinical commissioning of our proton system was based on the beam delivery sequence such that
irradiation begins from the deepest layer to the most proximal layer. In this case (“down”
direction), beam optics was performed with all the magnets in the beamline regulated in the current
(CR) mode. Furthermore, the layer switching time for the “down” direction is about 1 second, but
it can be up to 6 seconds for the “up” direction when operated in CR mode. Hence, due to slower
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layer switching time for the “up” direction in CR mode, the total beam-on time will increase if the
user wants to deliver a volumetric repainting treatment plan that includes the beam delivery
sequences in both the “down” and “up” directions.
Recently, our proton therapy vendor has come up with a magnetic field regulation (FR) – a feature
to reduce the layer switching time by introducing the Hall probes, which allow measuring the
magnetic field in real-time. Specifically, Hall probes are mounted inside specific groups of
magnets in the beamline (Figure 3.1). By applying a magnetic field setpoint (instead of a current
setpoint) to the specific groups of magnets, there is no requirement of cycling the magnets, except
for the first layer of the map, thus reducing the beam stabilization delays and layer switching time
in both the “down” and “up” directions. This has decreased the layer switching time for the “up”
direction from about 6 seconds in CR mode to about 1.2 – 1.3 seconds in FR mode. The
experimental measurements using FR mode is yet to be performed.
There are different approaches of beam re-scanning when volumetric repainting plan is delivered
on the proton machine. The volumetric repainting in an alternating order with a reduced layer
switching time provides a new option to rescan the beam and mitigate the interplay effect in PBS
protons. The decreased layer switching time in the “up” direction is an important step towards the
clinical implementation of the volumetric repainting with an alternating order on the IBA’s latest
ProteusPLUS PBS proton machine.

Figure 3.1: Hall probes mounted inside the 30⁰ bending magnet (B2E) of the energy selection
system (ESS) and bending magnets (B1Gx at 45⁰ and B2Gx at 135⁰) of the gantry.
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The proton beam model in our treatment planning system (TPS) is based on the measurements
performed in CR instead of FR. In FR mode, all range steps use magnetic field setpoints, which
are then linked to the current setpoints by a look up table. Furthermore, FR mode has a Hall probe
in the energy selection system (ESS). This brings up the questions – does FR impact the proton
beam energy/ranges? Is it necessary to have a new beam model based on range measurements
acquired in FR mode? Another critical parameter that could be impacted due to use of FR is the
spot position. Psoroulas et al.(46) investigated that the incorrect magnetic field from the magnets
on the gantry can result in spot position errors. The work of Psoroulas et al.(46) was primarily
focused on the CR mode in PSI gantry 2. The addition of Hall probes to the bending magnets in
the gantry beam line to measure the magnetic field in real-time further increases the uncertainty of
the spot position errors. If the spots are not delivered at their intended locations during the patient
treatment, it will affect the quality of the treatment delivery. Since FR is now available for the
clinical use, it is not clear how does the beam delivery direction (“down” vs. “up”) impact the spot
position and range in FR mode. Additionally, there is no published literature that provides the
guidance on if the quality assurance (QA) protocol needs to accommodate the FR and volumetric
repainting technique. To the best of our knowledge, these critical questions have not been
answered in the literature by providing the experimental data.
In the current study, the authors sought to investigate how the combination of FR and volumetric
repainting technique impacts the spot positions and range on the PBS beam delivery system. The
authors believe that the methodology/technique and results presented herein will serve as the
reference for the clinical physicists who are looking to implement FR and volumetric repainting at
their proton centers.

3.2

Materials and Methods

For our proton therapy system, the clinically available energies range from 70 MeV to 226.5 MeV.
Readers are recommended to refer to the published literature (26, 121) for more information on
the ProteusPLUS PBS beam delivery system. Figure 3.1 shows the beam delivery design in FR,
which includes a Hall Probe positioned at the entrance/exit of one magnet of the B1234E
quadruplet, B1Gx, and B2Gx. B1234E are four 30° bending magnets connected in series. Those
are part of the energy selection system (ESS) and contribute to the selection of the correct beam
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energy. The B1Gx is the bending magnet of the gantry (45°) and the B2Gx is the last bending
magnet of the gantry (135°).
3.2.1

Range Measurements

Range measurements were performed using Giraffe (IBA Dosimetry, Schwarzenbruck, Germany)
– a commercial multilayer ionization chamber array. A Giraffe can be used to measure the
longitudinal depth-dose distribution of central-axis pencil beams. It consists of 180 independent
air-vented, plane-parallel ionization chambers with a radius of 6.0 cm. More details on Giraffe can
be found in the publication by Vai et al. (122). For range measurements in FR mode, a spot map
was generated representing “down” direction followed by “up” direction. Specifically, “down”
direction consisted of 32 layers for energies ranging from 225 MeV to 70 MeV at decrements of 5
MeV, whereas the “up” direction consisted of the same number of layers, but the energies ranged
from 70 MeV to 225 MeV at increments of 5 MeV. For a comparative purpose, a separate spot
map for the “down” direction in CR mode was generated. It included 32 layers for energies ranging
from 225 MeV to 70 MeV at decrements of 5 MeV. For both the FR and CR modes, each layer
consisted of a single spot at the isocenter. Proton beam was delivered without pausing in between
the layers. All measurements were carried out in a movie mode using OmniPro Incline software
(IBA Dosimetry, Schwarzenbruck, Germany).
3.2.2

Off-Axis Spot Position Measurements

Off-axis spot positions measurements were done utilizing the Lynx 2D (IBA Dosimetry,
Schwarzenbruck, Germany) – a gadolinium-based scintillation detector (resolution = 0.5 mm;
active surface area = 300 mm × 300 mm).(123) The Lynx detector was placed at the isocentric
plane using the Lynx holder such that the beam is perpendicular to the detector. Three spot maps
representing high-, medium, and low-energies (Table 3.1) were generated. Specifically, the first
layer of each map included 226.5 MeV at the iscoenter for the reference purpose, whereas the
delivery sequence of remaining 36 layers is shown in Figure 3.2 such that the energy of the spot is
in decreasing order from row 1 (R1) to row 6 (R6). For a given row, the energy of all six spots
remained the same. All three maps were delivered at eight gantry angles (0⁰, 45⁰, 90⁰, 135⁰, 180⁰,
225⁰, 270⁰, and 315⁰) for three groups of energies, as listed in Table 3.1. Data acquisition was made
in a movie mode utilizing myQA software (IBA Dosimetry, Schwarzenbruck, Germany).
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Table 3.1: A spot map shown in Figure 3.2 is delivered for three groups of energies: high, medium,
and low. A spot of 226.5 MeV at the isocenter (0,0) is used as the reference spot.
High

Energy Medium Energy Low Energy

(MeV) Group

(MeV) Group

(MeV) Group

Row 1
Row 2
Row 3
Row 4
Row 5
Row 6

Row 1
Row 2
Row 3
Row 4
Row 5
Row 6

Row 1
Row 2
Row 3
Row 4
Row 5
Row 6

225
220
215
210
205
200

160
155
150
145
140
135

95
90
85
80
75
70

Figure 3.2: (left) An example of spot map representing beam delivery sequences in “down” and
“up” directions; (right) Measured 2D DICOM image of the spot map.
3.2.3

Central-Axis Spot Position Measurements

Central-axis spot position measurements were done at gantry angle 0° using XRV-124 (Logos
Systems Int'l, Scotts Valley, CA) – a cone-shaped scintillator detector. The resolution of the CCD
camera using BeamWorksPlus software (Logos Systems Int'l, Scotts Valley, CA) is 1280 x 960
pixels, whereas the BeamWorksPlus software runs at 640 x 480 pixels (binned from 1280 x 960
pixels). The cone has a 140 mm long field of view over 360°, whereas width of the cone varies
from 30 mm to 60 mm. (124, 125) Details on the XRV-124 can be found in previous publications
(124, 125).
For FR measurements, a spot map was generated for the energies ranging from 225 MeV to 70
MeV (“down” direction) followed by 70 MeV to 225 MeV (“up” direction). Each energy layer
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consisted of a single spot at the isocenter (0, 0), and the energy spacing was 2.5 MeV. For a
comparative purpose (FR vs. CR), a similar spot map was generated but for beam delivery
sequence in the “down” direction for the energies ranging from 225 MeV to 70 MeV at the
decrements of 2.5 MeV. Prior to beam delivery, the XRV-124 detector was aligned to the imaging
isocenter by following the procedure described in the literature (124, 125). Data acquisition was
made in a movie mode using BeamWorksPlus software. The beam was delivered without pausing
between the layers. The software provides the centricity of the spot in lateral, longitudinal, and
vertical directions (124, 125).
Additionally, the beam delivery log files were retrieved to analyze the spot positions at the entrance
and exit of the nozzle. Specifically, the first ionization chamber (IC1) provided the X and Y
positions at the nozzle entrance, whereas the second ionization chamber (IC2) and third ionization
chamber (IC3) provided the Y and X positions, respectively, at the nozzle exit.

3.3

Results

3.3.1

Measurements in FR Mode

3.3.1.1

Range Measurements

Figure 3.3(a) illustrates the difference in range between the “up” and “down” directions in FR
mode. In the current study, the range is defined as the R90 (measured as the penetration depth of
the proton beam at 90% point of the normalized percent depth dose (PDD)). The average difference
in R90 for given energy between “up” and “down” directions was 0.0±0.1 mm.
3.3.1.2

Central-Axis Spot Position Measurements

Figure 3.3(b) shows the difference in the position of the central-axis spots that were delivered to
the XRV-124 scintillation detector at the isocenter. In both the “up” and “down” directions, the
positions of the delivered spots (n=126) were within ±0.5 mm. The spot position evaluation
between “up” and “down” directions for given energy also showed the minimal difference (within
±0.25 mm).
Figure 3.3(c) and Figure 3.3(d) show the IC1, IC2, and IC3 results, which were retrieved from the
log files of the central axis spot position measurements (XRV-124) as described in section 2.3. At
the nozzle entrance, the average difference in X and Y positions for given energy between “up”
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and “down” directions was 0.02±0.21 mm (range, -0.57 – 0.53 mm) and -0.03±0.36 mm (range, 0.84 – 0.88 mm), respectively. At the nozzle exit, the average difference in X and Y positions for
given energy between “up” and “down” directions was -0.01±0.14 mm (range, -0.35 – 0.32 mm)
and -0.07±0.08 mm (range, -0.27 – 0.12 mm), respectively.

Figure 3.3: The difference in range and spot positions between the “down” (i.e., distal to
proximal) and “up” (proximal to distal) directions for various energies in magnetic field
regulation mode.
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Figure 3.4: Spot position (X and Y) differences for a spot map shown in Figure 3.2 at the gantry
angles 0°, 45°, 90°, 135°, 180°, 225°, 270°, and 315°. The spot map was delivered for high-,
medium, and low-energies as shown in Table 3.1. In the x-axis of each group of energy, the
columns from left to right represent the respective columns of spot map displayed in Figure 3.2.

33

3.3.1.3

Off-Axis Spot Position Measurements

Figure 3.4 show the difference in positions of various off-axis spots that are delivered in a 2D
plane (Lynx detector) using the spot map as shown in Figure 3.2. The spot at the isocenter was
used as the reference spot. The spot maps were delivered for high-, medium, and low-energies
(Table 3.1) at eight different gantry angles. A total of 864 off-axis spots were evaluated to
investigate how close these spots can be delivered from their intended locations. The difference in
off-axis spot positions ranged from -0.7 mm – 1.1 mm for gantry 0⁰, -0.9 mm – 0.8 mm for gantry
45⁰, -1.0 mm – 1.1 mm for gantry 90⁰, -1.1 mm – 0.7 mm for gantry 135⁰, -1.2 mm – 1.1 mm for
gantry 180⁰, -1.2 mm – 0.7 mm for gantry 225⁰, -0.6 mm – 1.1 mm for gantry 270⁰, and -0.9 mm
– 0.7 mm for gantry 315⁰. Overall, the off-axis spot position results demonstrated that 97.9%
(846/864) of the spots were within ±1 mm, and all off-axis spot positions were within ±1.2 mm.
Additionally, the evaluation among three different energy groups showed that several spots in the
low- and medium energy groups had position differences outside ±1 mm.
3.3.2

FR mode vs. CR Mode (“down” direction only)

The comparison between FR and CR modes showed the range difference within ±0.2 mm. The
comparison between FR and CR modes showed the selection of either FR or CR had very minimal
impact on the spot position. The difference in spot positions ranged from -0.1 mm to 0.1 mm in
both the X- and Y-directions.

3.4

Discussion

In the current study, the authors investigated the impact of the FR and volumetric repainting
technique on the spot positions and range of proton pencil beams. In our proton therapy system,
each magnet has a current setpoint that is linked to the proton beam range through set range tables.
However, it is possible to have more than one magnetic field value for a given current setpoint
because of the hysteresis of the electromagnets. Hence, for the “down” direction, all magnets are
cycled during the set range of the first layer of the delivery map such that the magnetic field is
always the same for given proton energy. It is not required to cycle the magnets for the subsequent
layers in the “down” direction. However, for the “up” direction in our present site configuration,
it is required to cycle the magnets at each set range to ensure the correct magnetic field. The need
of cycling the magnets at each set range increases the layer switching time by several seconds in
34

the “up” direction. The placement of Hall probes in the magnets (one in ESS and other two in the
gantry beamline) removes the requirement of cycling of the magnets at each set range in the “up”
direction, thus reducing layer switching time.
The FR implemented within the IBA ProteusPLUS delivery system allows faster layer switching
both in the “down” and “up” directions. The use of FR in the clinical environment is promising,
but our proton therapy vendor has made it available after the proton beam model was
commissioned. Specifically, beam optics and commissioning have been performed based on the
CR mode. Recommissioning the entire proton beam model using FR mode would take a significant
amount of time and resources to complete this task. After discussions with the vendor, it was
determined that FR mode could potentially affect the proton range and spot positions.
The experimental data presented in the current study demonstrated that the FR resulted in
acceptable differences in spot position and range when compared to the CR. The range differences
between FR and CR modes were found to be within ±0.2 mm, which is smaller than the range
tolerance of ±1 mm recommended by AAPM TG224 (126). Furthermore, the selection of beam
delivery direction (“down” vs. “up”) had very minimal impact on the ranges. Hence, if the proton
beam model has beam ranges acquired in CR mode, it may not be necessary to obtain new ranges
in FR mode for the beam model.
The results from the central axis spot position measurements showed a trend similar to that of the
range measurements. The comparison between FR vs. CR showed that the positions of the spots
are almost identical (±0.1 mm) whether spots are delivered either in FR or CR modes. For a spot
map (“down” and “up” directions in FR mode), the position of the central-axis spots at given
energy differed by up to 0.25 mm (Figure 3.3). This difference is small compared to the spot
position tolerance (±1 mm) recommended by TG224 (126). However, the off-axis spot
measurements (Figure 3.4) showed a larger difference (up to ±1.2 mm) in the spot positions than
the central-axis spot measurements.
As FR is becoming available for the existing and new proton centers, the QA involving FR is not
well established yet. Hall probes used in FR may suffer from the variation in temperature, noise,
and aging of the detector. (46) This may result in inaccurate beam delivery due to drift in the range
and positions of the spots. Thus, if the FR is implemented clinically, the inclusion of volumetric
repainting technique for the routine range and spot positions QA could provide more realistic
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scenario resembling clinical volumetric repainting beam delivery. It is recommended to use the
energy steps of 5 MeV or less to represent the clinical plan.
In this study, the authors did not address the delivery of volumetric repainting maps utilizing
patient treatment plans to the detector. This is a limitation of our work. We primarily focused on
delivering fields containing several layers, and each layer included a single spot. However, in a
real clinical scenario, tumor volume will consist of many spots in each layer depending on the spot
spacing and spot width. Currently, we are working with our TPS vendor to design volumetric
repainting patient treatment plans. As part of the volumetric repainting project, our next work will
include a phantom study that will mimic the tumor motion and quantify the number of volumetric
repainting needed to reduce any interplay effect. Despite this limitation, the authors believe that
the experimental results from the current study may be useful to the users who are looking to
implement FR and volumetric repainting at their proton center. Additionally, the study design and
measurement techniques presented in this paper can serve as examples for the experimental
validation of a volumetric repainting project.

3.5

Conclusion

The combination of FR and volumetric repainting technique resulted in clinically acceptable
differences in the spot positions and range for our beam delivery system. The range differences
passed within ±1 mm (TG224). For the spot positions (TG224: ±1 mm), all central axis
measurements passed within ±1 mm, whereas for the off-axis measurements, 97.9% (846/864) of
the spots met the passing criteria of ±1 mm, and all spots were within ±1.2 mm.
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Chapter 4
Evaluation of spot size using volumetric repainting
technique on a ProteusPLUS PBS Proton Therapy
System
This chapter has been published in the Journal of Physics Conference Series:
Rana S, Bennouna J, Gutierrez AN, Rosenfeld AB. Evaluation of spot size using volumetric
repainting technique on a ProteusPLUS PBS Proton Therapy System. Journal of Physics
Conference Series. 2020;1662:012027.

4.1

Introduction

In recent years, pencil beam scanning (PBS) is becoming a preferred technique in proton therapy
in comparison to the passive scattering techniques such as double-scattering and uniform scanning.
One of the key dosimetric differences between these two techniques is that PBS produces more
conformal dose distributions compared to the passive scatting technique (127). PBS technique
allows the dose deposition in the volume by delivering a single pristine pencil beam such that its
properties – spot shape, spot position, range, and intensity – can be varied. Since PBS technique
irradiates one position at a time, this possesses challenges in treating mobile tumors due to the
interplay effect (40). Several motion management techniques such as breath-hold (128), gating
(129), tracking (31), layer repainting(40), and volumetric repainting (40, 46) are mentioned in
proton therapy.
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For repainting techniques, the time to switch energy layers becomes critically important. Although
volumetric repainting for motion mitigation was quite well known in the proton therapy
community, the clinical application of the volumetric repainting technique is very limited. The
volumetric repainting implies repetitive scanning through the whole target volume (40, 46). One
of the volumetric repainting strategies can be such that the irradiation begins from the distal to the
most proximal layer (Dist-Prox or “down” direction) followed by irradiation from the most
proximal to the distal layer (Prox-Dist or “up” direction). This strategy necessitates the fast layer
switching in both the “down” and “up” directions.
At Miami Cancer Institute, we use a ProteuPLUS proton therapy system with a PBS dedicated
nozzle (Ion Beam Applications, Louvain-la-Neuve, Belgium). For our current clinical treatment
delivery, different types of magnets are employed in order to transport the proton beam from the
cyclotron to the treatment room. The clinical commissioning of our system was done for the beam
delivery in the “down” direction only with a site configuration that has all magnets being regulated
in the current (CR). Recently, IBA has implemented a “field regulation” (FR) – a new feature to
reduce the switching time between layers in order to decrease the total delivery time. In FR mode,
the layer switching is accomplished by applying a magnetic field setpoint (instead of a current
setpoint) to three specific groups of magnets (B1234E, B1Gx, and B2Gx) in the beamline. The
B1234E are four 30° bending magnets connected in series, whereas B1Gx is the first bending
magnet of the gantry (45°) and B2Gx is the last bending magnet of the gantry (135°). The
quadrupoles, on the other hand, are non-field regulated magnets. The fluctuations of current to the
quadrupoles and variations in the magnetic field in B1234E, B1Gx, and B2Gx during “down” and
“up” directions can potentially change the spot size of a given energy, thus adding to the beam
delivery uncertainty that can affect the quality of the delivered volumetric repainting plan.
One of the primary dosimetric components of the PBS proton beam model within RayStation
(RaySearch Laboratories, Stockholm, Sweden) treatment planning system is in-air spot size
(hereafter referred as spot size). Since our clinical treatment and beam model are based on the CR,
we investigated the impact of FR before its clinical use. In this study, we focused on the spot size
and sought to understand how the combination of FR and volumetric repainting technique affects
the spot sizes of various energies on a ProtusPLUS proton therapy system with a PBS dedicated
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nozzle. The difference in spot sizes measured in CR and FR modes is expected to be minimal, and
this hypothesis needs to be validated in a clinical environment.

4.2

Materials and Methods

The energies produced by the cyclotron at our proton center ranges from 70 MeV to 226.5 MeV.
For more details on the ProteusPLUS beam delivery system, readers are advised to refer to
publications by Rana et al.(26) and Lin et al. (121). For spot profile measurements, we utilized the
Lynx 2D (IBA Dosimetry, Schwarzenbruck, Germany) – a gadolinium-based scintillation detector
that has active surface area of 300 mm × 300 mm and a resolution of 0.5 mm. (123) For our
experimental setup, the Lynx detector was setup at the isocenteric plane such that the gantry angle
is 90⁰ and the beam is perpendicular to the Lynx.
Spot size measurements included three groups of energies (Groups A, B, and C) as illustrated in
Figure 4.1. Group A included a spot map consisting of a total of 33 layers with a delivery sequence
of energies starting from 226.5 MeV to 70 MeV (“down”). Group B included a spot map of 34
layers with a beam delivery sequence of energies starting from 226.5 MeV to 150 MeV (“down”)
followed by 150 MeV to 226.5 MeV (“Up”). Group C included a spot map of 32 layers with beam
delivery sequence of energies starting from 145 MeV to 70 MeV (“down”) followed by 70 MeV
to 145 MeV (“Up”). For all three groups, each layer consisted of a single spot.
Figure 4.2 shows the x and y coordinates of five measurement locations: isocenter (0, 0) and four
off-axis points: top-left (TL; -10 cm, 10 cm), top-right (TR; 10 cm, 10 cm), bottom-left (BL; -10
cm, -10 cm), and bottom-right (BR; 10 cm, -10 cm). For each of these measurement locations, 2
different spot maps were generated for beam delivery sequences, as provided in Figure 4.1. For
example, the TL point has two spot maps – one for Group B and one for Group C (figure 4.1), and
the X and Y positions of a spot in both the groups for TL are -10 cm and 10 cm, respectively, with
respect to the isocenter (0, 0). For measurement at the isocenter, an additional spot map with the
beam delivery sequence of Group A was generated. In order to mimic a real clinical treatment
delivery scenario, spot maps were delivered in continuous mode (i.e., without pausing the beam
after delivering each layer). For spot profile data acquisition, the Lynx plug-in within myQA
software (IBA Dosimetry, Schwarzenbruck, Germany) was operated in a movie mode. The Lynx
plug-in was used to calculate the spot sizes (one sigma).
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Figure 4.1: (left) Group A – spot map consisting a total of 33 layers with a delivery sequence of
energies starting from 226.5 MeV to 70 MeV (layers 1-33: “down” direction); (middle) Group B
– spot map consisting a total of 34 layers with a delivery sequence of energies starting from 226.5
MeV to 150 MeV (layers 1-17: “down” direction) followed by 150 MeV to 226.5 MeV (layers 1834: “up” direction); (right) Group C – spot map consisting a total of 32 layers with a delivery
sequence of energies starting from 145 MeV to 70 MeV (layers 1-16: “down” direction) followed
by 70 MeV to 145 MeV (layers 17-32: “up” direction)

Figure 4.2: Spot locations at the isocenter (0, 0) and four off-axis points: top-left (TL; -10 cm, 10
cm), top-right (TR; 10 cm, 10 cm), bottom-left (BL; -10 cm, -10 cm), and bottom-right (BR; 10 cm,
-10 cm).

4.3

Results
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Figure 4.3(a) illustrates the spot sizes for energies of Group A (“down” direction only). The
average difference in spot sizes between CR and FR in “down” direction was less than 0.5% with
a mean absolute deviation of 0.3%. Figures 4.3(b) and 4.3(c) show the spot sizes for Groups B and
C energies, respectively, at five different measurement locations (Iso, TL, TR, BR, and BL) using
FR mode. The difference in spot size between two delivery sequences (“down” vs. “up” directions)
in FR mode for given energy at all five locations was within ±2.0% (Figure 4.4).

Figure 4.3: (left panel) Spot size measurements (Group A) at the isocenter in “down” direction
using current regulation and field regulation; (middle panel) spot sizes for Group B at five
different measurement locations (Iso, TL, TR, BR, and BL) using field regulation; (right panel)
spot sizes for Group C at five different measurement locations (Iso, TL, TR, BR, and BL) using
field regulation.

Figure 4.4: The difference in spot sizes between “up” and “down” directions at five different
measurement locations (Iso, TL, TR, BR, and BL) using field regulation (FR). The difference was
calculated by subtracting the spot size of given energy during “up” direction from the spot size of
the same energy during “down” direction. Error bars represent the range within 1.5 times
interquartile range (IQR). Mean and Median are represented by square and solid line,
respectively. The outlier is shown by a triangle.
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Figure 4.5: Combined results of Group B and Group C at all five points (Iso, BL, BR, TL, and TR)
showing the difference in spot size between “up” vs. “down” directions.

4.4

Discussion

In this study, we investigated variations in spot size as a result of FR feature on a ProteusPLUS
proton system with a PBS dedicated nozzle. For “down” direction of Group A energies, we noticed
a very minimal deviation (within ±0.5%) in spot sizes at the isocenter when comparing FR against
the CR. For Groups B and C, which included the combination of FR and volumetric repainting
(i.e., “down” direction followed by “up” direction), the difference in spot size between “up” and
“down” directions was within ±2%, which is less than spot size tolerance of ±10% recommended
by the AAPM TG224. (126)This was true for measurement locations at the isocenter as well as
four off-axis points (BL, BR, TL, and TR). Further analysis of Group B and Group C results
combined together yielded the average difference of 0.6±0.5% with 3 sigma of ±1.6%. (Figure
4.5). These results indicate that the combination of FR and volumetric repainting has a very
minimal impact on the spot size.
The current study was focused on determining the impact of FR on the spot size. Other two
fundamental dosimetric parameters spot position and range were not investigated in this study.
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This is the limitation of our work. The beam delivery design in FR includes a Hall Probe positioned
at the entrance/exit of the B1Gx, B2Gx, and one magnet of the B1234E quadruplet. This allows
the measurement of the magnetic field of the above-mentioned magnets in real-time. The
fluctuations in the magnetic field detected by Hall probes can potentially cause the displacement
of positions of the spots and range. The future should investigate how does the combination of FR
and volumetric repainting impact the spot position, range, dose output, and patient-specific quality
assurance results.

4.5

Conclusion

The impact of FR on the spot size was very minimal (±2.0%) and this was true for both the
volumetric and non-volumetric techniques on the ProteusPLUS proton system with a PBS
dedicated nozzle.
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Chapter 5
Parametrization of in-air spot size as a function of
energy and air gap for the ProteusPLUS pencil beam
scanning proton therapy system
The chapter has been published in the Radiological Physics and Technology:
Rana S, Rosenfeld AB. Parametrization of in-air spot size as a function of energy and air gap for
the ProteusPLUS pencil beam scanning proton therapy system. Radiological Physics and
Technology. 2020;13(4):392-397.

5.1

Introduction

Pencil beam scanning (PBS) proton therapy is gaining broader attention in the radiotherapy
community. Advancements in proton therapy technology have continued to grow over the last
decade (130). One such improvement is the reduction of the in-air spot size (hereafter referred to
as the spot size) of a pencil beam delivered by a proton machine (51, 131). The spot size is one of
the fundamental parameters of the proton beam model. The accuracy of the proton beam
model/treatment planning system (TPS) in predicting spot sizes at various energies is critical for
ensuring dose homogeneity within the target volume (51) (52).
Beam modifying devices, such as range shifters/pre-absorbers, enhance the spot size and lateral
penumbra of a pencil proton beam (51-54). In 2005, Pedroni et al. (132) provided a detailed
description of the factors affecting the beam width of a primary proton beam. The impact of beam
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broadening due to multiple Coulomb scattering in the range shifter has been reported in the
literature (54, 132). Recently, Rana et al. (51) quantified the one sigma spot size of a pencil proton
beam in the presence of a range shifter with a 75 mm water equivalent thickness (WET) (RS75).
Specifically, Rana et al. (51) measured the spot sizes at various energies using an IBA
ProteusPLUS PBS dedicated nozzle (Ion Beam Applications, Louvain-la-Neuve, Belgium).
Furthermore, a graph exhibiting the spot size results for various air gaps at increments of 5 cm was
reported. The aforementioned study (51) prompted us to investigate the analytical equations used
to predict the spot size. The motivation of this study was to further extend the work of Rana et al.
(51) by parametrizing the spot size as a function of energy and air gap. In addition to the 75 mm
WET range shifter, a range shifter with a 40 mm WET (RS40) was also considered, and the effect
of these range shifters (RS75 vs. RS40) on the spot size was investigated. Furthermore, in this
study, the measurements for various air gaps were performed with smaller increments of 2.5 cm
instead of 5 cm. The analytical equations presented in this report can prove useful to clinical proton
physicists for estimating the spot size of a pencil proton beam when a range shifter and various air
gaps are present in the proton beam path.

5.2

Materials and Methods

In this study, spot size (one sigma) measurements at the isocenter were performed on an IBA
ProteusPLUS proton therapy system with a PBS dedicated nozzle. A description of the
ProteusPLUS proton therapy system can be found in the literature (51, 133, 134). The energies
available for clinical use at the Miami Cancer Institute range from 70–226.5 MeV.

Figure 5.1: The 2D Lynx detector was placed at the isocenter. The range shifter with a 40 mm
water equivalent thickness (WET) was placed in front of the nozzle. The air gap in this example
measurement setup was 25 cm.
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5.2.1

Experimental Setup, Detector, and Software

For all the spot size measurements, the Lynx (IBA Dosimetry, Schwarzenbruck, Germany) was
employed in conjunction with the myQA software (IBA Dosimetry, Schwarzenbruck, Germany).
The experimental setup used in this study was similar to that previously employed by Rana et al.
(51). The Lynx 2D detector was placed at the isocenter such that the proton beam was
perpendicular to the Lynx at the gantry angle of 270°, as shown in Figure 5.1. For RS75,
measurements were acquired for energies ranging from 120 to 225 MeV in increments of 2.5 MeV,
whereas the air gap was varied from 5 to 35 cm in increments of 2.5 cm. For RS40, measurements
were acquired for energies ranging from 80 to 225 MeV in increments of 2.5 MeV, whereas the
air gap was varied from 5 to 25 cm in increments of 2.5 cm. For the 5 cm and 10 cm air gaps,
solid-water blocks of 4 cm WET and 7.5 cm WET were used to mimic RS40 and RS75,
respectively. Specifically, the solid-water blocks (hereafter referred to as the range shifter) were
placed in the beam path at a distance of 5 cm and 10 from the Lynx surface to generate air gaps of
5 cm and 10 cm, respectively. For the spot profile acquisition and data analysis, the Lynx plug-in
in the myQA software (IBA Dosimetry, Schwarzenbruck, Germany) was used to calculate the inair spot sizes (one sigma).
5.2.2

Analytical Model

For each range shifter, an analytical equation demonstrating the relationship of the spot size with
the proton energy at the nozzle exit and air gap was obtained. The following energies and air gaps
were used to generate the equations:
 Energy : 80  225 MeV in increments of 2.5 MeV
RS 40 : 
Air Gap : 5  25 cm in increments of 2.5 cm

 Energy :120  225 MeV in increments of 2.5 MeV
RS 75 : 
Air Gap : 5  35 cm in increments of 2.5 cm


Analytical equation 1 was formulated by parametrizing the spot size as a function of the air gap
and proton energy at the nozzle exit. Specifically, we used a linear regression model in conjunction
with a polynomial surface fit to generate the analytical model. The best parametrization results
were obtained with the 3rd degree polynomial fits of the energy and air gap parameters.
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The constants (A–J) in equation 1 are detailed in Table 5.1.
Spot Size  mm   A  B  Energy   C  AirGap   D  Energy 

2

 E  Energy  AirGap   F  AirGap   G  Energy 
2

3

 H  Energy 2  AirGap   I  Energy  AirGap 2   J  AirGap 
(Eq. 5.1)
3

where the in-air spot size (mm) is one sigma, Energy is in MeV at the nozzle exit, and AirGap is
in cm.
5.2.3

Validation of the Analytical Model

Validation of the analytical model was performed by comparing the measured spot sizes with those
predicted by the analytical model for various energies and air gaps.

5.3

Results and Discussion

Table 5.1 lists the constants (A–I) in equation 1 along with the goodness-of-fit statistics from the
polynomial surface fitting. Figure 5.2 illustrates the measured and modeled spot sizes for both
range shifters, while the ratio of measured spot sizes (RS75/RS40) is provided in Figure 5.3. In
the case of both RS40 and RS75, the spot size increased with an increase in the air gap and decrease
in energy. For RS40, the spot sizes increased from 3.1 mm (E=225 MeV and air gap=5 cm) to 10.4
mm (E=80 MeV, air gap=25 cm), whereas the spot sizes for RS75 increased from 3.3 mm (E=225
MeV and air gap=5 cm) to 13.1 mm (E=120 MeV, air gap=35 cm).
A comparison between the results for RS40 and RS75 demonstrated the impact of the range shifter
thickness on the spot size. [Figure 5.3] The WET difference between RS40 and RS75 was 3.5 cm.
All the energies presented in this study are defined at the nozzle exit (i.e., prior to traversing the
range shifter). As shown in Figure 5.3, the difference of 3.5 cm WET had a larger impact at lower
energies and larger air gaps. Focusing on the impact of the 3.5 cm WET difference in the range
shifter for energies in the 120–150 MeV range, we can observe an increase in the spot size by 0.4–
0.7 mm for the 5 cm air gap and 2.2–3.5 mm for the 25 cm air gap. If smaller spot sizes are
preferred in the treatment plan, Figure 5.3 demonstrates the advantages of using RS40 over RS75
when a range shifter is needed for PBS treatment. For example, in intensity modulated proton
therapy (IMPT) breast cancer treatment, the tumor volume may extend close to the skin (67, 99,
135, 136). In such a scenario, a range shifter is inserted in the proton beam path to reduce the
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proton beam energy so that the tumor volume can be covered by full dose modulation (67, 99, 135,
136).
Table 5.1: Goodness-of-fit statistics and polynomial surface fitting parameters for the in-air one
sigma spot size calculation as a function of energy and air gap in pencil beam scanning proton
therapy
RS40

RS75

A=

15.27

23.57

B=

−0.1661

−0.3089

C=

0.217

0.5665

D=

0.000849

0.001629

E=

−0.002802

−0.005104

F=

0.006285

0.005342

G=

−0.000001581

−0.000002944

H=

0.000008231

0.00001184

I=

−0.00001561

−0.000007177

J=

−0.0000465

−0.00004375

The sum of squares due to error (SSE)

1.912

1.522

Goodness-of-

R-square

0.9984

0.9993

Fit Statistics

Adjusted R-square

0.9984

0.9993

Root mean squared error (RMSE)

0.06058

0.05265

Constants

Figure 5.4 shows the validation results of the analytical model. The difference was calculated by
subtracting the predicted spot size from the measured spot size. The average difference between
the modeled and measured spot sizes was 0.0±0.1 mm (range, −0.24 ─ 0.21 mm) for RS40, and
0.0±0.1 mm (range, −0.23 ─ 0.15 mm) for RS75. Overall, the analytical model showed good
agreement with the measurements, as the differences were within ±0.25 mm. This difference is
within the Lynx detector resolution of 0.5 mm.
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Figure 5.2: In-air one sigma spot sizes (measured and modeled) for various energies and air gaps
on a ProteusPLUS PBS proton system with a PBS dedicated nozzle. The top and bottom graphs
show the results for the range shifters with water equivalent thicknesses of 40 mm and 75 mm,
respectively.
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Figure 5.3: (top) Ratio of the measured spot sizes (RS75/RS40); (bottom) Difference between the
measured spot sizes (RS75 − RS40) at various energies and air gaps.
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Figure 5.4: Difference between the modeled and measured spot sizes for RS40 and RS75.
For the commissioning of the spot profile, the spot sizes for a given range shifter thickness might
have to be measured. The analytical model presented in this paper can prove useful for estimating
the spot sizes of different energies and range shifter thicknesses (RS75 and RS40) as specified in
this paper. Overall, the analytical model largely agrees within ±0.25 mm of the measured values.

5.4

Conclusion

An analytical model was developed to estimate the spot size in air for various energies and air gaps
in situations where range shifters of 40 mm and 75 mm WET are encountered in the proton beam
path. In summary, the analytical model agrees within ±0.25 mm of the measured spot sizes on a
ProteusPLUS PBS proton system with a PBS dedicated nozzle.
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Chapter 6
Investigating Volumetric Repainting to Mitigate
Interplay Effect on 4D Robustly Optimized Lung
Cancer Plans in Pencil Beam Scanning Proton
Therapy
This chapter has been published in the Journal of Applied Clinical Medical Physics:
Rana S, Bennouna J, Gutierrez AN, Rosenfeld AB. Investigating volumetric repainting to
mitigate interplay effect on 4D robustly optimized lung cancer plans in pencil beam scanning
proton therapy. Journal of Applied Clinical Medical Physics. 2021 Mar;22(3):107-118.

6.1

Introduction

Lung cancer treatment using pencil beam scanning (PBS) proton therapy presents two major
challenges. First, the proton beam needs to transverse inhomogeneities, and the accuracy of the
proton dose calculation algorithm in predicting the dose in the lung becomes paramount. Published
literature has reported that the analytical pencil beam algorithms over-estimate the dose in the lung
(66). Monte Carlo dose calculation engines are becoming available in the commercial treatment
planning systems (TPS). Researchers are advocating the use of the Monte Carlo for dose
calculations if the proton beam encounters low- and high-density interfaces in its path, such as in
the case of lung cancer treatment (62, 63, 66, 137), as well as if the proton beam traverses a range
shifter, which creates an air gap between the distal end of the range shifter and patient body (57,
99, 135). The second challenge in treating lung cancer with the PBS proton beam is the interplay
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effect between dynamic pencil proton beams and motion of the lung tumor (31, 38-41, 61, 69, 114,
138-141). To mitigate the interplay effect in proton therapy, several strategies have been proposed.
These strategies include breath-hold, abdominal compression, gating, large spots, and repainting
(31, 34, 38).
Repainting (also referred to as rescanning) allows the energy layers of the proton beam to be
delivered more than once to achieve statistical averaging of motion effects (38-40). Volumetric
repainting is delivered by repetitive scanning through the whole target volume, whereas in layered
repainting, the energy layer is rescanned more than once before switching to the next energy layer
(38-40). A benefit of volumetric and layered repainting over gating and breath-hold is the lack of
external equipment that could require patient cooperation (41). Several studies (38, 39, 61, 62)
have investigated the potential use of volumetric repainting in lung cancer and compared the
volumetric repainting against layered repainting, providing contradictory conclusions. For
instance, Seco et al. (39) showed that the volumetric repainting produced better results than layered
repainting, whereas Grassberger et al. (61) showed that layered repainting is superior or equal to
volumetric repainting. Engwall et al. (38) found that offline breath-sample layered repainting is
superior to simple layer repainting and volumetric repainting. In offline breath-sample layered
repainting strategy, the layer rescans for each energy level are spread uniformly over the breathing
cycle (38). Recently, Wang et al. (62) reported that a total of four volumetric repaintings were
found to be optimal on ProteusPLUS proton system (Ion Beam Applications, Louvain-la-Neuve,
Belgium) when they examined it on a moving anthropomorphic lung phantom. Wang et al. (62)
demonstrated the feasibility of delivering volumetric repainting plans in a clinical setting.
To take advantage of the volumetric repainting technique in mitigating interplay in lung cancer,
the proton delivery system needs to have a faster layer switching mechanism (40, 41). However,
the volumetric repainting technique is manufacturer-specific, and volumetric repainting capability
may vary among different proton machines from the same manufacturer (41). The abovementioned volumetric repainting studies (38, 39, 61, 62) on the lung cancer were conducted with
beam delivery sequence in “down” direction only such that the proton beam is delivered from the
deepest layer (highest energy) to the most proximal layer (lowest energy), and then scans are
repeated (i.e., from the highest energy to the lowest energy). [Figure 6.1] At Miami Cancer
Institute, ProteusPLUS proton therapy system with a PBS dedicated nozzle is employed (26, 100).
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Recently, in an effort to decrease the layer switching time, a magnetic field regulation feature has
been implemented on the proton delivery system (28, 29). For magnetic field regulation mode,
Hall probes are mounted inside specific groups of magnets in the beamline. This allows the
reduction in beam stabilization delays and layer switching time in both “down” and “up” directions
(28, 29). The “up” direction means the proton beam is delivered from the most proximal layer
(lowest energy) to the distal layer (highest energy). [Figure 6.1] The use of magnetic field
regulation has decreased the layer switching time to ~0.9 s in the “down” direction and ~1.3 s in
the “up” direction (28, 29). This provides the feasibility of delivering volumetric repainting using
an alternating order with beam delivery sequences in “down” and “up” directions. [Figure 6.1]

Figure 6.1: Examples of beam delivery directions in nominal VR1 (no repainting) and volumetric
repainting plans with an alternating order; VR2= 2 repaintings, VR5 = 5 repaintings, VR8 = 8
repaintings; Note: beam delivery starts from the distal energy layer to the proximal energy layer,
and then follows an alternating order.
The availability of faster energy layer switching in PBS proton therapy has generated a renewed
interest in utilizing volumetric repainting in a clinical environment. In the current study, the
authors aim to investigate the interplay effect on the volumetric repainting lung plans that are
generated using an alternating order (“down” and “up” directions), and explore the number of
volumetric repaintings needed to achieve acceptable lung cancer PBS proton treatment plan. For
a volumetric repainting plan with beam delivery sequence in “down” direction only, the beamline
needs to be switched from the lowest energy to the highest energy of the given treatment field
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when scans are repeated in depth. Such a delivery technique with big energy steps in magnetic
field regulation mode may lead to destabilization of the magnets. It has been reported that big
energy steps (of the order of the full energy range) can cause the beam positioning displacements
of 1 to 3 mm (120). A faster layer switching time in both “up” and “down” directions in magnetic
field regulation mode provides the choice in terms of delivering a volumetric repainting plan, i.e.,
repainting in both “up” and “down” directions. To date, previous volumetric repainting studies
(38, 39, 61, 62) on the lung cancer utilized beam delivery in “down” direction only. In the current
study, the authors investigated the volumetric repainting technique with an alternating order (“up”
and “down” directions) with a focus on several key items that are relevant for its clinical
implementation: (i) the interplay effect evaluation on 4D robustly optimized volumetric repainting
plans with an alternating order, (ii) the worst-case-scenario (WCS) evaluation based on ten
different breathing phases from 4D computed tomography (4DCT) as the starting phases, and (iii)
a method to determine the number of volumetric repaintings needed for an acceptable PBS lung
cancer treatment plan.

6.2

Methods and Materials

6.2.1

Patient Cohort

The current retrospective study includes ten lung cancer patients. The selection of the patients was
made based on the following criteria:


4DCT data set includes all ten phases.



Tumor motion is greater than 3 mm but less than 15 mm.



Tumor is not attached to the mediastinum.



Clinical target volume (CTV) is less than 200 cc.

The location of the CTV in all ten patients are provided in Figure 6.2. The dimension of the CTV
ranged from 22.10 cc to 181.03 cc. The tumor motion ranged from 3.8 mm to 13.2 mm. The overall
tumor motion was calculated from the magnitude of a 3D vector in the left-right (LR), anteriorposterior (AP), and superior-inferior (SI) directions.
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Figure 6.2: The location of the CTV (red contour) in ten lung patients in the current study. The
CTV ranged from 22.10 cc to 181.03 cc, whereas the tumor motion ranged from 3.8 mm to 13.2
mm.
6.2.2

Contouring, Registration, and Treatment Planning

In this retrospective study, gross tumor volume (GTV) was contoured in all ten phases of the
4DCT. The CTV was then generated by an isotropic margin of 5 mm around the GTV in all ten
phases. Deformable registration was performed between the average intensity projection CT and
ten phases from the 4D CT data set using ANAtomically CONstrained Deformation Algorithm
(ANACONDA) within RayStation TPS (139).
In the current study, the total dose prescription to the CTV was 70 Gy(RBE) with a fractional dose
of 2 Gy(RBE). PBS plans were generated in RayStation TPS (v9B; RaySearch Laboratories,
Stockholm, Sweden) using the beam model of an IBA ProteusPLUS PBS machine that has an inair one sigma spot size of 3 mm (at the isocenter) for the highest energy of 226.5 MeV (23, 77).
All treatment plans were robustly optimized (patient setup uncertainty = 5 mm; range uncertainty
= 3.5%) on all ten phases in the 4D data set. Specifically, 4D robust optimization (139, 142) was
performed with the goal of 99% of the CTV receiving at least 99% of the prescription dose. The
organs at risk (OARS) such as the heart, spinal cord, normal lung, and esophagus were included
in the 4D optimization. The robust objective was applied to the CTV only. All treatment plans
were based on the single field uniform dose (SFUD) technique utilizing 2 – 3 proton fields. The
layer spacing was set by default in RayStation using automatic with scale 1. The layer spacing is
calculated based on the on the Bragg peak width between the proximal 80% and distal 80% of
each layer (143) . The spot spacing was also set by default in using automatic with scale 1. The
spot spacing varies as a function of depth (143). The Monte Carlo algorithm was used for the 4D
robust optimization (10,000 ions/spot), as well as for the final dose calculation (statistical
uncertainty of 0.5%) with a grid size of 3 mm. Treatment plans were then normalized, such that
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99% of the CTV received 6930 cGy(RBE). These plans are referred to as nominal plans (VR1)
with beam delivery in “down” direction only.
6.2.3

Volumetric repainting

For each patient, the VR1 plan is used to generate volumetric repainting plans with an alternating
order, as shown in Figure 6.1. The scripting environment within RayStation was utilized to
generate the volumetric repainting plans. Engwall et al. (38, 139) has detailed the method to
generate the volumetric repainting plans using a script in RayStation TPS. A minimum monitor
unit (MU) of 0.015 as the spot weight was applied for all volumetric repainting plans to ensure the
deliverability of the spots on the machine. If the alternating order includes X paintings, the plan is
denoted as a VRX plan. For instance, the plan with five paintings with an alternating order is
denoted as a VR5 plan.
6.2.4

Interplay effect

The interplay effect study was also performed within the RayStation scripting environment (38,
139). The interplay effect was evaluated for both the nominal VR1 plan (i.e., without repainting)
as well as volumetric repainting plans (VRX) that have X paintings in alternating order. For the
time structure of the proton beam delivery on the machine, the following parameters were used:
motion speed between spots = 250 cm/s; spot delivery time = 4.0 ms/MU; minimum spot weight
of the machine = 0.015 MU; energy layer switching time = 1.0 s. For more details on the interplay
evaluation process, the readers are recommended to refer to the publications by Engwall et al. (38,
139) and Pfeiler et al.(144) The interplay evaluation was carried out for each of the ten different
phases as the starting phases.
6.2.5

Worst-case-scenario analysis

For each treatment plan (VR1 and VRX) of a given patient, the results were obtained for each
phase including the starting phase. The following metrics were used to evaluate the worst-casescenario (WCS) values and DVH bandwidths from the results of treatment delivery starting in ten
different phases.


Target coverage: D95% and D99%.



Hot spot: D1%
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Homogeneity Index: D99%/D1%



DVH bandwidths

Table 6.1: Metrics to evaluate the WCS and bandwidth based on the results obtained from
treatment delivery starting in ten different breathing phases. Each phase is considered as one
scenario.
Metric

Criteria 1 (CR1)

Criteria 2 (CR2)

D95%

≥98% (6860 cGy(RBE))

97%≤x<98%

D99%

≥97% (6790 cGy(RBE))

96%≤x<97%

∆D1%

<1.5%

1.5%≤x<2.5%

∆Davg.

<2%

2%≤x<2.5%

∆HI

<0.030

0.030<x<0.040

BWavg. for target coverage

<100 cGy

<150 cGy

BWavg. in high-dose region

<100 cGy

<150 cGy

6.2.6

Criteria for acceptable plan

Currently, there is no consensus on acceptable interplay effect evaluation criteria for lung proton
therapy. The acceptance criteria used in the current study are provided in Table 6.1. If a given
treatment plan with X number of repaintings met the criteria 1 (CR1) of all seven metrics, it was
considered “acceptable”. However, if X number of repaintings did not meet the CR1 of all seven
metrics, the number of repaintings was increased until CR1 of each metric was fulfilled. The
maximum allowable repainting was set to 10. If a final plan met CR1 of at least five metrics but
met criteria 2 (CR2) of all metrics, it was considered “acceptable with a minor deviation”.
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Where, DRx is prescription dose; and X = 95%, 96%, 97%, 98%, and 99%.
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Where, BW = bandwidth of all ten scenarios from the DVHs at dose to the X% of the CTV; X =
95%, 96%, 97%, 98%, and 99%.
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Where, BW = bandwidth of all ten scenarios from the DVHs at dose to the X% of the CTV; X =
1%, 2%, 3%, 4%, and 5%.

6.3

Results

6.3.1

Target coverage

Figures 6.3 (a) and 6.3(b) show the WCS results for the CTV D95% and D99%, respectively. The
maximum number of repaintings needed to meet the target coverage varied among patients. The
number of repaintings needed to meet the CR1 (D95%≥98% and D99%≥97%) ranged from 2 to 10.
Another observation made for the target coverage was that if X number of repaintings meets the
CR1 for D95%, the same number of repaintings may not always meet the CR1 for D99%. For
instance, in patient 1, four repaintings were not sufficient to meet the CR1 for D99% but were able
to satisfy the CR1 for D95%. Figure 6.3(d) shows the WCS results for the CTV ∆Davg. The number
of repaintings needed to meet the CR1 (∆Davg <2%) ranged from 2 to 10. One patient (#8) did not
meet the CR1 of D99% and ∆Davg. but met the CR2 of these metrics.
6.3.2

Homogeneity and hot spot

Figure 6.4(a) shows the WCS results for the CTV ∆HI. To meet the CR1 (∆HI < 0.03), the
following observations were made: three repaintings in patients #9 and #10, four repaintings in
patients #1, 2, 3, and 5, nine repaintings in patients #4 and #6, and ten repaintings in patients #7
and 8. Figure 6.4 (b) shows the WCS results for the CTV ∆D1%. The observation for ∆D1% was
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similar to the one for ∆HI. The number of repaintings needed to meet the CR1 (∆D1% <1.5%)
ranged from 2 to 7. Two out of ten patients needed more than five repaintings to achieve ∆D1%
<1.5%.

Figure 6.3: The WCS CTV (a) D95%, (b) D99%, (c) DVHBWavg., and (d) ∆Davg. for the target
coverage in ten patients. Note: CR1 = Criteria 1, CR2 = Criteria 2; VR1 = Nominal plan with
no repaintings, VRX = Volumetric repainting with an alternating order where X is the number of
repaintings.
6.3.3

DVH Bandwidth

The evaluation of the average DVH bandwidth (BWavg.) is illustrated in Figures 6.3(c) and 6.4(c).
As shown in equations 5 and 6, the BW at a given dosimetric parameter was obtained by
calculating the widths of DVHs from ten scenarios. For the target coverage region (Figure 6.3(c)),
the number of repaintings needed to meet CR1 (<100 cGy) ranged from 3 to 10. For the high-dose
region (Figure 6.4(c)), the number of repaintings needed to meet CR1 (<100 cGy) ranged from 1
to 7.
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Figure 6.4: The WCS of CTV (a) ∆HI, (b) ∆D1%, (c) DVHBWavg.in high-dose region, and (d)
expected beam delivery time per treatment field in the nominal plan (VR1) and selected volumetric
repainting plans (VRX) with an optimal number (X) of repaintings in alternating order. The
selection
of
VRX
plans
is
illustrated
in
Figure
6.5.
Note: CR1 = Criteria 1, CR2 = Criteria 2; VR1 = Nominal plan with no repaintings, VRX =
Volumetric repainting with an alternating order where X is the number of repaintings.
6.3.4

Overall plan evaluation

Based on the criteria described in section 6.2.6, the final plan evaluation showed that acceptable
plans were achieved for nine patients, whereas one patient had an acceptable plan with a minor
deviation. Figure 6.5 shows the chart of each patient displaying if the metric has met CR1 and
CR2. Figures 6.6 and 6.7 illustrate the interplay DVHs for treatment delivery starting in ten
different phases, an average of interplay DVHs, and nominal DVH in all ten patients.


For patient #10 (CTV = 103.92 cc; tumor motion = 4.7 mm), three repaintings were
sufficient to achieve acceptable plans.



For patients #3 (CTV = 26.46 cc; tumor motion = 8.1 mm) and #9 (CTV = 63.26 cc; tumor
motion = 3.8 mm), four repaintings were sufficient to achieve acceptable plans.
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For patients #1 (CTV = 36.45 cc; tumor motion = 7.2 mm), #2 (CTV = 34.22 cc; tumor
motion = 5.8 mm), and #5 (CTV = 24.37 cc; tumor motion = 4.8 mm), five repaintings
were sufficient to achieve acceptable plans.



For patient #4 (CTV = 26.05 cc; tumor motion = 10.1 mm), nine repaintings were sufficient
to achieve acceptable plans.



For patients #6 (CTV = 39.25 cc; tumor motion = 10.2 mm) and #7 (CTV = 22.10 cc; tumor
motion = 8.8 mm), ten repaintings were sufficient to achieve an acceptable plan.



For patient #8 (CTV = 181.03 cc; tumor motion = 13.2 mm), ten repaintings were needed
to achieve acceptable plan with a minor deviation.

Figure 6.5: A chart displaying a selection of an optimal number of repaintings based on the
criteria described in section 6.2.6; VR1 = Nominal plan with no repaintings, VRX = Volumetric
repainting with an alternating order where X is the number of repaintings.
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Figure 6.6: Patients 1 – 5; Interplay DVHs (red lines) for treatment delivery starting in ten
different phases, an average of interplay DVHs (blue dashed line), and nominal DVH (black line).
The left panel displays the results for the nominal plan (VR1) without repaintings, and the right
panel shows the results for the selected volumetric repainting plans (VRX) with an optimal number
of repaintings.
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Figure 6.7: Patients 6 – 10; Interplay DVHs (red lines) for treatment delivery starting in ten
different phases, an average of interplay DVHs (blue dashed line), and nominal DVH (black line).
The left panel displays the results for the nominal plan (VR1) without repaintings, and the right
panel shows the results for the selected volumetric repainting plans (VRX) with an optimal number
of repaintings.
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6.3.5

Layers and Spots

For nominal plans (VR1), the number of layers per beam ranged from 13 to 28, whereas the total
spots per beam ranged from 598 to 2150. For acceptable plans, the number of layers per beam
ranged from 61 to 213, and the number of spots per beam ranged from 2519 to 4886. For an
acceptable plan with minor deviation, the number of layers per beam ranged from 171 to 233, and
the number of spots per beam ranged from 5961 to 6490.
6.3.6

Treatment Delivery Time

The expected treatment delivery times for the nominal plans without repainting (VR1) and selected
volumetric repainting plans (VRX) with an optimal number of repaintings of each patient are
provided in Figure 6.4(d). For acceptable plans, treatment delivery time per beam varied from
1.22 min (VR5 in patient #2) to 3.87 min (VR10 in patient #6). For an acceptable plan with minor
deviation, treatment delivery time per beam varied from 3.42 min (VR10 in patient #4) to 4.49
min (VR10 in patient #8).

6.4

Discussion

The current study evaluated the interplay effect of 4D robustly optimized volumetric repainting
lung cancer plans. We have presented the volumetric repainting technique with an alternating
order, which was not explored in previous studies (38, 39, 61, 62) on lung cancer. Recently, Rana
et al. (28) performed an experimental study quantifying the impact of magnetic field regulation in
conjunction with the volumetric repainting technique (alternating order) on the spot positions and
range in PBS protons. Rana et al. (28) demonstrated the feasibility of delivering volumetric
repainting QA plans with an alternating order on the clinical proton machine. While the study by
Rana et al. (28) was focused on the machine QA, the current study was performed on the 4DCT
data set of lung cancer to investigate the mitigation of interplay effect by using an alternating order
in volumetric repainting technique.
The volumetric repainting is not clinically implemented at many proton centers. One of the reasons
could be due to longer treatment time because of slower energy layer switching time. In the current
study, we approximated the layer switching time of 1 s for both “down” and “up” directions based
on the findings by Rana et al. (28), although layer switching time could slightly vary from 1 s
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when plans are delivered on the machine. The simulated treatment delivery time for the cohort of
patients in the current study showed the feasibility of delivering volumetric repainting plans
mitigating the interplay effect. The average time per beam to deliver the acceptable plans, as well
as acceptable plans with minor deviation, was 2.2 min (range, 1.2 min – 4.5 min). These estimated
beam times could slightly vary during the actual delivery of the volumetric repainting plans on the
proton machine.
Since the current study was primarily focused on the interplay effect, the robustness of the lung
plans was not investigated. However, treatment plans were generated with the objective of
achieving clinically acceptable and deliverable robust plans. To achieve this, the current study was
performed using a 4D robust optimization feature available in the RayStation TPS. As described
in Engwall’s papers (38, 139), the 4D optimization ensures the entire treatment volume is
encompassed in each breathing phase if the proton beam delivery were instantaneous and resulting
distortions are purely caused by the interference between the tumor motion and the dynamic proton
beam delivery. The addition of robust objective to the CTV with respect to the setup (5 mm) and
range uncertainties (3.5%) during 4D robust optimization can make treatment plans more robust,
especially for the lung tumor volume that has large density variations in the beam path. Such
dosimetric benefit comes at the cost of decreasing computational efficiency if robust optimization
process includes all ten breathing phases from 4DCT data set (142).
Currently, there is no consensus in the proton therapy community regarding which metrics can be
used to evaluate the interplay effect. In the current study, we included metrics such as D95%, D1%,
and HI. Literature (145) has shown the importance of achieving homogeneous dose distribution
within the target volume. To create homogenous dose distributions in the treatment plan, the
current study used the SFUD technique utilizing 2 – 3 beams. D99% was included in the evaluation
process since this metric could be correlated to the clinical outcome in lung cancer patients (146).
For the evaluation of these metrics, we utilized the WCS approach based on the results of beam
delivery, starting in ten different breathing phases. Each individual phase was considered as one
scenario. During the lung cancer treatment, treatment beam delivery could start at any breathing
phase, and this can be considered as a random variable. In general, the increase in the number of
volumetric repaintings improved the WCS value of given metric and allowed us to mitigate the
interplay effect and meet the criteria provided in Table 1. Additionally, we measured the average
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DVH bandwidths by evaluating dose at several dosimetric parameters that are relevant in the target
coverage and high-dose regions. In general, the DVH bandwidths became tighter with an increase
in the number of repaintings. For patients #4 and #8, there was no clear trend showing the increase
in repaintings resulting in an improvement in bandwidths after 5 repaintings.
The results presented in the current study demonstrated that the interplay effect for lung cancer
was highly patient dependent. This observation is in alignment with previously published studies
on the PBS proton therapy for lung cancer (31, 34, 38, 61, 69, 138-140, 147). For ten patients in
the current study, it was not possible to determine the exact correlation between the number of
repaintings vs. tumor size, tumor location, and tumor motion. Although a larger tumor motion
seems to require a higher number of repaintings in the current study, more data with varying tumor
motion is necessary to establish the correlation between the number of repaintings and tumor
motion. Hence, for the volumetric repainting with an alternating order, instead of applying a fixed
number of repaintings across all lung cancer patients, a patient-specific interplay evaluation
strategy must be adopted. This will yield an optimal number of volumetric repaintings for an
individual lung cancer patient.
The current study was focused on the volumetric repainting technique with an alternating order.
We did not investigate other repainting strategies such as layer repainting and volumetric
repainting technique in the “down” direction only. These are the limitations of our study. One of
the goals of the current study was to demonstrate the feasibility of mitigating the interplay effect
using a volumetric repainting technique with an alternating order rather than to make a comparison
against the layer repainting. The use of layer repainting to mitigate the interplay effect cannot be
ignored. In the next study, we will make the direct comparison between the volumetric repainting
(with alternating order) and layer repainting by providing the dosimetric and radiobiological
results.
On the IBA ProteusPLUS machine, if the current regulation feature is employed, the energy layer
switching time in the “up” direction can take up to 6 seconds (28, 29). Such a large energy
switching time is not clinically acceptable. However, the use of magnetic field regulation feature
on the IBA ProteusPLUS machine can reduce the energy layer switching time in the “up” direction
from ~6 s to ~1.3 s (28, 29). Such a decrease in the energy layer switching time demonstrates the
feasibility of delivering the volumetric repainting plan with an alternating order and improve the
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beam delivery efficiency. Another important point to note is that the current study was performed
with an assumption of proton beam delivery using magnetic field regulation on the IBA
ProteusPLUS machine. In this scenario, Hall probes in the beamline measure the magnetic field in
real-time and remove the requirement of cycling of the magnets at each set range in the “up”
direction (28, 29). This has led to a decrease in the energy layer switching time and making it
feasible to deliver the field in smaller energy steps in the “up” direction (28, 29). Pedroni et al.
(120) reported up to 3 mm in beam positioning displacements for big energy steps (of the order of
the full energy range). In the magnetic field regulation mode, big energy steps in in the treatment
field may cause destabilization of the magnets and a greater fluctuation in Hall probe readings,
thus potentially producing errors in spot positions (28). The utilization of the “up” direction in the
treatment plan can eliminate the need to switch from the lowest energy (proximal layer) to the
highest energy (distal layer) of the given treatment field when volumetric scans are repeated. In
the magnetic field regulation mode on the IBA ProteusPLUS machine, we recommend delivering
a volumetric repainting plan with smaller energy steps (5 MeV or less). More technical details on
the magnetic field and current regulation features and volumetric repainting technique on the IBA
ProteusPLUS machine can be found in previous publications (28, 29).
The interplay effect results presented herein are more relevant for an IBA ProteusPLUS PBS
machine, which employs magnetic field regulation feature, but not for the current regulation
feature. The readers must be aware of the fact that the proton beam delivery systems are machineand manufacturer-specific, and performance of repainting can vary among different PBS proton
machines (113). An independent machine-specific validation for the repainting techniques can
provide more accurate estimations of the interplay effect. We acknowledge that the experimental
measurements for the interplay effect were not performed in the current study. In the near future,
we aim to perform an experiment using a moving phantom simulating different magnitudes of
motion and investigate the computed vs. measured doses of repainting plans (layer and
volumetric).
At present, to the best of our knowledge, an interplay evaluation module is not currently available
in the clinical versions of the proton TPSs. The implementation of interplay evaluation within TPS
would not only give us the confidence in using the volumetric repainting technique in the clinical
environment but also provides a tool to the clinicians to select the optimal number of repaintings.
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This can result in homogenous dose distributions and maintain target coverage leading to a better
clinical outcome for PBS lung cancer patients.

6.5

Conclusion

The interplay effect was evaluated on the 4D robustly optimized lung cancer plans (tumor motion
< 15 mm) for the volumetric repainting technique with an alternating order. The number of
repaintings required to mitigate the interplay effect was found to be patient dependent.
Determining the optimal number of repaintings based on the bandwidth and WCS approach from
DVHs of ten breathing phases could mitigate the interplay effect in PBS lung cancer treatment. It
is recommended to perform patient-specific interplay evaluation for PBS lung cancer plans.
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Chapter 7
Impact of proton dose calculation algorithms on the
interplay effect in PBS proton based SBRT lung plans
The chapter has been published in the Biomedical Physics and Engineering Express:
Rana S, Rosenfeld AB. Impact of proton dose calculation algorithms on the interplay effect in
PBS proton based SBRT lung plans. Biomedical Physics & Engineering Express. 2021; 7(4):
045006.

7.1

Introduction

In recent years, there has been an increasing interest in using pencil beam scanning (PBS) proton
therapy to treat lung cancer (34). PBS lung cancer treatment presents a unique challenge for dose
computation due to large density heterogeneities between air and lung. The accuracy of the proton
dose calculation algorithm is essential in estimating accurate dose in the tumor and organs at risk
(OARs). Recently, Monte Carlo (MC) algorithm has been made available in commercial treatment
planning systems (TPSs) (63, 148), whereas the analytical pencil beam (APB) algorithm has been
used for proton dose calculations for many years.
RayStation TPS (RaySearch Lab, Stockholm, Sweden) includes both MC and APB algorithms for
proton dose calculations. Investigations by several researchers (57, 62-67) have shown that
RayStation MC is more accurate than APB when range shifter and inhomogeneities are
encountered in the proton beam path. Huang et al. (43, 149) investigated the accuracy of the proton
APB algorithm in Eclipse TPS (Varian Medical System, Palo Alto, CA, USA) and compared it
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against the open-source MC code, MCsquare, and TOPAS. The limitation of the proton APB
algorithm was reported (43, 149).
Other studies have investigated the use of RayStation MC and APB algorithms for disease sites
such as breast and lung (68, 99, 135, 150). Maes et al. (150) performed a dosimetric analysis
between RayStation MC and APB algorithms in ten lung cancer patients and reported a reduction
of 10% in target coverage (D95%) using APB algorithm. More recently, Teoh et al. (68) investigated
the use of RayStation MC and APB algorithms in lung cancer patients. It is interesting to note that
Teoh et al. (68) found RayStation APB algorithm may be acceptable when PBS lung cancer plans
involve the mediastinum and range shifters are absent in the proton beam path. Teoh et al. (68)
found the overall median target coverage (D99%) overestimation of 5% when RayStation APB
algorithm is used.
Previous studies (68, 150) on lung cancer characterizing the dosimetric differences between
RayStation MC and APB algorithms have been limited to nominal scenarios without considering
the tumor motion. For PBS lung cancer treatment, there can be an interplay effect between the
motion of the lung tumor and dynamic pencil proton beams (31). The interplay effect in PBS
proton therapy can be influenced by several parameters such as beam delivery characteristics (e.g.,
scanning path, spot size, and type of repainting), plan characteristics (e.g., dose calculation
engines, treatment fields, directions of the treatment fields), and patient characteristics (e.g., tumor
size, tumor motion, and tumor location) (151). It has been reported that the interplay effect in
radiotherapy can lead to the under-dose of the tumor volume (33). Tome and Fowler (33)
demonstrated the correlation between the local control and minimum dose delivered to the tumor
volume. This is particularly important if a lung tumor is treated using a PBS proton-based
stereotactic body radiation therapy (SBRT) technique because hypofractionation reduces the
averaging effect of interplay (152).
Currently, to the best of our knowledge, the literature on the impact of RayStation proton dose
calculation algorithms on the interplay effect is not available. The interplay effect in lung cancer
can deteriorate the dose homogeneity and target coverage (31, 38, 139). The volumetric repainting
technique has been suggested as one of the motion management techniques to mitigate the
interplay effect (34). Since both RayStation MC and APB algorithms are now available for clinical
use in PBS proton therapy, it is imperative to investigate the combined effect of dose calculation
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algorithms and interplay in SBRT lung treatment plans. In the current study, the authors aim to
investigate the following items regarding PBS proton based SBRT lung treatment:


Impact of RayStation APB and MC algorithms on the interplay effect.



Combined effect of the volumetric repainting and dose calculation engines (RayStation
MC and APB) on the interplay effect.

7.2

Methods and Materials

The current retrospective in-silico planning study included CT data set of six cases (Table 1),
which met the selection criteria such that (a) 4DCT data set consists of all ten breathing phases,
(b) tumor motion is less than 10 mm, (c) tumor is not attached to the mediastinum, and (d) clinical
target volume (CTV) is less than 100 cc.
Table 7.1: The CTV, location of the disease site, and tumor motion in six patients.
CTV Location Motion (mm)
Patient 1
36.45
RUL
7.2
Patient 2
34.22
LLL
5.8
Patient 3
26.46
RLL
8.1
Patient 4
24.37
LUL
4.8
Patient 5
22.10
RLL
8.8
Patient 6
63.26
LUL
3.8
Abbreviations: RUL = right upper lobe; LUL = left upper lobe; RLL = right lower lobe; LLL =
left lower lobe
7.2.1

Contouring

The CTV was generated by an isotropic margin of 5 mm around the internal gross tumor volume
(IGTV). The IGTV is then overridden with the density of the water. The average intensity
projection CT was used for treatment planning. Deformable registration was performed between
the average intensity projection CT and ten phases from the 4DCT data set using ANAtomically
CONstrained Deformation Algorithm (ANACONDA) within RayStation TPS (139). The CTV and
OARs (heart, normal lung, esophagus, and spinal cord) were mapped from the average CT to all
ten breathing phases of 4DCT.
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7.2.2

Beam delivery system

A beam model in the current study is based on an IBA ProteusPLUS proton therapy system with
a dedicated PBS nozzle (Ion Beam Applications, Louvain-la-Neuve, Belgium). In brief, the nozzle
includes several components such as ionization chamber 1 (verifies alignment of the beam at
nozzle entrance), quadrupole magnets (focus the beam at the isocenter), vertical and horizontal
scanning magnets, ionization chambers 2 and 3 (monitor beam characteristics). The Hall probes
are mounted inside specific groups of magnets in the beamline. The Hall probes allow measuring
the magnetic field in real-time. The detailed characterization of the proton machine can be found
elsewhere (23, 28).
7.2.3

RayStation APB and MC algorithms

RayStation APB algorithm divides the beam into many pencil beams (65). The calculation of each
beam pencil beam is performed by factorization of the integrated depth dose and lateral proton
fluence (65). RayStation APB algorithm uses the infinite slab approximation, which means the
patient model is composed of semi‐infinite layers transverse to the central axis of the pencil beam
(65). The total dose distribution from the APB calculations is obtained by summing all the
individual pencil beams (65).
MC dose calculation algorithms track the energy deposited by individual particles inside the
medium. The total dose distribution from the MC calculations is obtained by summing
contributions of the energy deposited in respective voxels from all simulated particles (63, 153).
Recently, RaySearch released MC algorithm for fast and accurate proton dose calculations in a
clinical environment. The improved computations in MC dose calculations in a clinical setting
comes with approximations for physical processes. For MC dose calculations, transport occurs in
a rectilinear voxel grid, which enhances the efficiency of geometry tracking compared to general
purpose MC codes (153). For MC algorithm in RayStation, RaySearch manual (65) states: “a
Class II transport algorithm is used for primary and secondary protons, while heavier secondary
particles such as deuterons and alphas are transported only by taking energy loss into account
using the Continuous Slowing Down Approximation (CSDA). Neutral products such as neutrons
and Gammas are not transported, but their fractions of absorbed energy are subtracted from the
remaining beam.” A detailed explanation of RayStation MC can be found in the published
literature (63-65, 153).
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7.2.4

Treatment planning

In this in-silico planning study, the authors assumed the SBRT fractionation to be delivered for a
total dose of 5000 cGy(RBE) in 1000 cGy(RBE) per fraction using an average RBE of 1.1.
Treatment plans of 2 – 3 fields were generated in RayStation TPS (version 9B) using a single field
uniform dose (SFUD) technique.
First, for each patient, a nominal treatment plan was generated using APB algorithm (version 5.0)
for both optimization and final dose calculation. These plans were denoted as PB-PB. All PB-PB
plans were robustly optimized on the CTV using a setup uncertainty of 5 mm and a range
uncertainty of 3.5%, with a goal of 99% of the CTV receiving at least 100% of the prescription
dose. Once the final dose calculations (2 mm grid size) were completed, PB-PB plans were
normalized, such that CTV D99% = 5000 cGy(RBE).
Second, for each PB-PB plan, it was re-computed using MC algorithm (version 4.3) using 0.5%
statistical uncertainty and 2 mm grid size. These plans were denoted as PB-MC. Third, for each
patient, a new plan (denoted as MC-MC) was generated by using MC algorithm (version 4.3) for
plan optimization (Monte Carlo; 10,000 ions/spot; SFUD technique) on the CTV using the
identical robustness values and optimization settings and constraints. The final dose calculations
were performed using MC algorithm (version 4.3) for a statistical uncertainty of 0.5% and a grid
size of 2 mm. All MC-MC plans were normalized, such that CTV D99% = 5000 cGy(RBE).
7.2.5

Volumetric repainting

Volumetric repainting is considered to be one of the motion management techniques in proton
therapy. Volumetric repainting allows the delivery of the treatment field by repetitive scanning
through the whole target volume (39, 40, 154). Based on the nominal plans described in section
2.4, volumetric repainting plans were generated in RayStation using a methodology described by
Engwall et al. (38). In brief, the number of scans for each energy layer is calculated by (38)
4

rsM

= rs

O,LNu

(Eq. 7.1)

Where,
n = number of rescans for energy layer i
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MUi = MU for layer i
MUl,max = the limiting maximum MU per layer
Engwall et al. (38) explain that “the division into layers also respects the minimum MU per spot,
MUs,min, which means that some of the spots in the layer might be rescanned less times than ni.”
For all volumetric repainting plans, the minimum MU limit for each spot was set to 0.015.
In the current study, we used a total of 5 volumetric repaintings (VR5) for all patients. Specifically,
for each patient, PB-MCVR5 and MC-MCVR5 plans were generated based on PB-MC and MC-MC
plans, respectively. The volumetric repainting technique included an alternating order, which
includes the beam delivery sequences in “down” and “up” directions (28, 29). The “down”
direction means the proton beam is delivered from the deepest layer (highest energy) to the most
proximal layer (lowest energy), whereas the “up” direction means the proton beam is delivered
from the most proximal layer (lowest energy) to the distal layer (highest energy) (28).
7.2.6

Interplay effect evaluation

Interplay evaluation in the current study is performed using the methodology described by Engwall
et al. (38, 139). First, spots are distributed over different breathing phases according to starting
phase for the beam delivery and spot timings. Each phase from the 4DCT data set was considered
as the starting phase. We used an energy layer switching time of 1.0 s, whereas the spot delivery
time was 4.0 ms/MU, and the motion speed between spots was set to 250 cm/s. Second, the dose
is computed on different breathing phases based on the spot distribution. Third, the dose is mapped
to the reference phase through deformable registration followed by accumulation of the mapped
doses on the reference phase.
To understand the combined effect of dose calculation algorithms and interplay effect, the
evaluation was performed on PB-MC plans. It included the DVHs calculated in all ten breathing
phases of the 4DCT data set. This process was repeated for MC-MC plans. In the next step, the
interplay effect evaluation was performed for the volumetric repainting plans (PB-MCVR5 and MCMCVR5) using the same parameters and methodology as in nominal plans (PB-MC and MC-MC).
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7.2.7

Dosimetric analysis

The interplay DVHs were used to evaluate the CTV coverage using metrics D95% and D99% (dose
received by 95% and 99% of the volume, respectively). For the interplay DVHs, each breathing
phase was considered as one scenario. For a given metric (e.g., D99%), the worst-case-scenario
(WCS) value among ten scenarios was recorded. The difference (∆D) between the WCS value and
nominal value for a given metric is calculated using equation 1. Additionally, the homogeneity
index (HI) was calculated for the nominal and interplay DVHs. Total lung was evaluated for the
mean dose and V20 (relative volume receiving at least 20 Gy(RBE)).
∆Df% =
T =
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>(U41VW
− Df%
&
Df%
>(U41VW
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× 100
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5000 wx
&
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7.3

Results

7.3.1

PB-PB vs. PB-MC vs. MC-MC

7.3.1.1

Nominal scenario without considering interplay effect

Figure 7.1 illustrates the dosimetric differences in the CTV coverage between APB and MC
algorithms in an example patient. In all six patients, the target coverage was reduced when PB-PB
plans were re-computed using MC algorithm. In a nominal scenario without considering the
interplay effect, the difference in D95% between PB-PB and PB-MC plans ranged from -2.7% to 4.3%. (Figure 7.2) Similarly, the difference in D99% between PB-PB and PB-MC plans ranged
from -3.3% to -5.3%. (Figure 7.2) A similar trend was observed for the dose homogeneity in the
target volume. The average HI in PB-PB plans was 1.58±0.06, whereas PB-MC plans showed an
inferior dose homogeneity with an average HI of 4.29±0.84. (Figure 7.3)
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In MC-MC plans in which MC algorithm is used for both optimization and final dose calculations,
the decrease in the CTV coverage that was observed in PB-MC plans was recovered, as shown in
Figure 7.1. However, the dose homogeneity in MC-MC plans was slightly inferior (average HI =
2.46±0.18) than in PB-PB plans but superior to the one in PB-MC plans. (Figure 7.3)
In addition to the target coverage, we evaluated the mean dose and V20 for the total lung. The mean
dose to the total lung was identical (2.5 Gy(RBE)) in PB-PB and PB-MC plans, whereas the MCMC plans had a slightly higher mean dose (2.9 Gy(RBE)) to the total lung. The average V20 of the
total lung in MC-MC plans was 6.3%. Both PB-PB and PB-MC plans produced the same result
for the average V20 of the total lung (5.5%).
7.3.1.2

Interplay effect

Figure 7.4 shows the example of interplay DVHs of the nominal (PB-MC) and volumetric
repainting plans (PB-MCVR5). If the interplay effect is considered for PB-MC plan, the difference
in D95% and D99% ranged from -5.3% to -8.4% and from -6.2% to -10.5%, respectively. (Figure
7.2) The WCS HI ranged from 6.6 to 10.1. (Figure 7.3) These interplay effect results suggest that
if motion management technique such as volumetric repainting is not applied, there can be a further
reduction in the target coverage and degradation in dose homogeneity when APB algorithm is used
to compute dose in lung plans with a tumor motion.
7.3.2

PB-MCVR5

The use of 5 repaintings in PB-MCVR5 has shown a reduction in interplay effect when compared
to the interplay results of PB-MC. In PB-MCVR5, the difference ranged from -4.0% to -7.9% (vs. 5.3% to -8.4% in PB-MC) for D95% and from -5.4% to -9.3% (vs. from -6.2% to -10.5% in PBMC) for D99%. (Figure 7.2) The WCS HI in PB-MCVR5 ranged from 5.2 to 8.7. (Figure 7.3)
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Figure 7.1: Dose distributions in PB optimization followed by APB dose calculation (PB-PB), PB
optimization followed by MC dose calculation (PB-MC), and MC optimization followed by MC
dose calculation (MC-MC) plans of an example patient. Note the substantial target coverage loss
in PB-MC plan. The target coverage was recovered in MC-MC plan.
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Figure 7.2: The difference in CTV D95% and D99%. Note: *means comparison made against PBPB (nominal treatment plan that was generated using APB algorithm during optimization followed
by APB algorithm for final dose calculation); † means comparison made against MC-MC (nominal
treatment plan which includes MC algorithm during optimization followed by MC algorithm for
final dose calculation).
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Figure 7.3: The CTV homogeneity index (HI) in various plans (PB-PB, PB-MC, MC-MC, PB-MC
Interplay, PB-MCVR5 Interplay, MC-MC Interplay, and MC-MCVR5 Interplay).

Figure 7.4: (top) Nominal DVHs of PB-PB and PB-MC, and Interplay DVHs of PB-MC with no
repainting; (bottom) nominal DVHs of PB-PB and PB-MC, and Interplay DVHs of PB-MCVR5 (5
repaintings) in an example patient.
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7.3.3

MC-MCVR5

In the absence of repainting, the average dose difference due to the interplay effect in MC-MC was
-3.5% for D95% and -4.7% for D99%. (Figure 7.2) The WCS HI in MC-MC ranged from 5.1 to 9.4.
(Figure 7.3) After 5 volumetric repaintings in MC-MCVR5, the average dose difference was
improved with -1.8% for D95% and -3.0% for D99%, whereas the WCS HI ranged from 2.5 to 4.7.

Figure 7.5: Nominal DVHs of MC-MC and Interplay DVHs of MC-MCVR5 (5 repaintings) in an
example patient.

7.4

Discussion

We have investigated the impact of RayStation APB and MC algorithms in PBS proton-based
SBRT lung plans. The limitations of RayStation APB algorithm have been widely documented in
the literature (57, 62-67). The RayStation APB algorithm uses the infinite slab approximation, and
this increases an error as a function of lateral inhomogeneity (63, 64). Additionally, if a range
shifter is placed in the proton beam path, RayStation APB algorithm does not properly handle the
transport of secondary protons created in the range shifter (64, 65). These limitations of APB
algorithm have led the researchers to recommend MC algorithm for both plan optimization and
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final dose calculations when inhomogeneities and range shifters are involved in the proton beam
path (63, 64, 99, 135, 150). One of the challenges utilizing MC algorithm for routine clinical use
has been decreased computational efficiency as compared to APB algorithm. Another critical point
that needs to be addressed is that if MC algorithm is clinically feasible to rapidly adapt lung plans
to anatomical changes. Recently, Nenoff et al. (155) reported that “dose degradations caused by
anatomic changes are substantially larger than uncertainties introduced by the use of analytical
instead of MC dose calculations. Thus, if the use of analytical calculations can enable more rapid
and efficient plan adaption than MC approaches, they can and should be used for plan adaption
for these patient groups.” RayStation TPS provides 4D robust optimization feature. For proton
SBRT lung planning, if MC algorithm is used for 4D robust optimization by including all ten
breathing phases, one can expect the computational efficiency to be decreased significantly. At
present, the combination of MC algorithm and 4D robust optimization maybe not be optimal in
terms of computational efficiency if daily online plan adaptions to anatomical changes are
performed.
In our in-silico planning study, the major dosimetric differences between RayStation dose
calculation engines occurred in the tumor volumes. It was distinct that the APB algorithm
overestimated the CTV coverage. The reduction in CTV coverage could lead to unfavorable
clinical outcomes in lung patients. Recently, Sood et al. (146) suggested the correlation between
the D99% and clinical outcome in SBRT lung patients. In the absence of the interplay effect, the
overestimation of the D99% by APB algorithm was found to be up to 5.3%. These results are in
agreement with those of Teoh et al. (68), in which they found a reduction of 5% (median value) in
D99% when PB-PB plans were re-calculated with MC algorithm. The findings from Teoh et al. (68)
did not include the interplay effect. In our study, after considering the interplay effect in nominal
plans (no repainting), it was found that the overestimation of the D99% by APB algorithm could
increase twofold (up to 10.5%). Figure 7.6 displays the line dose profile across the target volume
in the beam path for three sets of dose distributions: nominal PB-PB (solid line), nominal PB-MC
(dotted line), and interplay of PB-MC on an example breathing phase (dashed line). In Figure 7.6,
dosimetric differences among these three sets of dose distributions are very distinct inside the
target volume as well as in the distal fall-off region. However, for normal total lung, the dosimetric
impact of the dose calculation algorithm was very minimal.
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In proton therapy, motion management techniques such as repainting, breath-hold, gating, and
abdominal compression have been proposed to mitigate the interplay effect (34). In our in-silico
planning study, the volumetric repainting technique was applied. If lung cancer patients have poor
lung function, they may have difficulty in holding their breath during beam delivery. In such
situations, the breath-hold technique can be challenging. However, during volumetric repainting
beam delivery, the patient can breathe in a normal manner. In this study, it was assumed that the
treatment delivery could start at any breathing phase among 10 phases from 4DCT data set. Figure
7.4 (top) shows the variation in D99% among 10 interplay DVH curves (red color) in the absence
of repainting. Each curve in Figure 7.4 (top) represents a breathing phase. Such variation
demonstrates the uncertainty in the minimum dose delivered to the target volume. However, in
Figure 7.4 (bottom), after applying 5 volumetric repaintings, the variation in D99% among 10
interplay curves was reduced. This can be attributed to the statistical averaging of motion effects.

Figure 7.6: Line dose profile across the central of CTV in PB-PB (solid line), PB-MC (dotted
line), and PB-MC Interplay (dashed line) plans of an example patient.
Although the number of repaintings needed to mitigate the interplay effect is dependent on
different variables such as patient, tumor size, tumor motion, tumor location, etc., for the sake of
simplicity, we applied five volumetric repaintings across all patients. The MC-MCVR5 (a
combination of volumetric repainting and MC algorithm for both optimization and final dose
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calculation) resulted in an improvement in target coverage and dose homogeneity. Although the
use of volumetric repainting in PB-MCVR5 resulted in better D95% and D99% results than the ones
from nominal PB-MC (no repainting), PB-MCVR5 still yielded lower target coverage compared to
interplay DVHs of nominal MC-MC. (Figure 7.2) This suggests that PB-MC plans with five
volumetric repaintings showed inferior interplay target coverage when compared against the
interplay target coverage of MC-MC plans with no repaintings. The most superior target coverage
results were obtained using MC-MC in conjunction with a volumetric repainting technique – a
reference plan in our study. It must be noted that the increase in the number of repaintings will
increase the total beam delivery time. For the treatment plan with five repaintings, the average
beam delivery time per field was estimated to be 101±33 s. If no repainting is applied, the average
beam delivery time per field was reduced to 23±7 s.
The current study includes limitations. First, the number of cases studied was limited to six. In
previous studies (38, 139, 154), the interplay effect was found to be patient-dependent, and no
correlation was obtained between the interplay effect and tumor motion and size. Since the current
study also includes interplay evaluation, we believe that the results presented herein revealed the
limitation of ABP algorithm for each patient when the interplay effect is considered. Second, the
setup and range uncertainties were not combined with the interplay. In a real clinical treatment
scenario, both the setup and range uncertainties can occur, and these errors need to be included in
future interplay studies for PBS proton-based SBRT lung cancer. Third, due to the unavailability
of quality assurance (QA) CTs for patients in the current study, we were not able to evaluate the
impact of APB and MC algorithms on the interplay effect due to anatomical changes.

7.5

Conclusion

For PBS proton-based SBRT lung plans, the RayStation APB algorithm overestimated the target
coverage by up to 10.5% in non-volumetric repainting plans when the interplay effect is
considered. The use of MC algorithm for both optimization and final dose calculations in
conjunction with the volumetric repainting technique (5 repaintings) improved target coverage loss
(from 3.5% to 1.8%) D95% from and dose homogeneity.
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Chapter 8
Small spot size vs. large spot size: Effect on plan
quality for lung cancer in pencil beam scanning proton
therapy
This chapter has been published in the Journal of Applied Clinical Medical Physics:
Rana S, Rosenfeld AB. Small spot size vs. large spot size: Effect on plan quality for lung cancer
in pencil beam scanning proton therapy. Journal of Applied Clinical Medical Physics. 2022
Feb;23(2):e13512.

8.1

Introduction

Pencil beam scanning (PBS) proton therapy has shown a great potential in reducing the dose to the
organs at risk (OARs) and improving dose conformality when compared to the passive-scattering
proton therapy (156). However, uncertainties such as patient setup, beam range, and interplay
between tumor motion and proton beam delivery can have an impact on PBS treatment plans (157).
Recently, robust optimization has been implemented within treatment planning systems (TPS) to
compensate both setup and range uncertainties (158, 159). Robustly optimized plans are evaluated
in terms of plan robustness by simulating the range uncertainty due to the computed tomography
(CT) calibration error and isocenter shift of the patient due to inter-fraction variations in patient
position (98).
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The spot size of a pencil proton beam can influence the plan quality and robustness in PBS proton
therapy (50, 69, 70, 73, 76). Plan robustness becomes more critical for the PBS proton lung cancer
treatment because the proton beam needs to transverse low- and high-density interfaces in its path,
and lung tumor volume may contain large density variations. The evaluation of plan robustness
for PBS proton treatment is equally important (160). Robust optimization can take into account of
the combination of setup and range errors and minimize the impact of these errors on the CTV
coverage and dose to the OARs (38, 139). The literature addressing the impact of spot size on the
plan robustness (setup and range errors) for PBS lung cancer is limited. Liu et al. (70) investigated
the effect of spot size on plan robustness for PBS lung plans and reported that results were similar
in small spot and large spot plans. However, Liu et al. (70) evaluated the setup and range
uncertainties separately, whereas in a real clinical situation, it is possible that setup errors can occur
in conjunction with the range error.
Early investigators have compared small vs. large spot sizes to mitigate the interplay effect. Liu et
al. (70) demonstrated that small spot and large spot machines produced comparable interplay effect
in ten lung cancer patients. By contrast, Grassberger et al. (69) showed that large spot plans are
more robust to motion effects due to reduced interplay effect when compared to the small spot
plans. In a different study by Grassberger et al. (61), it was shown that large spot size plans needed
2 repaintings (either layer or volumetric) to restore the dose, whereas small spot size plans needed
2 to 6 repaintings to mitigate the interplay effect. Liu et al. (70) used synchrotron-based spot
scanning system (Hitachi ProBeat, Hitachi Ltd, Tokyo, Japan), whereas the study by Grassberger
et al. (69) was based on the earlier version of IBA machine at Massachusetts General Hospital.
One of the differences between these two studies was that Grassberger et al. (61, 69) used a nonrobust optimization technique for treatment planning, whereas Liu et al. (70) generated all plans
using a robust optimization technique.
Recently, volumetric repainting technique in an alternating order has been made available on the
ProteusPLUS IBA proton machines with a dedicated PBS nozzle (28). The use of repainting
techniques such as layer and volumetric can reduce the interplay effect by averaging out of hotand cold-spots (31). The alternating order in volumetric repainting allows beam delivery sequences
in “down” and “up” directions – which means beam can be delivered from the highest energy layer
to the lowest energy layer as well as from the lowest energy layer to the highest energy layer. A
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faster energy layer switching in the “down” and “up” directions is achieved by using a magnetic
field regulation feature. In previous studies (28, 29), experiments were performed investigating the
impact of magnetic field regulation in conjunction with the volumetric repainting technique on the
spot size, spot position, and range in PBS proton therapy. In a separate publication (154), a small
spot size beam model was used to investigate the volumetric repainting technique in mitigating the
interplay effect for 4D robustly optimized PBS proton lung plans. However, the impact of large
spot size on plan robustness and interplay effect was not addressed in that study (154).
In recent years, new proton therapy centers are equipped with a small spot size. Proton therapy
vendors may also provide an additional option for the large spot size on the same machine. There
is not enough scientific data available to determine if it is worth purchasing of a PBS proton
machine that can provide both small and large spot sizes. It is not evident how can the proton
center utilize both small and large spot sizes for the volumetric repainting technique in an
alternating order. It is important to understand if there are any dosimetric and radiobiological
benefits in using a small spot size vs. large spot size in PBS proton therapy.
The primary aim of the current study was therefore to investigate the following items:
i.

Impact of spot size on the interplay effect in lung cancer if proton beam is delivered using
a volumetric repainting technique in an alternating order.

ii.

Impact of spot size on plan robustness for lung cancer. For plan robustness, the setup error
is combined with the range error, whereas previous study (70) evaluated the setup and
range errors separately.

iii.

Impact of combination of range and setup errors on the equivalent uniform dose (EUD)
and normal tissue complication probability (NTCP) for the OARs in lung cancer.

8.2

Materials and Methods

8.2.1

Contouring and treatment planning

In this IRB approved retrospective dosimetric study, a total of thirteen lung cancer patients were
selected. Table 8.1 shows the location of CTV and their motions and volumes in the thirteen lung
cancer patients. The selection criteria included the presence of 4DCT scans of ten breathing phases
and the lung tumor motion of less than 15 mm. The mediastinum involvement in the target volume
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was allowed. The 4DCT data set of each patient was anonymized. The tumor motion range ranged
from 2.2 mm to 13.2 mm. The clinical target volume (CTV) was generated by an isotropic margin
of 5 mm around the internal gross tumor volume (IGTV). The average intensity projection CT was
used for treatment planning. Treatment plans were generated in RayStation TPS (clinical version
9B; RaySearch Laboratories, Stockholm, Sweden) based on a single field uniform dose (SFUD)
technique for a total dose of 70 Gy(RBE) with a fractional dose of 2 Gy(RBE) using an average
RBE of 1.1. For a given patient, treatment planning was performed in three steps.
First, a small spot beam model (1σ = 3 mm at isocenter for energy 226.5 MeV) was used to generate
small spot plans with no repainting (SSNR). This model is based on the IBA ProteusPLUS proton
therapy system with a dedicated PBS nozzle (23). For each patient, the optimal beam angles were
selected based on the location of the CTV and OARs. The number of beams in a treatment plan
varied from 2 to 3. Treatment plans were robustly optimized (Monte Carlo; 10,000 ions/spot;
SFUD technique) on the CTV using 5 mm setup uncertainty and 3.5% range uncertainty (158)
with a goal of 99% of the CTV receiving at least 99% of the prescription dose. Once the final dose
calculations (Monte Carlo; 0.5% statistical uncertainty; 3 mm grid size) were completed, SSNR
plans were normalized, such that CTV D99% = 6930 cGy(RBE).
Second, a large spot beam model (1σ = 8 mm at isocenter for energy 226.5 MeV) was used to
generate large spot plans with no repainting (LSNR). Spot profiles in a large spot beam model
were generated by scaling the spot profiles from a small spot beam model. [Figure 8.1] Other beam
model components such as absolute dose output and integrated depth doses (IDDs) remained
identical in large spot and small spot beam models. For a given patient, a SSNR plan was copied
and switched to a large spot beam model. The plan was then robustly re-optimized using the same
settings as the ones in small spot plan optimization. Also, the number of treatment fields,
optimization settings, and optimization objectives remained identical in large spot and small spot
plans. To be consistent with SSNR plans, all LSNR plans were calculated with Monte Carlo (0.5%
statistical uncertainty; 3 mm grid size) and normalized, such that 99% of the CTV received 6930
cGy(RBE).
Third, for a given patient, a SSNR was used to generate a volumetric repainting plan with five
continuous paintings in an alternating order (28) (hereafter referred to as SSVR plans). Dose
distributions in nominal SSNR and SSVR plans were identical. Figure 8.2 shows the schematic of
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the volumetric repainting technique in an alternating order. Similarly, a LSNR plan was used to
generate a volumetric repainting plan with five paintings in an alternating order (hereafter referred
to as LSVR plans). It was verified there was no change in the dose distributions when generating
a LSVR plan from LSNR plan. In order to ensure the deliverability of spots on the machine, a
minimum MU of 0.015 was applied to all SSVR and LSVR plans. All volumetric repainting plans
were generated based on the methodology described by Engwall et al. (38, 139). Prior to dose
computation for robustness testing, both sets of plans (SSVR and LSVR) were verified, such that
CTV D99% = 6930 cGy(RBE).
Table 8.1: The location of CTV and its motion and volume in thirteen lung cancer patients.
Patient #

CTV (cc)

Motion (mm)

Location

Mediastinum
Involvement

1

174.6

2.7

RL

Yes

2

103.9

4.7

LUL

No

3

36.5

7.2

RUL

No

4

181.0

13.2

RLL

No

5

24.4

4.8

LUL

No

6

34.2

5.8

LLL

No

7

23.2

4.2

RL

No

8

22.1

8.8

RLL

No

9

26.0

10.1

RLL

No

10

39.3

10.2

RLL

No

11

366.3

2.5

LL

Yes

12

186.8

2.2

RL

Yes

13

26.5

8.1

RLL

No

Abbreviations: RL = right lung, LL = left lung, LUL = left upper lobe, RUL = right upper lobe,
LLL = left lower lobe, RLL = right lower lobe

8.2.2

Robustness analysis

Plan robustness was investigated for 12 perturbed scenarios, which combined the isocenter shift
and range uncertainty. The isocenter of the patient was shifted by a 5 mm in the superior-inferior,
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anterior-posterior, and right-left directions, whereas ±3.5% was used for the range uncertainty.
The following metrics were used to evaluate the worst-case-scenario (WCS) values based on 12
perturbed scenarios.


CTV: D95%, D96%, D97%, D98%, and D99%.



CTV: D0.03cc



CTV Homogeneity Index (HI): D99%/D1%



Total Lung: Dmean, V20, and V5 (note: total lung includes both lungs except CTV)



Heart: Dmean



Esophagus: Dmean



Spinal Cord: D0.03cc

The difference (Δ) between SSVR and LSVR plans was calculated using equation 1.
∆Df = DfyZze − DfZZze &

A. 8.1&

Where, Df = dosimetric metric (e.g., Dmean, V20, etc.); DfyZze = dosimetric result of Df in LSVR

plan; DfZZze = dosimetric result of Df in SSVR plan;

Figure 8.1: Example of spot profiles from the small spot and large spot models at the isocenter
for 100, 150, and 225 MeV.
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Figure 8.2: Beam delivery directions in a volumetric repainting plan with an alternating order;
Note: beam delivery starts from the distal energy layer to the proximal energy layer, and then
follows an alternating order. All plans in the current study included five repaintings.
8.2.3

Radiobiological analysis

EUD and NTCP evaluation was performed using the dose-volume histograms (DVHs) of the
SSVR and LSVR plans. EUD is based on Niemierko’s phenomenological model. (161, 162) To
estimate the clinical outcomes of the SSVR and LSVR plans, the EUD-based NTCP (161, 162)
was calculated for all perturbed scenarios. The Total lung, heart, and esophagus were evaluated
for the endpoints of pneumonitis, pericarditis, and esophagitis, respectively (161, 162). The
difference (Δ) in radiobiological results were evaluated using equation 1.
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(Eq. 8.2)

(Eq. 8.3)

(Eq. 8.4)

a = unit-less model parameter that is specific to the normal structure or tumor of interest
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vi = unit-less ith partial volume receiving dose Di in Gy
EQD = biologically equivalent physical dose of 2 Gy
nf = number of fractions
df = D/nf = dose per fraction size of the treatment course
TD50 = tolerance dose for a 50% complication rate at a specific time interval when the whole organ
of interest is homogeneously irradiated
γ50 = unit-less model parameter that is specific to the normal tissue of interest and describes the
slope of the dose-response curve
The values of a, γ50, and TD50 for OARs were obtained from the published literature (163-165).
8.2.4

Interplay effect analysis

The interplay effect was studied in RayStation TPS (clinical version 9B) using the methodology
described by Engwall et al. (38, 139). First, deformable registration was performed between the
average intensity projection CT and breathing phases from the 4DCT data set using ANAtomically
CONstrained Deformation Algorithm (ANACONDA) (139). For the interplay effect analysis, we
used the energy layer switching time of 1 s and spot delivery time of 4.0 ms/MU. The motion
speed between spots was set to 250 cm/s. The analysis was performed with an assumption of
treatment delivery starting in two phases:

0% representing end-inhalation (T0) and 50%

representing end-exhalation (T50). The spots in a treatment plan were distributed over ten
breathing phases according to starting phase (T0 and T50) for the beam delivery and spot timings
as mentioned above. Dose was computed on ten different breathing phases based on the spot
distribution (38, 139). This was followed by mapping of the dose to the reference phase through
deformable registration (38, 139). The final step included the accumulation of the mapped doses
on the reference phase (38, 139). The interplay DVHs were utilized to evaluate CTV D95%, D99%,
and HI.
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8.3

Results

8.3.1

Target volume

8.3.1.1

Plan robustness

Figure 8.3(a) shows the WCS results of the CTV D95%, D96%, D97%, D98%, and D99%. For a given
dosimetric metric, the WCS result in the SSVR plan (denoted by a circle in Figure 8.3(a)) was
higher than in the LSVR plan (denoted by a star in Figure 8.3(a)), thus clearly indicating that SSVR
plans were more robust than LSVR plans. Specifically, on average, the WCS values at D95%, D96%,
D97%, D98%, and D99% were higher by 2.2% (range, 0.3% ― 3.7%), 2.3% (range, 0.5% ― 4.0%),
2.6% (range, 0.6% ― 4.4%), 2.7% (range, 0.9% ― 5.2%), and 2.7% (range, 0.3% ― 6.0%),
respectively. For robustness acceptance criteria of D95% ≥ 6860 cGy(RBE), seven SSVR plans had
all 12 perturbed scenarios meeting the criteria, whereas, for thirteen LSVR plans, there were more
than ≥2 scenarios failing to meet the criteria. For treatment plans failing to meet the robustness
criteria for all scenarios (Figure 8.3(b)), the number of scenarios that met the criteria ranged from
9 to 11 in SSVR plans (n = 6) and from 6 to 10 in LSVR plans (n = 13). Hot spot evaluation showed
that the average difference in WCS values of D0.03cc was lower in SSVR plans by 0.4±1.4%.
Figures 8.3(c) and 8.3(d) show the nominal HI and WCS HI of perturbed scenarios, respectively,
for all thirteen patients. For both nominal and perturbed scenarios, small spot plans produced more
homogenous dose distributions compared to large spot plans. Specifically, for a nominal scenario,
dose homogeneity was superior in SSVR plans (HI = 0.97) than in LSVR plans (HI = 0.95). A
similar trend was observed for the perturbed scenarios. The WCS HI was 0.91 and 0.88 in SSVR
and LSVR, respectively.
8.3.1.2

Interplay effect

Figure 8.4 illustrates an example of nominal and interplay dose distributions in small spot and
large spot plans with and without volumetric repainting technique. Figure 8.5 provides the
difference in CTV D95% and D99% from interplay DVHs between small spot and large spot plans.
In the absence of volumetric repainting, large spot plans were found to be more robust to interplay
effect when compared to small spot plans. Specifically, the average differences in D95% and D99%
between LSNR and SSNR plans were 1.2±1.0% and 1.3±1.4%, respectively. Figures 8.4 (c) and
(d) illustrate the interplay dose distributions in LSNR and SSNR plans, respectively. The loss of
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CTV D99% (blue color) is clearly visible in interplay SSNR dose distribution as shown in Figure
8.4(d). However, after utilizing volumetric repainting technique in both sets of plans, the interplay
dose distributions between small and large spot plans were found to be comparable. The average
differences in D95% and D99% between LSVR and SSVR plans were 0.4±0.6% and 0.4±0.8%,
respectively. Figure 8.4(f) illustrates that the target coverage loss was recovered in interplay SSVR
dose distribution after applying five volumetric repaintings. Figure 8.5 shows the summary of HI
results from interplay DVHs of small spot and large spot plans. If no volumetric repainting
technique was used, the HI in LSNR was slightly better than in SSNR plans (0.94±0.02 vs.
0.92±0.03). The use of volumetric repainting technique resulted in similar HI results in LSVR
(0.95±0.01) and SSVR (0.96±0.01) plans.

Figure 8.3: (a) The worst-case-scenario (WCS) values in the LSVR and SSVR plans at different
dosimetric metrics; (b) Number of perturbed scenarios passing meeting the robustness criteria in
LSVR and SSVR plans; (c) Nominal HI in LSVR and SSVR plans; and (d) WCS HI in LSVR and
SSVR plans.
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Figure 8.4: Nominal and interplay dose distributions in small spot and large spot plans with and
without volumetric repainting technique in an example patient. Note: Red contour = CTV, Blue =
6930 cGy(RBE), yellow = 6650 cGy(RBE); green = 3000 cGy(RBE); Abbreviations: LSNR = large
spot plan with no volumetric repainting, SSNR = small spot plan with no volumetric repainting,
LSVR = large spot plan with 5 volumetric repaintings, SSVR = small spot plan with 5 volumetric
repaintings
8.3.2

OARs

Figure 8.6(a) shows the difference in D0.03cc to the spinal cord in nominal plans. The difference in
WCS D0.03cc to the spinal cord are presented in Figure 8.6(b). For a nominal scenario, a large spot
beam model resulted in a higher D0.03cc by an average difference of 1570 cGy(RBE). A similar
observation was made for the WCS D0.03cc to the spinal cord (Δ = 1562 cGy(RBE)). Both the
nominal and WCS Dmean to the esophagus, heart, and total lung were higher in LSVR plans.
(Figures 8.6(c) and 8.6(d)) Specifically, for a nominal scenario, the average difference for the
esophagus, heart, and total lung was 576 cGy(RBE), 212 cGy(RBE), and 505 cGy(RBE),
respectively, whereas the difference in WCS values from the perturbed scenarios was 572
cGy(RBE), 258 cGy(RBE), and 549 cGy(RBE), respectively. The average difference in V20 and
V5 of the total lung for a nominal scenario was 8.3% and 12.0%, respectively. (Figure 8.6(e)) A
similar difference was found for the WCS V20 (Δ = 8.9%) and V5 (12.4%) of the total lung. (Figure
8.6(f))
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Figure 8.5: Difference in CTV D95%, D99% and HI from interplay DVHs between small spot and
large spot plans.
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Figure 8.6: (a) Difference in D0.03cc of nominal results for the spinal cord between LSVR and
SSVR plans; (b) Difference in D0.03cc of WCS results for the spinal cord between LSVR and SSVR
plans; (c) Difference in Dmean of nominal results for the OARs (esophagus, heart, and total lung)
between LSVR and SSVR plans; (d) Difference in Dmean of WCS results for the OARs (esophagus,
heart, and total lung) between LSVR and SSVR plans; (e) Difference in V20 and V5 of nominal
results for the total lung between LSVR ad SSVR plans; (f) Difference in V20 and V5 of WCS
results for the total lung between LSVR ad SSVR plans.
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Figure 8.7: EUD of total lung for twelve perturbed scenarios (S1 to S12) in SSVR and LSVR plans
of all thirteen patients.
Table 8.2 provides the WCS results of EUD and NTCP for the total lung, heart, and esophagus.
Figure 8.7 shows the total lung EUD for twelve perturbed scenarios in all thirteen patients. On
average, the difference in EUD was 469 cGy(RBE) for the total lung, 495 cGy(RBE) for the heart,
and 557 cGy(RBE) for the esophagus. For the NTCP, the difference ranged from 0% to 1.91% for
the total lung, from 0% to 0.34% for the heart, and from 0% to 32.80% for the esophagus.
Table 8.2: EUD and NTCP for the total lung, heart, and esophagus in SSVR and LSVR plans.
Total Lung
EUD (cGy(RBE))
Patient #
SSVR LSVR Δ
1
636
1128
492
2
708
931
223
3
497
1064
566
4
548
1087
540
5
259
600
341
6
407
806
400
7
99
281
181
8
484
1117
633
9
431
728
296
10
671
1359
688
11
752
1262
510
12
977
1641
664
13
426
990
564

NTCP (%)
SSVR LSVR
0.00
0.10
0.00
0.02
0.00
0.06
0.00
0.07
0.00
0.00
0.00
0.01
0.00
0.00
0.00
0.09
0.00
0.00
0.00
0.44
0.00
0.24
0.03
1.94
0.00
0.03
98

Δ
0.10
0.02
0.06
0.07
0.00
0.01
0.00
0.09
0.00
0.43
0.24
1.91
0.03

Heart
EUD (cGy(RBE))
Patient #
SSVR LSVR Δ
1
2200
2866
666
2
49
331
282
3
1831
2644
813
4
1953
2705
752
5
4
229
225
6
658
1508
850
7
0
7
7
8
1097
1441
344
9
250
414
164
10
681
1041
361
11
32
631
599
12
2356
3003
647
13
1655
2386
731
Esophagus
EUD (cGy(RBE))
Patient #
SSVR LSVR Δ
1
4002
4896
894
2
981
1520
538
3
3
137
133
4
1779
3266
1487
5
387
629
242
6
463
1503
1040
7
3184
3722
538
8
0
34
34
9
0
0
0
10
535
597
63
11
4399
4870
471
12
3529
4792
1263
13
198
738
540

8.4

NTCP (%)
SSVR LSVR
0.01
0.20
0.00
0.00
0.00
0.08
0.00
0.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.02
0.36
0.00
0.02

Δ
0.20
0.00
0.08
0.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.34
0.02

NTCP (%)
SSVR LSVR
12.57
41.91
0.00
0.01
0.00
0.00
0.02
2.75
0.00
0.00
0.00
0.01
2.25
7.44
0.00
0.00
0.00
0.00
0.00
0.00
23.45
40.87
5.00
37.79
0.00
0.00

Δ
29.34
0.01
0.00
2.73
0.00
0.01
5.19
0.00
0.00
0.00
17.42
32.80
0.00

Discussion

The current study was performed to determine if there is a dosimetric and radiobiological benefit
of using small spot size vs. large spot size for lung plans in PBS proton therapy. All treatment
plans in our study were robustly optimized against the setup and range uncertainties. Also, we
assumed that range uncertainties occurred in conjunction with an isocentric shift of the patient in
a given direction (superior-inferior, anterior-posterior, and right-left), thus resulting in 12
perturbed scenarios. In order to make a fair plan comparison, both sets of plans (SSVR and LSVR)
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were normalized, such that CTV D99% = 6930 cGy(RBE). The WCS results at various dosimetric
metrics of the CTV showed that the target coverage in LSVR plans was reduced by up to 6%. In
comparison to LSVR plans, the number of scenarios passing the robustness criteria (D95% ≥ 6860
cGy(RBE)) in each patient was higher in SSVR plans, except for patient #8 and patient #12 – both
plans (SSVR and LSVR) produced the same number of scenarios passing the criteria for these two
patients.
Recently, new proton centers are installing machines with smaller spot size. Plan robustness results
from our study demonstrated that if a lung plan is robustly optimized with a small spot beam model
(~3 mm) and volumetric repainting is applied, it is feasible to generate a treatment plan that is
robust against the setup and range errors. However, if an SSVR plan requires the use of a range
shifter in the beam path, this will create an air gap between the downstream of a range shifter and
patient body/immobilization devices. Since in-air spot size increases within an increase in the air
gap (15, 27, 77), it is recommended to minimize the air gap between the range shifter and patient.
This will allow maintaining the robustness of the target volume against the setup and range errors
as well as decrease the EUD for the OARs.
The OARs results from our study showed that the smaller spot model produced a lower dose to
the normal total lung, heart, esophagus, and spinal cord. These findings are in agreement with Liu
et al. (70). We also noticed that the small spot model resulted in a decrease in EUD for the total
lung, heart, and esophagus. The NTCPs for the total lung and heart were found to be comparable
in both sets of plans, whereas the difference in NTCP of esophagus between large spot and small
spot plans was found to vary from 0% to 32.8%. Such a large difference in NTCP of esophagus
between two sets of plans can be attributed to the location of tumor volume. In patient #1 (ΔNTCP
= 29.3%), #11 (ΔNTCP = 17.4%), #12 (ΔNTCP = 32.8%), the mediastinum is included in the
CTV. The location of the CTV in proximity of esophagus and wider penumbrae from large spots
were found to be contributing factors for increased EUD and NTCP of esophagus in large spot
plans of patients # 1, 11, and 12. The NTCP results presented in our study include the uncertainty
in the calculations. The NTCP calculations included the parameters that are derived from the
photon therapy. Proton specific radiobiological parameters for the lung cancer are needed to obtain
more accurate NTCP calculations, which can be correlated to the tissue toxicities.
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Although our study was undertaken on the lung disease site, it is relevant to mention plan
robustness studies conducted on other disease sites. For instance, Moteabbed et al. (50)
investigated the impact of spot size on fourteen patients (7 CNS, 4 head & neck, 2 pelvic and 1
thoracic solid tumors) and concluded that plan quality improved as the spot sized decreased. More
recently, Kraan et al. (76) investigated the impact of spot size on plan robustness in seven patients
of different cancer sites (pelvis, chest wall, rectum, chordoma, cardiac, retroperitoneal, and
sarcoma). The results from Kraan et al. (76) showed that small spot plans are more robust against
spot size changes than large spot plans.
Treatment of lung cancer using PBS protons can raise the concern of the interplay effect between
tumor motion and delivery of pencil proton beams. The interplay effect evaluation from our study
provided two major observations. First, if PBS lung plans with motion did not include the
volumetric repainting, small spot plans were found to be more sensitive to the interplay compared
to large spot plans. Similar observation was reported by Grassberger et al. (69) in their PBS lung
cancer study (no repainting strategies utilized). The repainting techniques were applied by
Grassberger et al. (61) in a separate study with focus on layer and volumetric repainting techniques.
It was demonstrated that the number of repaintings needed in large spot plans was lower than in
small spot plans. The robust optimization technique was not applied in their study (61). Our second
observation was that, after applying 5 volumetric repaintings, the interplay effect in SSVR and
LSVR plans were found to be comparable. Liu et al. (70) also reported the comparable interplay
effect results for small spot and large spot plans using layer repainting strategies. In the current
study, we applied a total of five volumetric repaintings across all patients. For a given treatment
field in a patient, the beam-on time and number of energy layers in small spot vs. large spot plan
was found to be similar. Overall, for 5 volumetric repaintings, beam-on time per treatment field
ranged from 72 seconds to 216 seconds, whereas the energy layers ranged from 65 to 165. The
number of volumetric repaintings needed to reduce the interplay effect could vary from one patient
to another (38, 154). The readers must not assume that five repaintings used in the current study
are an ideal number for the volumetric repainting technique in PBS lung cancer plans. Instead,
patient specific interplay effect evaluation is recommended to determine the optimal number of
repaintings (38, 154).
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8.5

Conclusion

For robustly optimized PBS lung cancer plans in our study, a small spot machine resulted in a
more robust CTV against the setup and range errors when compared to a large spot machine.
Overall, small spot plans produced lower EUD for the OARs. In the absence of volumetric
repainting technique, large spot PBS lung plans were more robust against the interplay effect such
that the average differences in D95% between large spot and small spot plans was 1.2±1.0%.
However, the use of a volumetric repainting technique in an alternating order in both small and
large spot PBS lung cancer plans led to comparable interplay target coverage with an average
difference in D95% of 0.4±0.6%.
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Chapter 9
Impact of errors in spot size and spot position in
robustly optimized pencil beam scanning proton-based
stereotactic body radiation therapy (SBRT) lung plans
This chapter has been published in the Journal of Applied Clinical Medical Physics:
Rana S, Rosenfeld AB. Impact of errors in spot size and spot position in robustly optimized pencil
beam scanning proton-based stereotactic body radiation therapy (SBRT) lung plans. Journal of
Applied Clinical Medical Physics. 2021 Jul;22(7):147-154.

9.1

Introduction

In pencil beam scanning (PBS) proton delivery, the accuracy of the size and position of a pencil
proton beam is very critical to minimize the discrepancies between the delivered and computed
dose. Spot sizes on the proton beam delivery system can be affected by the fluctuations in the beam
extraction and transport systems (72). Additionally, the presence of different scattering materials
in the nozzle (72), as well as the air gap between the range shifter and patient, can have an impact
on the spot size (77). Similarly, the positioning of the spots can be affected by the fluctuations in
the steering magnetic fields (71, 75). Hence, the variations in the delivered spot sizes and positions
could lead to perturbation of dose distributions impacting the quality of the treatment plan
delivered to the patient (71-77).
In order to minimize the discrepancies between the computed and delivered dose distributions in
PBS proton therapy, tolerance levels are proposed for the spot size and position errors. Parodi et
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al. (72) evaluated the impact of spot size on spherical phantom plans and proposed the tolerance
of ±50%. Chanrion et al. (73) studied the variations in spot sizes on prostate and skull-base patients
and reported negligible to moderate changes in dose distributions when spot sizes are changed by

⩽25%. Lin et al. (44) performed a study on 28 patients of different disease sites (breast, sarcoma,
central nervous system, pediatric, gastrointestinal, genitourinary, and gynecological). Based on

their gamma analysis, the spot size tolerance of ±10% was proposed (44). Kraan and colleagues
(76) demonstrated that the variation in spot size is patient and spot width dependent. Their study
(76) included seven patients of different disease sites (pelvis, chest wall, rectum, chordoma,
cardiac, retro-peritoneal, and sarcoma) and a phantom. If in-air one sigma (σ) of a pencil beam is
2.5 mm, the tolerance is ±25% (76). Similarly, for σ of 5 mm and 10 mm, the proposed tolerances
are ±25% and ±10%, respectively (76). For the spot position errors, the tolerance of ±1 mm has
been reported by the investigators (44, 75, 78, 166). Recently, the AAPM TG224 report (126)
recommended the tolerance of ±10% for the spot size and ±1 mm for the spot position.
Previous publications (44, 71-78) have reported the variations in spot size and position in the
phantoms and disease sites but not for the lung. For PBS lung cancer treatment, the accuracy of
the dose calculation algorithm in predicting spot size and dose distributions becomes more critical
due to varying tissue densities in the proton beam path. In commercial proton treatment planning
systems (TPS), Monte Carlo algorithms have been shown to be more accurate in estimating spot
sizes than analytical pencil beam algorithms (17, 148). A growing number of publications (62, 64,
66, 142) have now recommended using the Monte Carlo algorithm for the dose calculations in
PBS lung cancer. Recently, robust optimization (139, 142) feature has been made available in the
clinical environment, whereas previous studies (44, 72-74, 76) did not address the impact of
variation in spot size on robustly optimized clinical plans. It is essential to understand the effects
of errors in spot sizes on the Monte Carlo algorithm-based robustly optimized PBS lung cancer
plans. Additionally, none of the previous studies (44, 71-78) have studied the impact of the errors
in spot sizes and positions simultaneously. In the current study, we aim to investigate the following
items regarding the robustly optimized PBS proton based stereotactic body radiation therapy
(SBRT) lung plans:


Dosimetric impact of spot size errors of ±10%, ±15%, and ±20%.
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Dosimetric impact of spot size and position errors occurring simultaneously. The
simultaneous evaluation is performed by combining spot size and position errors (spot size:
±10% and spot position: ±1 and ±2 mm).



Overall effect of spot size (±10%) and position (±1 mm) errors in conjunction with either
setup (±5 mm) or range (±3.5%) errors.

9.2

Methods and Materials

9.2.1

Contouring and treatment planning

In this retrospective study, PBS lung plans were re-planned on the computed tomography (CT)
data set of five lung patients. The clinical target volume (CTV) ranged from 24.27 cc to 63.24 cc.
The CTV was created by an isotropic margin of 5 mm around the internal gross tumor volume
(IGTV). The IGTV was obtained based on the 4-dimensional computed tomography (4DCT)
images. For proton planning, the average intensity projection CT was utilized.
RayStation TPS (version 9B; RaySearch Laboratories, Stockholm, Sweden) was used for treatment
planning. The Proton beam model is based on the IBA ProteusPLUS proton therapy system with
a PBS dedicated nozzle (Ion Beam Applications, Louvain-la-Neuve, Belgium) (23, 26). The in-air
one sigma (σ) for 226.5 MeV at the isocenter is ~3 mm (23). For each patient, a nominal plan was
re-generated for a total dose of 5000 cGy(RBE) in 5 fractions using an average RBE of
1.1.Treatment plans were robustly optimized using a single field optimization (SFO) technique.
The Monte Carlo algorithm (10,000 ions/spot) was utilized for the robust optimization. The
robustness (range uncertainty = 3.5% and setup error = 5 mm) was applied on the CTV such that
it's 99% of the relative volume receives at least the prescription dose (5000 cGy(RBE)). Based on
the input values of robustness parameters, RayStation optimized each plan for a total of 21
scenarios. The final dose calculations were performed using the Monte Carlo (grid size: 2 mm;
statistical uncertainty = 0.5%). This was followed by the creation of a volumetric repainting plan
with five paintings in an alternating order (28, 154). The resulting plan was then normalized such
that the CTV D99% = 5000 cGy(RBE). The final nominal plan was denoted as D(0%, 0 mm), which
means 0% error in spot size and 0 mm error in spot position.
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9.2.2

Spot size errors simulation

In order to simulate the spot size errors of ±10%, ±15%, and ±20%, additional six beam models
were generated. These were simulated by scaling the spot profiles in the nominal beam model. In
the simulated beam models, absolute dose output and integrated depth doses (IDDs) remained
identical as in the nominal beam model.
9.2.3

Dose calculations for spot size errors only

The spot size errors calculation was performed by re-computing D(0%, 0 mm) plan using the
simulated beam models (±10%, ±15%, and ±20%). For instance, if D(0%, 0 mm) plan was recomputed for the spot size error of +10% and spot position error of 0 mm, the resulting plan was
denoted as D(+10%, 0 mm). Similarly, for -20% spot size and 0 mm spot position errors, the plan
was denoted as D(-20%, 0 mm). Dose re-computations were performed using the Monte Carlo
algorithm without plan re-optimization.
9.2.4

Spot position errors simulation

The D(0%, 0 mm) plan containing the spot position information was exported from the TPS to a
local computer. Then, spot positions in the treatment plan were varied systematically by -1 mm
and +1 mm, thus resulting in two simulated plans, D(0%, -1 mm) and D(0%, +1 mm), respectively.
This process was repeated for the systematic shift of spot positions by ±2 mm to generate D(0%,
-2 mm) and D(0%, +2 mm) plans. The simulation of spot position errors was performed using an
in-house developed MatLab code (version R2019b; MathWorks, Natick, MA, USA).
9.2.5

Dose calculation for the spot size and position errors occurring simultaneously

For each patient, simulated plans for spot positions (as described in section 8.2.D) were imported
back into RayStation TPS. The D(0%, -1 mm) plan was re-computed using Monte Carlo algorithm
(without re-optimization) for the spot size errors of -10% and +10%, resulting in D(-10%, -1 mm)
and D(+10%, -1 mm) plans, respectively. The D(0%, +1 mm) plan was re-computed using Monte
Carlo algorithm (without re-optimization) for the spot size errors of -10% and +10%, resulting in
D(-10%, +1 mm) and D(+10%, +1 mm) plans, respectively. Similarly, the D(0%, -2 mm) and
D(0%, +2 mm) plans were re-computed using Monte Carlo algorithm (without re-optimization)
for ±10% spot size errors.
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9.2.6

Robustness

The D(±10%, ±1 mm) plans were evaluated for a total of eight scenarios. The setup uncertainty
was simulated by a 5 mm isocenter shift in the left-right, superior-inferior, and anterior-posterior
directions of the patient resulting in six scenarios. The range uncertainty was evaluated for two
scenarios (±3.5%).
9.2.7

Analysis

The analysis was divided into three groups. The first group (Group 1) consisted of plans simulated
for spot size errors only, as described in section 8.2.C. The second group (Group 2) included the
plans that were simulated for spot size and position errors occurring simultaneously. The simulated
plans in the Group 2 are described in section 2.E. Finally, the third group (Group 3) included the
evaluation of D(±10%, ±1 mm) plans for setup (±5mm) and range (±3.5%) uncertainties as
described in section 2.F.
The difference (∆) at a dosimetric metric (e.g., D99%) between simulated and nominal plans was
calculated using equation 1.
∆=
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The difference was averaged (Δavg) over five patients.
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The CTV dose homogeneity index (HI) was evaluated using equation 3, as shown below:
T =

D@% − D]]% &

A. 9.3&

where, Rx is the prescription dose (5000 cGy(RBE)). Based on equation (3), the HI value of 0 is
considered an ideal HI result.
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9.3

Results

9.3.1

Group 1: Spot size errors

The spot size errors resulted in a loss of the target coverage. [Figure 9.1] The reduction in target
coverage increased as the magnitude of spot size error was increased.
D95%: The Δavg. at D95% for -10% and +10% errors were -0.4% and -0.6%, respectively. The Δavg.
at D95% was -1.0% for ±15% errors. The Δavg. at D95% was -1.6% for ±20% errors.
D99%: The Δavg. at D99% for -10% and +10% errors were -0.7% and -1.1%, respectively. The Δavg.
at D99% was -1.4% for -15% error and -1.9% for +15% error. The Δavg.at D99% was -2.1% for -20%
error and -2.8% for +20% error.

Figure 9.1: The average difference in CTV D95% (left panel) and D99% (right panel) between
simulated plans in Group 1 and nominal plans for the spot size errors (±10%, ±15%, and ±20%).
The results are averaged over all five patients.
HI: On average, the difference in HI results between nominal D(0%, 0 mm) and simulated plans
for ±10% errors (D(+10%, 0 mm) and D(-10%, 0 mm)) was 0.01. For ±15% and ±20% spot size
errors, decreasing spot sizes resulted in less homogeneous plans compared to increasing spot sizes.
Specifically, for the spot size errors of ±15%, it was found that the average difference in HI was
worse for D(-15%, 0 mm) plan (0.03) than D(+15%, 0 mm) plan (0.01) when their results were
compared against D(0%, 0 mm) plan. A similar trend was observed for the spot size errors of
±20%, with the average difference in HI being worse for D(-20%, 0 mm) plan (0.04) than D(+20%,
0 mm) plan (0.02) when their results were compared against D(0%, 0 mm) plan.
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Figure 9.2: Dose distributions in an example patient: (a) nominal plan, (b) simulated plan for the
decreasing spot size (-10%) and spot position (+1 mm) evaluated simultaneously; (c) simulated
plan for the increasing spot size (+10%) and spot position (+1 mm) evaluated simultaneously. The
loss of target coverage in the simulated plans is shown by the red arrows on the right panel.
9.3.2

Group 2: Spot size and position errors occurring simultaneously

Figure 9.2 illustrates the dose distributions in an example patient for the nominal plan and
simulated plan for the combined errors of the decreasing (increasing) spot size -10% (+10%) and
spot position (+1 mm). Figure 9.3 shows the reduction in target coverage between the nominal
plan and simulated plans for the spot size errors (±10%) and spot position errors (±1 mm). For a
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10% increase in spot size and ±1 mm shift in spot position, the Δavg. at D99% was -1.5% for
D(+10%, -1 mm) plan and -1.8% for D(+10%, +1 mm) plan. For a 10% decrease in spot size and
±1 mm shift in spot position, the Δavg. at D99% was -0.8% for D(-10%, -1 mm) plan and -0.9% for
D(-10%, +1 mm) plan. Figure 9.3 also exhibits the results from D(±10%, ±2 mm) plans (n=20) for
the spot size errors of ±10% and spot position errors of ±2 mm. For D(±10%, ±2 mm) plans, the
Δavg. at D99% was -2.4%.

Figure 9.3: The average difference in CTV D99% between simulated plans in Group 2 and
nominal plans for the spot size errors (±10%) in conjunction with spot position errors (±1 and ±2
mm). The results are averaged over all five patients.

Figure 9.4: (left panel) The average CTV D99% (left panel) from 120 plans of 5 patients from
Group 3 analysis; (right panel) The average difference in CTV D99% between simulated plans in
Group 3 and nominal plans. The results are averaged over all five patients.
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9.3.3

Group 3: Setup and Range errors

Figure 9.4 shows the results for simulated plans when setup (6 scenarios) and range (2 scenarios)
errors are evaluated in conjunction with spot size (±10%) and position (±1 mm) errors occurring
simultaneously. The results are based on 160 plans (1 scenario × 4 plans for spot size (±10%) and
position (±1 mm) errors × 8 scenarios × 5 patients). The average D99% was 4748 cGy(RBE), with
an average reduction of 5.0%.
Figure 9.5 illustrates the difference in HI for various scenarios. The worse HI result was obtained
for a 5 mm isocenter shift in the superior-inferior directions (y = ±5 mm). The average difference
in HI was 0.06.

Figure 9.5: (left panel) The difference in CTV homogeneity index (HI) for eight different scenarios
between simulated plans in Group 3 and nominal plans; (right panel) Robustness parameters for
eight scenarios of Group 3 analysis. The D(±10%, ±1 mm) plans are evaluated for setup (±5mm)
and range (±3.5%) uncertainties as described in section 9.2.6.

9.4

Discussion

The current study was performed to investigate the dosimetric impact of variations (errors) in the
spot sizes and spot positions in PBS proton-based SBRT lung plans. The results reported in the
current study complement previous findings (44, 72, 73, 76) by adding the impact of variations in
spot sizes and positions in robustly optimized PBS lung plans. Due to the availability of the Monte
Carlo algorithm in commercially available TPS, researchers are recommending the Monte Carlo
algorithm for the optimization and dose calculations in the proton lung plans (62, 64, 66, 142). The
current study provides additional information regarding the impact of spot size and position errors
111

on the dose distributions of the lung plans, which were robustly optimized (SFO technique) and
calculated using the Monte Carlo algorithm.
For a patient cohort in the current study, the variations in spot sizes resulted in decreased target
coverage and dose homogeneity. This was true for both the increasing and decreasing spot sizes.
For the spot size errors of ±10%, the average loss of target coverage was almost identical. Also,
there was a minimum difference in the loss of target coverage between the increasing vs.
decreasing spot sizes for the ±15% category. However, for the spot size errors of ±20%, it was
found that the increasing spot sizes resulted in a greater loss of target coverage at D99% when
compared to the decreasing spot sizes. The loss of target coverage due to the increasing and
decreasing spot sizes can be attributed to the change in the lateral penumbra. The increase in spot
size led to the broadening of the lateral penumbra, whereas the decrease in spot sizes led to the
contraction of the lateral penumbra (73, 76). The evaluation at D1% showed that, for the same
magnitude of error, the average difference was higher (positive difference) for the decreasing spot
sizes than for the increasing spot sizes. These findings suggest that the decreasing spot sizes will
also result in overdosage and loss dose homogeneity in the target volume.
During proton beam delivery, there is a probability of variations in both spot sizes and positions.
Previous studies (44, 71-78) did not investigate the variations in spot sizes and positions
simultaneously but rather focused either on the spot sizes or spot positions. According to AAPM
TG224, the recommended tolerances for the spot sizes and spot positions are ±10% and ±1 mm,
respectively. By simulating the errors in spot sizes (±10%) and positions (±1 mm) during beam
delivery, we quantified the loss of target coverage for a situation when both of these parameters
could deviate from the planned parameters. For the decreasing spot sizes (-10%) in conjunction
with ±1 mm spot position errors, the target coverage was reduced by up to 1.1% (at D99%). For the
increasing spot sizes (+10%) in conjunction with ±1 mm spot position errors, the target coverage
was reduced by up to 2.5% (at D99%). If all the results of ±10% spot size errors in conjunction with
±1 mm spot position errors are analyzed together, the average difference in the target coverage at
D99% was -1.3% (range, -0.5% to -2.5%). [Figure 9.3] The results from the combined effect of spot
size and position errors demonstrated the need for having stringent quality assurance (QA)
tolerances to avoid the loss of target coverage due to variations in spot sizes and positions. It is
important to note that clinical outcomes can be correlated to the minimum dose to the delivered
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tumor volume (33, 146). In a more recent study, Sood et al. (146) noted the D99% as a potential
predictive parameter for clinical outcome in photon-based lung SBRT.
The majority of the proton centers evaluate the robustness of PBS plans against the setup and range
uncertainties (98), but there appears to be no common consensus on the plan robustness criteria in
the proton therapy community. During PBS proton beam delivery, there is a possibility of
delivered spots deviating from their calculated sizes and positions. In the current study, we
demonstrated how the variations in spot sizes and positions could be combined with either setup
uncertainty or range uncertainty. By assuming the spot size and position errors (±10% and ±1 mm,
respectively) occurring simultaneously in conjunction with setup errors, the D99% was decreased
by the average difference of 6.1%. Similarly, for the range errors in conjunction with the spot size
and spot position errors, we noticed that the average decrease in D99% by 2.0%. These results
suggest that the impact of setup errors was greater by threefold than the impact of range errors in
robustly optimized PBS lung plans when spot size and position errors are included in plan
robustness evaluation. The spot size and position errors in our study were simulated systematically.
During a real clinical scenario of proton beam delivery, the deviations in spot size and position
may not be systematic. Future studies should investigate the impact of random occurrence of spot
size and position errors in PBS lung cancer plans.

9.5

Conclusion

The increasing and decreasing spot sizes resulted a reduction in D99% (up to 1.1% for ±10% error)
and dose homogeneity (up to 0.01 for ±10% error). The addition of spot size (±10%) and position
(±1 mm) errors to plan robustness parameters (setup and range uncertainties) showed the average
reduction in D99% by 5% and in dose homogeneity by 0.06.
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Chapter 10
Quantitative analysis of dose-averaged linear energy
transfer (LETd) robustness in pencil beam scanning
proton lung plans
This chapter has been published in Medical Physics:
Rana S, Traneus E, Jackson M, Tran L, Rosenfeld AB. Quantitative analysis of dose-averaged
linear energy transfer (LETd) robustness in pencil beam scanning proton lung plans. Medical
Physisc. 2022 May;49(5):3444-3456.

10.1 Introduction
The current clinical practice in proton therapy uses a constant relative biological effectiveness
(RBE) of 1.1(167). The RBE can vary depending on the dose, treatment technique, cell type,
radiosensitivity of the tissues, α/β ratio, oxygenation, clinical or biological endpoint, and linear
energy transfer (LET) (79, 167). LET is related to local ionization density and results in a higher
probability of DNA double-strand break (DSB) production (81). Previous studies (85, 88, 96, 167)
have reported that the increase in RBE can be predicted from the increase in dose-averaged LET
(LETd) for therapeutic proton energies. In LETd calculations (equation 10.1), the electronic
stopping power of each individual particle is weighted over its contribution to the local deposited
dose (81). In proton therapy, LETd varies from 1 to 15 keV/µm from entrance to the distal part of
the spread-out Bragg peak.(81, 82)
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where, Li = total electronic stopping power and εi = energy loss of particle i in a small volume.
Several RBE models have been proposed in proton therapy (83). From a clinical perspective, the
correlation between LETd and biologically effective dose has been demonstrated by showing
increased radiation-induced brain toxicity with high LETd in the high-dose regions in glioma
patients (94, 95). In most situations the highest LETd is associated with low physical doses at the
very distal part of the spread-out Bragg peak (SOBP) (94, 95). Nevertheless, increasing LETd lead
to propagation of higher RBE-weighted dose in depth in comparison with physical dose multiplied
by 1.1 that should be considered when OAR in close proximity to the CTV (94, 95). In pencil
beam scanning (PBS) proton therapy, an advanced robust optimization feature is available to
generate proton plans (158, 159). In this paper, robust optimization is used to compensate the setup
and range uncertainties. It is well documented that proton therapy is highly sensitive to the range
and setup uncertainties (97, 98). The LETd distributions may vary in a patient due to treatment
uncertainties. Hahn et al. (101) investigated the impact of range uncertainty (±3.5%) on the LETd
distributions in the brain, head and neck, and prostate patients and it was demonstrated that the
LETd distributions in the target volumes were more homogeneous than in organs at risk (OARs)
which are in close proximity to the target volumes. Several other investigators have quantified the
LETd values in the target volumes for head and neck (104, 105, 108, 109), liver (102), prostate
(102, 106), and brain (102, 103, 107, 109) cancers. In a more recent study, Shang et al. (110)
investigated the impact of multiple beams on the LETd distributions in lung plans. However, the
impact of treatment uncertainties on the LETd distributions in lung plans was not considered(110).
Also, the impact of different breathing phases on the LETd distributions was not quantified (110).
To date, it is not very clear how the range and setup uncertainties may impact the LETd
distributions in robustly optimized (in terms of the range and setup uncertainties) pencil beam
scanning (PBS) proton lung cancer plans. The proton therapy community continues to treat lung
cancer using PBS protons (32, 34). This may include various motion management techniques (32,
34). Underwood et al.(168) performed a retrospective analysis of lung density changes in chestwall patients previously treated with protons or photons. Their study concluded that proton RBE
could be more than 1.2 due to lung density changes leading to an increase in LET and related RBE
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in higher density lung regions resulting in lung fibrosis. Due to large density variations between
air and lung tissue, range and setup uncertainties may further degrade the quality of the delivered
lung plan. Chartier et al. (169) had demonstrated the effect of target volume motion with realistic
patient-specific lung pattern on RBE variation at different points of spread-out Bragg Peak (SOBP)
and in OARs closed to the distal part of the SOBP. However, they focused on passive Carbon-12
beam delivery. To the best of our knowledge, there is no data available to show if a breathing
phase has any impact on the LETd distributions in PBS proton lung plans and related to that
modification of biologically weighted dose in OARs.
During the proton treatment planning, it is possible to take into account both range and setup
uncertainties occurring simultaneously. Additionally, treatment delivery can start in any breathing
phase when treating a moving lung tumor. The quantitative assessment of the impact of the
breathing phase and range and setup uncertainties will provide guidance for LET evaluation in the
clinic. Therefore, the primary objective of our study was to perform a quantitative robustness
analysis of the LETd and related RBE-weighted dose in robustly optimized PBS proton lung cancer
plans by investigating the following items:


Combined effect of range and setup uncertainties on the LETd distribution in the target
volumes and OARs.



Variation in the LETd in the target volumes and OARs due to breathing phases.



Combined effect of range and setup uncertainties on the RBE-weighted dose to the OARs.



Effect of breathing phase on the RBE-weighted dose values in the OARs.

10.2 Methods and Materials
10.2.1 Patient Characteristics and Contouring
In this Institutional Review Board (IRB)-approved retrospective in-silico treatment planning
study, we included the 4DCT data set of 6 lung cancer patients (170). The tumor motion in the
selected group of patients ranged from 3.8 mm to 8.8 mm and the clinical target volume (CTV)
ranged from 22.1 cc to 63.3 cc. The CTV was generated by an isotropic margin of 5 mm around
the internal gross tumor volume (IGTV). The CTV was overridden to the density of water.
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10.2.2 Treatment Planning
All work in this study was performed in the research version (8.99) of RayStation TPS (RaySearch
Laboratories, Stockholm, Sweden). For each patient, a nominal treatment plan was generated on
the average CT using the Monte Carlo algorithm for both robust plan optimization (10,000
ions/spot; single-field-optimization (SFO) technique) and final dose calculations (0.5% statistical
uncertainty; 2 mm voxel size). In the current study, we utilized a PBS beam model generated for
the physical dose based on the IBA ProteusPLUS proton machine with a PBS dedicated nozzle
(23). All nominal treatment plans were generated for a total dose of 5000 cGy(RBE) in 5 fractions
using the RBE of 1.1. The location of the CTV and beam arrangement for each patient are provided
in Figure 10.1.
Treatment plans were robustly optimized on the CTV using a setup uncertainty (±5 mm) and a
range uncertainty (±3.5%) for 21 scenarios, with a goal of 99% of the CTV receiving at least 100%
of the prescription dose. The following dose constraints were applied in the current study: heart
mean dose (Dmean) <200 cGy(RBE), esophagus Dmean <200 cGy(RBE), and total normal lung Dmean
<500 cGy(RBE), and spinal cord max dose <200 cGy(RBE). For each nominal plan, a volumetric
repainting (38) plan was generated. In each volumetric repainting plan, a total of 5 repaintings in
alternating order was applied (170). The volumetric repainting plan was then normalized such that
at least 99% of the CTV received 100% of the prescription dose.

Figure 10.1: The location of the clinical target volumes (CTVs) in six patients. The beam
arrangement includes either 2 or 3 treatment fields (indicated by the arrows).
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Table 10.1: Simulated scenarios for the range and setup uncertainties
Scenarios

Range Uncertainty (%)

Lateral Shift
(mm)

Longitudinal Shift
(mm)

Vertical Shift
(mm)

1

0

0

0

0

2

-3.5

0

0

0

3

3.5

0

0

0

4

-3.5

5

0

0

5

+3.5

5

0

0

6

-3.5

-5

0

0

7

+3.5

-5

0

0

8

-3.5

0

5

0

9

+3.5

0

5

0

10

-3.5

0

-5

0

11

+3.5

0

-5

0

12

-3.5

0

0

5

13

+3.5

0

0

5

14

-3.5

0

0

-5

15

+3.5

0

0

-5

Note: Group 3 comprises of ten different breathing phases. The range uncertainties of -3.5% and
+3.5% mean the mass density from the CT of the patient was scaled by -3.5% and 3.5%,
respectively.
10.2.3 Range and Setup Uncertainties
The range uncertainty (±3.5%) is modeled by scaling the mass density from the CT of the patient
and is universal for all beams in the given plan. Such scaling the mass density may result from
errors in the measurements or in converting from Hounsfield units to stopping power. In this study,
the range uncertainties of -3.5% and +3.5% mean the mass density was scaled by -3.5% and 3.5%,
respectively. The patient setup uncertainty was simulated for a 5 mm shift in RayStation.
Specifically, the patient setup uncertainty relates to the maximum patient shift relative to the
isocenter along the main directions (left-right, superior-inferior, and anterior-posterior). Table 10.1
provides different simulation scenarios which combine the range uncertainty and setup
uncertainty.
10.2.4 Breathing Phases
The average intensity projection CT was registered to all ten phases (Group 3) from the 4DCT data
set. We utilized the deformable registration between the average intensity projection CT and ten
phases from the 4DCT data set using ANAtomically CONstrained Deformation Algorithm
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(ANACONDA) within RayStation TPS. The spot map and beam parameters of a nominal
volumetric repainting plan were applied to each breathing phase CT in RayStation.
10.2.5 LETd Calculations
The LETd distributions were calculated using a 2 mm voxel size (101, 107). The details on the
LETd calculations in the research version of RayStation have been described elsewhere (101, 107,
109, 171). The LETd scoring in RayStation includes primary and secondary protons. In RayStation,
the LETd is defined as the voxel-wise unrestricted dose-averaged LETd (101). The LETd is reported
in the local material in unit density tissue (101). The mean LETd values were recorded for the CTV
and lung for all patients. However, for the heart and esophagus, the mean LETd values were
recorded only if the mean dose to the OAR was ≥100 cGy(RBE). In this study, cGy(RBE) refers
to a product of physical dose and the RBE of 1.1. The LETd was not evaluated for the spinal cord
since its maximum dose was less than 100 cGy(RBE) in all six patients. For the LETd analysis in
this study, we included the only voxels that have a total physical dose higher than 100 cGy (101).
The variation in the mean LETd (∆LETd) in a patient was calculated using equation 10.2.
∆: ;2 = ”ki : ;2
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(Eq. 10.2)

and ”ki : ;2W(– are the highest and lowest mean LETd values of the

structure (CTV and OAR), respectively, in each group, as shown in Table 10.1 for a particular
patient when compared to the nominal plan.

The ∆LETd change in each patient was compared for scenarios with the range uncertainties only
(Group 1: scenarios 2 and 3). Similarly, the ∆LETd in a patient was compared for Group 2
(scenarios 4 – 15) as shown in Table 1 as well as for ten breathing phases (Group 3).
10.2.6 RBE-Weighted Dose Calculations
For each OAR (heart, esophagus, and total lung), the RBE-weighted dose was calculated. The
RBE-weighted dose is defined as D + (D × cLETd), where D is the physical dose, and c is the
empirical fitting parameter with units of µm/keV (91, 96). Different RBE models for RBE
prediction in proton therapy have been published (83) while RayStation implemented Unkelbach
model (96). Specifically, in our study, we used c = 0.04 µm/keV based on the findings from
Unkelbach et al (96). The use of c = 0.04 µm/keV yields an RBE of 1.1 in the center of 5 cm SOBP
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as acceptable currently in planning (96). In mean RBE-weighted dose calculations, D and LETd
represent the arithmetic mean values, which were obtained by taking the average of results from
all voxels in the given OAR.

Figure 10.2: (a) Log-linear plot showing physical dose (top), dose-averaged linear energy
transfer (LETd) (middle), and RBE-weighted dose (bottom) distribution in the voxels (n = 89538)
in the heart of patient #1; (b) Line profiles displaying RBE-weighted dose and LETd. The line
profiles were drawn along the central axis of the left lateral beam in the same patient. This figure
represents the nominal plan without considering range and setup uncertainties.
Figure 10.2 (a) illustrates the physical dose, LETd values, and RBE-weighted dose in the voxels
(n=89538) in the heart of patient #1. For RBE-weighted dose calculations, no minimum cut-off
dose was applied, whereas for the LETd calculations (section 10.2.5), only the voxels that have a
total physical dose higher than 100 cGy were considered. This implies that the results from all the
voxels of given OAR were included in the RBE-weighted dose calculations. The variation (∆& in
the mean RBE-weighted dose in a patient was calculated using equation (equation 10.3):
∆

gk#jℎ$k D"ok = ”ki

(Eq. 10.3)

gk#jℎ$k D"ok•4\• − ”ki

gk#jℎ$k D"ok W(–

where, Mean RBE Weighted dosehigh and Mean RBE Weighted Doselow are the highest and lowest
mean RBE-weighted dose values of the OAR, respectively, in the evaluation group. (Groups 1, 2,
and 3)
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10.2.7 Statistical Analysis
The one-way ANOVA analysis (GraphPad Prism; GraphPad Software, San Diego, CA) was
performed for each group to determine the statistical significance (p value less than 0.05).
Specifically, for each patient, the results from difference scenarios were compared against that of
nominal plan.

Figure 10.3: An example of (a) dose distribution in a nominal plan, (b) dose-averaged linear
energy transfer (LETd) distribution in a nominal plan, (c) LETd distribution for a range uncertainty
of -3.5%, and (d) LETd distribution for a range uncertainty of +3.5%.. The dose in the nominal
plan is the product of the physical dose and the RBE of 1.1. The displayed dose and LETd
distributions are from patient #1. Note that high LETd (>6 keV/µm) is seen outside the clinical
target volume (red contour). Note: The range uncertainties of -3.5% and +3.5% mean the mass
density from the CT of the patient was scaled by -3.5% and 3.5%, respectively.

10.3 Results
10.3.1 Impact of Range and Setup Uncertainties
10.3.1.1

CTV

Figure 10.3 illustrates an example of dose and LETd distributions in the nominal plans (Figure
10.3(a-b)) as well as LETd distributions for the scaling of the mass density by -3.5% (Figure
10.3(c)) and +3.5% (Figure 10.3(d)) scenarios in patient 1. In this study, the scaling of the mass
density by 3.5% and +3.5% is denoted by range uncertainty of -3.5% and 3.5%, respectively. The
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mean dose to the CTV in nominal plans among six patients ranged from 5083 to 5196 cGy(RBE).
The worst-case scenario result for the mean dose to the CTV in a patient among 14 simulated
scenarios (S2-15 in Table 10.1) was lower by 1.2 – 1.5% when compared to the nominal result of
the same patient. The LETd distributions in Figure 10.3(c) and 3(d) show the minor but noticeable
differences in 2 keV/µm color map inside the CTV for the -3.5% and +3.5% range uncertainties
scenarios, respectively, as compared to the LETd distributions in the nominal plan (Figure 10.3(b)).
Figure 10.4 shows the mean LETd in the CTV of all six patients for various scenarios. In the
absence of range and setup uncertainties (i.e., nominal plan – scenario 1 in Table 10.1), the mean
LETd ranged from 2.2 to 2.6 keV/µm among nominal plans of six patients. For -3.5% range
uncertainty (i.e., scaling of the mass density by -3.5%) without considering setup uncertainties
(i.e., scenario 2 in Table 10.1; Figure 10.4(a)), the mean LETd among six patients ranged from 2.0
to 2.5 keV/µm. For +3.5% range uncertainty (i.e., scaling of the mass density by +3.5%) without
considering setup uncertainties (i.e., scenario 3 in Table 10.1; Figure 10.4(a)), the mean LETd
values among six patients ranged from 2.4 to 2.8 keV/µm.
For scenarios 4 – 15 (Group 2 in Table 10.1), the range uncertainties were combined with the setup
uncertainties. In the case of lateral (±5 mm; S4–7 in Table 10.1; Figure 10.4(b)), longitudinal (+5
mm; S8–9 in Table 10.1; Figure 10.4(c)), vertical (±5 mm; scenarios 12 – 14 in Table 10.1; Figure
10.4(d)) shifts, the arithmetic mean of the mean LETd among six patients was 2.2±0.2 keV/µm and
2.6±0.2 keV/µm when evaluated simultaneously with -3.5% and +3.5% range uncertainties,
respectively. On average, the longitudinal shift of a -5 mm (S10–11 in Table 10.1; Figure 10.4(c))
among six patients resulted in mean LETd of 2.3±0.2 keV/µm and 2.7±0.1 keV/µm when combined
with -3.5% and +3.5% range uncertainties, respectively.
When only range uncertainties were considered (Group 1: S2-3 in Table 10.1), the ∆LETd in a
patient ranged from 0.3 to 0.5 keV/µm. When range and setup uncertainties are combined (Group
2: S4-15 in Table 10.1), the ∆LETd in a patient was slightly higher, ranging from 0.4 to 0.7
keV/µm.
10.3.1.2

OARs

10.3.1.2.1 LETd
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Table 10.2 summarizes the mean dose and mean LETd values in the CTV, heart, esophagus, total
lung, and spinal cord for nominal plans in six patients. Figure 10.6 illustrates the mean LETd results
in the OARs of six patients.
Total lung: In nominal plans, the mean LETd among six patients ranged from 2.4 to 4.0 keV/µm.
The ∆LETd in a patient ranged from 0.3 to 0.9 keV/µm when only the range uncertainties were
considered. The ∆LETd in a patient increased when both the range and setup uncertainties were
combined, ranging from 0.5 to 1.2 keV/µm.
Heart: The mean LETd was evaluated in patients #1 and #3, whereas the other four patients had
the mean dose to the heart <100 cGy(RBE) and LETd was not calculated. The mean LETd value
recorded in nominal plans ranged from 5.7 to 5.8 keV/µm. The ∆LETd in a patient ranged from
0.6 to 0.9 keV/µm when only the range uncertainties were considered. When the range and setup
uncertainties were evaluated simultaneously, the ∆LETd in a patient was greater, ranging from 1.2
to 1.7 keV/µm.
Esophagus: The mean LETd was evaluated in patient #6, whereas the other five patients had the
mean dose to the esophagus <100 cGy(RBE) and the LETd was not calculated. The mean LETd
value recorded in the nominal plan was 7.2 keV/µm. The ∆LETd in a patient was 0.4 keV/µm when
only the range uncertainties were considered. The simultaneous evaluation of the range and setup
uncertainties resulted in the ∆LETd value of 1.2 keV/µm.
Table 10.2: The mean dose and mean dose-averaged linear energy transfer (LETd) values in the
clinical target volume (CTV), heart, esophagus, total lung, and spinal cord for nominal plans in
six patients. Note: cGy(RBE) refers to a product of physical dose and the RBE of 1.1.
CTV
Patient

Dmean
(cGy(RBE)

P1
P2
P3
P4
P5
P6

5089
5090
5091
5094
5083
5196

Mean
LETd
(keV/µm)
2.2
2.3
2.6
2.3
2.3
2.5

Heart
Dmean
(cGy(RBE)
147
11
103
1
33
0

Mean
LETd
(keV/µm)
5.8
**
5.7
**
**
**

Esophagus
Mean
Dmean
LETd
(cGy(RBE)
(keV/µm)
1
**
8
**
22
**
36
**
0
**
156
7.3

Total Lung
Mean
Dmean
LETd
(cGy(RBE)
(keV/µm)
449
3.3
272
3.5
416
2.4
253
2.8
413
4.0
381
2.5

Spinal Cord
Mean
Dmax
LETd
(cGy(RBE)
(keV/µm)
0
**
0
**
21
**
0
**
1
**
47
**

**means the LETd is not evaluated for the OAR of a given patient since mean or max dose is <100 cGy(RBE)
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Figure 10.4: Mean dose-averaged linear energy transfer (LETd) in the clinical target volume
(CTV) in six patients. The results are shown for (a – d) nominal plans, (a) only range uncertainties,
(b) range uncertainty (RU) combined with lateral shifts, (c) RU combined with longitudinal shifts,
(d) RU combined with vertical shifts.

Figure 10.5: (a) Mean dose-averaged linear energy transfer (LETd) in the clinical target volume
(CTV) for different scenarios groups (nominal plan, only range uncertainties, and range
uncertainties combined with setup uncertainties) in all 6 patients, (b) mean LETd in the total lung
(6 patients), heart (2 patients) and esophagus (1 patient) for the range uncertainties combined
with setup uncertainties, and (c) ΔLETd in the CTV (6 patients), total lung (6 patients), heart (2
patients) and esophagus (1 patient) for ten breathing phases.
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Figure 10.6: Mean dose-averaged linear energy transfer (LETd) in the (a) lung, (b) heart, and (c)
esophagus for nominal (S1) and only range uncertainties (S2-S3) scenarios. Note: LETd in organ
at risk (OAR) was not evaluated if the mean or max dose to the OAR was <100 cGy(RBE).
10.3.1.2.2 RBE-Weighted Dose
Figure 10.7 (left panel) illustrates the RBE-weighted dose in the OARs for a nominal scenario
(S1), simulated scenarios (Groups 1 & 2: S2-15; see Table 10.1), and different breathing phases
(Group 3: B1-10) in six lung patients.
Heart: In patients #4 and #6, the mean RBE-weighted dose for nominal and simulated scenarios
was less than 1 cGy. Hence, these two patients were ignored in this analysis for the heart. In the
remaining four patients, the mean RBE-weighted dose in nominal plans ranging from 10 to 148
cGy (Figure 10.7(a)). The ∆RBE-weighted dose in a patient ranged from 10 to 49 cGy when only
the range uncertainties (Group 1: S2-3 in Table 1) were considered. When the range and setup
uncertainties (Group 2: S4-15 in Table 10.1) were evaluated simultaneously, the ∆RBE-weighted
dose in a patient ranged from 29 to 165 cGy. The highest mean RBE-weighted dose among all
scenarios in a given patient was ≤51 cGy in patients # 2 and #5 (Figure 10.7(a)). In patients # 1
and #3, a slightly higher mean RBE-weighted dose was observed. Specifically, when all scenarios
(S1-15 in Table 10.1) were considered, the mean RBE-weighted dose ranged from 77 to 242 in
patient #1 and from 64 to 137 cGy in patient #3 (Figure 10.7(a)).
Esophagus: In patients #1 and #5, the mean RBE-weighted dose for nominal and simulated
scenarios was less than 1 cGy. Hence, these two patients were ignored in this analysis for the
esophagus. In the remaining four patients, the mean RBE-weighted dose in nominal plans ranging
from 8 to 167 cGy (Figure 10.7(c)). When only the range uncertainties were considered (Group 2:
S2-3 in Table 10.1; Figure 10.7(c)), the mean RBE-weighted dose ranged from 3 to 12 cGy in
patient #2, from 17 to 37 cGy in patient #3, from 19 to 72 cGy in patient # 4, and from 120 to 230
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cGy in patient #6. When the range and setup uncertainties were evaluated simultaneously (Group
3: S4-15 in Table 10.1; Figure 10.7(c)), the mean RBE-weighted dose ranged from 3 to 55 cGy in
patient #2, from 11 to 58 cGy in patient #3, from 7 to 123 cGy in patient # 4, and from 78 to 258
cGy in patient #6.
Total lung: In nominal plans, the mean RBE-weighted dose ranged from 248 to 443 cGy (Figure
10.7(e)). The mean RBE-weighted dose among all scenarios (S1-15 in Table 10.1) ranged from
397 to 476 cGy in patient #1, from 229 to 287 in patient #2, from 380 to 442 cGy in patient #3,
from 224 to 261 cGy in patient #4, from 388 to 435 cGy in patient #5, and 328 to 399 in patient
#6 (Figure 10.7(e)). The ∆RBE-weighted dose in a patient ranged from 8 to 26 cGy when only the
range uncertainties (Group 1: S2-3 in Table 10.1) were considered. The ∆RBE-weighted dose in a
patient increased when both the range and setup uncertainties (Group 2: S4-15 in Table 10.1) were
combined, ranging from 37 to 79 cGy.
10.3.2 Impact of Breathing Phases
Figure 10.5(c) illustrates the variations in the mean LETd in the CTV, heart, esophagus, and total
lung among ten breathing phases. The mean LETd in the CTV in ten different breathing phases
among six patients ranged from 2.1 to 2.7 keV/µm. For the CTV, the ∆LETd in a patient ranged
from 0.1 to 0.3 keV/µm. For the total lung, the mean LETd ranged from 2.2 to 4.2 keV/µm, with
the ∆LETd in a patient ranging from 0.2 to 0.7 keV/µm. For the heart (only patients # 1 and 3 are
considered), the mean LETd ranged from 5.5 to 7.3 keV/µm, with the ∆LETd in a patient ranging
from 0.2 to 0.5 keV/µm. For the esophagus in patient #6, the mean LETd was 7.2 keV/µm, with
the ∆LETd of 0.4 keV/µm.
Figure 10.7 (right panel) shows the impact of breathing phases on the RBE-weighted doses in the
heart, esophagus, and total lung. The mean RBE-weighted dose to the heart among ten breathing
phases ranged from 0 to 165 cGy, with the ∆RBE-weighted dose in a patient up to 30 cGy (Figure
10.7(b)). The mean RBE-weighted dose to the esophagus among ten breathing phases ranged from
0 to 234 cGy, with the ∆RBE-weighted dose in a patient up to 109 cGy (Figure 10.7(d)). In the
total lung, the mean RBE-weighted dose among ten breathing phases ranged from 221 to 455 cGy,
with the ∆RBE-weighted dose in a patient up to 29 cGy (Figure 10.7(f)).
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Figure 10.7: Mean RBE-weighted dose in the organs at risk (OARs). The values for a nominal
scenario (S1) are shown by a horizontal solid line in blue color. For simulated scenarios (Group
1 & 2: S2-15 in Table 1) and ten different breathing phases (Group 3: B1-10), the values are
shown in boxplot.
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10.3.3 Statistical Results
The results from one-way ANOVA analysis for each group showed the statistical significance (p
< 0.05) in each patient. This was true for all evaluated parameters of the CTV and OARs (heart,
esophagus, and total lung).

10.4 Discussion
In the current study, we quantified the impact of the range uncertainty, setup errors, and breathing
phases on the LETd and related RBE-weighted dose in PBS lung cancer plans. Treatment plans
were generated based on the robust optimization technique, which included a robust objective on
the CTV for the setup and range uncertainties. The results presented in our study represent the
current standard of robust optimization technique for PBS lung planning implemented at various
proton centers. All lung plans were computed using the Monte Carlo algorithm, which is strongly
recommended for PBS lung planning in proton therapy (66).
Previous studies (102-110) have explored the LETd distributions in proton plans of various disease
sites. The LETd is very pronounced at the end of the range (79, 80). The addition of the setup errors
to the range uncertainties can further increase the uncertainty in the LETd. The range uncertainties
of -3.5% and +3.5% were simulated by scaling the mass density from the CT of the patient by 3.5% and 3.5%, respectively. The current study showed that the mean LETd in the CTV of nominal
PBS lung plans in six patients ranged from 2.2 to 2.6 keV/µm. Similar mean LETd results were
reported for the target volumes in nominal plans by other investigators. Specifically, the mean
LETd ranged from 2.8 to 2.9 keV/μm for prostate (102, 106, 108), from 2.7 to 2.8 keV/μm for
brain (102, 103, 109), from 2.6 to 2.8 keV/μm for head and neck (103, 107, 109), and from 3.1 to
3.2 keV/μm for lung (110). The +3.5% and -3.5% range uncertainty scenarios without the setup
uncertainties showed a systematic increase and decrease in the LETd, respectively. For the CTV,
the variations in the mean LETd were found to be ≤ 0.5keV/µm, with an average value of 0.4
keV/µm. Hahn et al. (101) reported the maximum differences in mean LETd due to range
uncertainties of less than 0.5 keV/μm for the prostate. The combination of range and setup
uncertainties showed that the mean LETd variation in the CTV among 12 scenarios in a given
patient was up to 0.7 keV/µm. The addition of setup uncertainties to the range uncertainties did
not alter the systematic increase and decrease of the LETd distributions in the CTV for the +3.5%
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and -3.5 range uncertainties scenarios, respectively. In this case, the average variation in the mean
LETd among 12 scenarios of all six patients was 0.6 keV/µm, which is slightly higher than when
only the range uncertainties were considered (0.4 keV/µm). These results suggest that the range
uncertainties, as well as the combination of range and setup uncertainties, produced homogenous
LETd distributions in the CTV. PBS beam delivery can start in any breathing phase when treating
lung cancer patients. The results from the current study showed that the variations in the mean
LETd in the CTV were minimal when evaluated for ten breathing phases, with the ∆LETd in a
patient ranging from 0.1 to 0.3 keV/µm.
The OARs were evaluated for variations in the mean LETd and mean RBE-weighted dose. For the
mean LETd evaluation, we included the OARs if the mean dose to the heart, lung, and esophagus
was >100 cGy(RBE) and the maximum dose to the spinal cord was >100 cGy(RBE). For the
selected OAR, only the voxels that have a total physical dose higher than 100 cGy were considered
so that voxels with high LETd values at low physical dose can be eliminated in the LETd analysis.
Based on these criteria, the LETd evaluation was performed for the total lung in all six patients.
The combined effect of range and setup uncertainties produced less homogeneous LETd
distributions in the total lung as compared to the CTV. When evaluating the ∆LETd in the total
lung, the impact of range uncertainties scenarios was slightly lower (more homogeneous) than that
of range and setup uncertainties combined scenarios. In the current study, we noticed the mean
LETd of total lung in nominal plans ranging from 2.4 to 4.0 keV/µm, which was slightly higher
than mean LETd (0.8─1.8 keV/µm.) of lung reported by Shang et al. (110) for a 3-beam
arrangement technique. Hahn et al. (101) found the OARs of brain cancer patients being the most
sensitive to the range uncertainties when compared to prostate and head and neck cancer. The
LETd hot spots of greater than 7 keV/μm were reported for the OARs (101).
The LETd distributions in the heart were evaluated in patients #1 and #3. The combined effect of
the range and setup uncertainties scenarios resulted in higher (less homogenous) ∆LETd in the
heart by a factor of two when compared to the results for the range uncertainties only scenarios.
For the esophagus, the LETd was evaluated in patient # 6. The combined effect of the range and
setup uncertainties scenarios on the ∆LETd in the esophagus was three times greater (less
homogeneous) than the range uncertainties scenarios only. For the heart and esophagus, the impact
of breathing phases on the LETd was also minimal (∆LETd ≤0.5 keV/µm). However, for the total
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lung, the LETd distributions were found to be less homogenous among ten breathing phases in
some patients, with the ∆LETd in a patient up to 0.7 keV/µm.
For RBE-weighted dose analysis in the OARs, we included all the voxels of given OAR to be
consistent with the current clinical standard of evaluating heart, esophagus, and lung in proton
plans. Figure 10.3 (b-d) illustrates an example of some of the voxels in the OARs outside the CTV
receiving LETd greater than 6 keV/µm. This can potentially lead to overdosage of some parts of
the OARs due to the presence of high LETd voxels in high-dose regions. Figure 10.2 illustrates
that some of the voxels in the heart of patient #1 nominal plan reach LETd > 6 keV/µm. For this
particular case, the mean RBE-weighted dose to the heart was 148 cGy. If a proton plan evaluation
requires the mean dose evaluation for the heart, then mean RBE-weighted dose of less than 200
cGy may be acceptable depending on the location of the tumor volume with respect to heart, patient
history, and institutional clinical protocol. A small number of events with LETd in a range of 4-14
keV/µm do not affect RBE-weighted dose for most of the voxels due to a small fractional part of
D × LETd for these voxels (i.e., a small number of such events with high LETd). High LETd events
correspond to low energy protons at the end of the range and also some secondaries due to nuclear
reactions (alpha particles, recoil nuclei, fragments)(82).
Darby et al (172) reported the correlation between mean heart dose and the probability of cardiac
event in breast cancer patients. It was reported that radiation dose to heart as low as 200 cGy could
result in cardiac event (172). Darby et al (172) also showed that the rate of major acute coronary
events increased by of 7.4% per one Gy increase in the mean heart dose. Wang et al. (173) and
Dess et al. (174) reported the association of mean heart dose to postradiotherapy cardiac events in
lung cancer patients. In our study, the mean-RBE weighted dose to the heart was found to be less
than the dose constraint (200 cGy(RBE)) for all scenarios and breathing phases in six patients
except for scenario 8 (242 cGy) in patient 1. Recently, it has been reported that radiation dose to
certain substructures can also contribute to the cardiac toxicity (175). Our study was focused on
the mean dose to the whole heart. Further investigations are needed to determine how RBEweighted dose can affect cardiac substructures in lung cancer patients treated with proton-based
stereotactic body radiation therapy (SBRT) technique.
In the nominal plan of patient #6, the mean LETd in the esophagus was 7.3 keV/µm which is 2.9
times higher than the mean LETd in the CTV. The mean RBE-weighted dose to the esophagus in
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the nominal plan of patient #6 was only 167 cGy, which is below the dose constraint of 200 Gy
(RBE). The mean RBE-weighted dose for the mentioned scenarios in the same patient was up to
336 cGy. Currently, to the best of our knowledge, there is no predictor of radiation esophagitis in
proton-based SBRT lung patients. It is not clear if the highest recorded mean RBE-weighted dose
to the esophagus in our study (336 Gy) will result esophagitis in lung patients. The RTOG 0617
recommends the mean dose to the esophagus to be below 3400 cGy, which was based on the
standard fractionation in conventional photon therapy (176). Recently, Luna et al. (177) performed
a machine learning analysis of radiation esophagitis predictors for lung cancer in photon therapy.
Their study reported the deficiency of currently available dosimetric constraints in predicting highgrade radiation esophagitis in non-small cell lung cancer treated with chemoradiation. Future study
warrants an investigation on radiation esophagitis predictor for the SBRT lung patients in proton
therapy.
In the current study, the mean RBE-weighted dose to the total lung for all scenarios and breathing
phases in all six patient was less than 500 cGy. Although we used the mean lung dose (MLD)
constraint of 500 cGy(RBE), the dose constraints for lung SBRT planning have not be validated
(178). Borst et al. (179) established the correlation between the MLD and radiation pneumonitis
in SBRT lung patients treated with 600–1200 cGy per fraction with a median MLD of 640 cGy.
While mean RBE-weighted dose to the heart, lung, and esophagus in this cohort of patients seem
to be tolerable in proton treatment clinical practice, it does warrant further investigation of variable
RBE-weighted dose proton planning rather than using a constant RBE value 1.1. If the OAR is
evaluated for the maximum point dose, one should be aware of the voxels with the high-LETd
values in the high-dose regions, thus resulting in a higher RBE-weighted maximum dose to the
OAR. In our study, the maximum dose to the spinal cord was very low (<50 cGy(RBE)) and did
not result in a clinically meaningful maximum RBE-weighted dose to the spinal cord. As more
proton center continue to treat lung patients using proton-based SBRT technique, predictors of
radiation-induced toxicities need to be investigated by correlating clinical outcome and dose
constraints. Robust clinical data can lead the way to establish the proton-based radiobiological
parameters in predicting normal tissue complication probability of OARs such as heart, lung, and
esophagus.
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Several research groups (105, 109, 180-183) have published LET-guided plan optimization in
proton therapy. Although LET-guided plan optimization techniques proposed by research groups
may differ, their primary goal is to minimize the impact of high LET in the critical structures that
have high physical dose. The current study did not investigate LET-guided plan optimization. Our
future work will include LET-guided robust plan optimization and investigate the feasibility of
increasing the LETd in the target volumes while reducing the high LETd in the OARs for PBS
proton lung cancer plans.

10.5 Conclusion
For the CTV, the variations in the mean LETd were found to be ≤ 0.5keV/μm, with an average
value of 0.4 keV/μm. The combination of range and setup uncertainties showed that the mean
LETd variation in the CTV among various scenarios in a given patient was up to 0.7 keV/μm. The
breathing phases had a very minimal impact (0.3 keV/μm) on the LETd in the CTV. The variations
in the LETd from ten breathing phases in a patient were slightly larger in the total lung (0.2 to 0.7
keV/μm) than in the heart (0.2 to 0.5 keV/μm). In comparison to the effect of breathing phases,
the combination of setup and range uncertainties had a greater impact on the variations in the RBEweighted dose to the OARs. Overall, the LETd distributions in the CTV were less sensitive to the
setup errors, range uncertainties, and breathing phases for robustly optimized (in terms of range
and setup uncertainties) PBS proton lung cancer plans. Future studies need to explore the
importance of considering variable RBE that can change essentially RBE-weighted dose in OARs
for different beam arrangements even when the PBS plan is robustly optimized for range and setup
uncertainties and require additional biological robust optimization.
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Chapter 11
11.1 Conclusion
This thesis investigated the application of volumetric repainting in PBS proton therapy with focus
on repainting technique in an alternating order. The measurements were delivered on an IBA
ProteusPLUS PBS proton system in “magnetic field regulation” mode. The advancement in
engineering and technology in “magnetic field regulation” provides the capability of delivering
the proton beam from the distal to proximal end as well as from the proximal to distal end with a
faster layer switching. Currently, there are no published literature on the implementation of such
commercially available advanced technology in a clinical environment. In-silico planning studies
were carried out using RayStation. This thesis provides experimental results for PBS proton beam
model as well as addresses the interplay effect, proton dose calculation algorithms, spot size and
position errors simulation, plan robustness, radiobiological analysis, and dose-averaged linear
energy transfer.
A summary of the major findings of this thesis are provided below under each of the aims:
Aim 1: Assess the impact of magnetic field regulation in conjunction with volumetric
repainting technique on the spot positions, spot size, and beam range in PBS proton
therapy.
Chapter 3 presents the experimental study on the spot position and beam range measurements. The
magnetic field regulation mode resulted in acceptable differences in spot position and range when
compared to the current regulation mode. The range differences between magnetic field regulation
and current regulation modes were found to be within ±0.2 mm. The selection of beam delivery
direction (“down” vs. “up”) had very minimal impact on the ranges. The comparison between
magnetic field regulation vs. current regulation showed that the positions of the spots are almost
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identical (±0.1 mm) whether spots are delivered either in magnetic field regulation or current
regulation modes. The central axis spots were within ±1 mm, whereas for the off-axis spot position
measurements, 97.9% (846/864) of the spots were within ±1 mm, and all spots were within ±1.2
mm.
Chapter 4 presents the experimental study on the spot size measurements. The average difference
in spot sizes between magnetic field regulation and current regulation modes in “down” direction
was less than 0.5% with a mean absolute deviation of 0.3%. The difference in spot size between
two delivery sequences (“down” vs. “up” directions) in magnetic field regulation for given energy
at five different locations was within ±2.0%. The impact of magnetic field regulation on the spot
size was very minimal, and this was true for both the volumetric and non-volumetric techniques.
Aim 2: Parametrization of in-air spot size as a function of energy and air gap for the
ProteusPLUS PBS proton therapy system
Chapter 5 presents the in-air spot size measurement results by parametrizing the spot size as a
function of energy and air gap. An analytical model was developed to estimate the spot size in air
for various energies and air gaps in situations where range shifters of 40 mm and 75 mm WET are
encountered in the proton beam path. The analytical model agrees within ±0.25 mm of the
measured spot sizes on a ProteusPLUS PBS proton system with a PBS dedicated nozzle.
Aim 3: Investigation on volumetric repainting to mitigate interplay effect on 4D robustly
optimized lung cancer plans in PBS proton therapy
Chapter 6 explores volumetric repainting technique in an alternating order with a focus on several
key items that are relevant for its clinical implementation in treating lung cancer with tumor motion
less than 15 mm. Currently, there is no consensus in the proton therapy community regarding
which metrics can be used to evaluate the interplay effect. This chapter shows that the number of
repaintings required to mitigate the interplay effect is patient dependent. Determining the optimal
number of repaintings based on the bandwidth and worst-case-scenario approach from DVHs of
ten breathing phases could mitigate the interplay effect. It is recommended to perform patientspecific interplay evaluation for PBS lung cancer plans.
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Aim 4: Assess the impact of proton dose calculation algorithms on the interplay effect in
SBRT PBS lung plans
Chapter 7 investigates the combined effect of RayStation proton dose calculation algorithms
(analytical pencil beam (APB) and Monte Carlo) and interplay in SBRT lung treatment plans. The
major dosimetric differences between RayStation dose calculation engines occurred in the tumor
volumes. It was distinct that the APB overestimated the CTV coverage. In the absence of the
interplay effect, the overestimation of the D99% by APB algorithm was found to be up to 5.3%. The
APB overestimated the target coverage by up to 10.5% in non-volumetric repainting plans when
the interplay effect is considered. The use of Monte Carlo algorithm for both optimization and
final dose calculations in conjunction with the volumetric repainting technique yielded better target
coverage and dose homogeneity.
Aim 5: Asses the dosimetric and radiobiological impact of spot size on the interplay effect,
plan robustness and normal tissue complication probability (NTCP) for volumetric
repainting lung cancer plans in intensity modulated proton therapy
Chapter 8 investigates if there are any dosimetric and radiobiological benefits in using a small spot
size vs. large spot size for lung cancer treatment in PBS proton therapy. The smaller spot model
produced a lower dose to the normal total lung, heart, esophagus, and spinal cord. The NTCPs for
the total lung and heart were found to be comparable in both sets of plans, whereas the difference
in NTCP of esophagus between large spot and small spot plans was found to vary from 0% to 33%.
The location of the CTV in proximity of esophagus and wider penumbrae from large spots were
found to be contributing factors for increased EUD and NTCP of esophagus in large spot plans.
For robustly optimized PBS lung cancer plans, a small spot machine resulted in a more robust
CTV against the setup and range errors when compared to a large spot machine. In the absence of
volumetric repainting technique, large spot PBS lung plans were more robust against the interplay
effect. However, the use of a volumetric repainting technique in an alternating order in both small
and large spot PBS lung cancer plans led to comparable interplay target coverage.
Aim 6: Investigation on the effect of errors in spot positions and sizes in conjunction with
setup and range uncertainties for volumetric repainting lung cancer PBS plans
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Chapter 9 highlights the impact of various errors on PBS proton based SBRT lung plans. For the
spot size errors of ±10%, the average loss of target coverage was almost identical. For the
decreasing spot sizes (-10%) in conjunction with ±1 mm spot position errors, the target coverage
was reduced by up to 1.1%. For the increasing spot sizes (+10%) in conjunction with ±1 mm spot
position errors, the target coverage was reduced by up to 2.5%. By assuming the spot size and
position errors (±10% and ±1 mm, respectively) occurring simultaneously in conjunction with
setup errors, the target coverage was decreased by the average difference of 6.1%. Similarly, for
the range errors in conjunction with the spot size and spot position errors, we noticed that the
average decrease in target coverage by 2.0%. The increasing spot sizes resulted in decreased target
coverage and dose homogeneity. Similarly, the decreasing spot sizes led to a loss of target
coverage, overdosage, and degradation of dose homogeneity.
Aim 7: Investigate the impact of range uncertainty, setup errors, and breathing phase on
the LETd distributions for PBS lung plans
Chapter 10 investigates the LETd robustness by simulating the uncertainties in the range and
patient setup. The undershoot and overshoot scenarios without considering the setup uncertainties
showed the systematic increase and decrease in the LETd, respectively. The variations in the LETd
were found to be ≤0.5 keV/µm. The addition of setup errors to the range uncertainties resulted
slightly less homogeneous LETd distributions in the CTV, heart, esophagus, and total lung. In
comparison to the effect of breathing phases, the combination of setup and range uncertainties had
a greater impact on the variations in the RBE-weighted dose to the OARs. Overall, the LETd
distributions in the CTV were less sensitive to the setup errors, range uncertainties, and breathing
phases for robustly optimized PBS proton lung cancer plans.

11.2 Future Work
This thesis explored the feasibility of clinical implementation of a magnetic field regulation feature
in conjunction with a volumetric repainting in an alternating order on the IBA’s ProtueusPLUS
PBS proton machine. The research work was focused on the experimental measurements for PBS
beam model and treatment planning studies for PBS proton lung cancer treatment. Future work
will include an experiment to investigate the impact of volumetric repainting techniques on a
moving phantom, which will mimic the tumor motion of various amplitudes. The experimental
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results will be quantified by comparing the calculated and measured doses. Since volumetric
repainting with an alternating order may not be available at all proton centers, the use of layer
repainting to mitigate the interplay effect cannot be ignored. In the next study, we will make the
direct comparison between the volumetric repainting (with alternating order) and layer repainting
by providing the dosimetric and radiobiological results.
As stated in previous chapters, the magnetic field regulation on the IBA’s proton therapy system
allows a faster laying switching time in the “up” direction (from 6 seconds to 1 second). Another
potential application of “down/up” rescanning with a faster layer switching could be extended in
proton arc therapy. Engwall et al. (30) showed that proton arc therapy plan can have energy jumps
in both the “up” and “down” directions. The reduction in layer switching time in the “up” direction
potentially improve the beam delivery efficiency in proton arc therapy.
Our future work will also include a simulation study with a focus on the LET-guided robust plan
optimization. This will allow to investigate the feasibility of decreasing the high LETd distributions
in the critical structures for various tumor sites including lung. Additionally, we will explore the
importance of considering variable RBE that can change for different beam arrangements and
OARs even when the PBS plan is robustly optimized for range and setup uncertainties and require
additional biological robust optimization.
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